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Abstract 
Natural killer (NK) cells protect the host against intracellular infection and cancer. These 
properties are exploited in oncolytic virus (OV) therapy, where anti-viral responses result 
in enhanced anti-tumour immunity. This study investigated the mechanisms by which 
reovirus, an oncolytic dsRNA virus, modulates human NK cell activity, in an in vitro 
model. Activation of NK cells within PBMC was dependent on soluble type I interferons 
(IFN-I). Blocking experiments and signalling pathway analysis support a model in which 
IFN-I acts directly on NK cells to activate them, inducing phosphorylation of signal 
transducer and activator of transcription 1 (STAT1) and STAT4. Microarray 
transcriptome profiling revealed the upregulation of genes involved in several relevant 
pathways: IFN-I signalling, granule and granule independent NK cytotoxicity, migration 
and proliferation. However, despite upregulation of cell cycle associated genes, NK cells 
did not proliferate in response to reovirus. In fact, priming with reovirus inhibited NK cell 
proliferation in response to the mitogenic cytokine interleukin 15 (IL-15). Further analysis 
showed that reovirus priming blocked the IL-15 induced accumulation of cell cycle 
proteins and inhibited Akt signalling. Inhibition of proliferation was dependent on IFN-I, 
demonstrating that interferon can have both stimulatory and inhibitory effects on NK cells 
in the context of oncolytic virus therapy. The observed upregulation of cell cycle 
associated genes during reovirus treatment might be due to the activation of a separate, 
pro-proliferative pathway, which is opposed by high levels of IFN-I. These results define 
a pathway of NK cell activation during oncolytic reovirus treatment, and show that OV 
treatment acts on the spectrum of NK cell activity.  
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Chapter 1. Introduction 
1.1 Immune system 
1.1.1 Innate and adaptive immunity 
The mammalian immune system is complex, consisting of numerous specialised cell 
types, adapted for diverse roles within the body. These cell types are typically grouped 
into either the adaptive or the innate immune system. While the adaptive immune system 
responds to specific antigens from invading pathogens, the innate system can respond 
non-specifically, as the first line of defence. A rapid innate defence is especially important 
since the adaptive immune system takes several days to mount a response to a new 
pathogen.  
The adaptive immune system consists of B lymphocytes (which mature in the bone 
marrow) and T lymphocytes (which mature in the thymus). Work by Jacques Miller first 
showed that antibody forming B cells and thymus derived T cells were two distinct 
immune cell types that both possess adaptive properties (Miller and Sprent, 1971). 
Advances in molecular techniques soon turned the focus of immunology to the molecular 
mechanisms underlying adaptive immunity. Studies of the B cell receptor gene, encoding 
secreted antibody, led to the discovery of antigen receptor gene rearrangement (Hozumi 
and Tonegawa, 1976), crucially explaining how the diverse repertoires of B and T cell 
receptors are formed. Both T cells and B cells undergo somatic rearrangement of their 
antigen receptor genes during development; dependent on the recombination-activating 
gene (RAG) system (Schatz et al., 1989). This creates a pool of adaptive immune cells 
with uniquely rearranged receptors, each with the potential to recognise a slightly 
different antigen structure. For a given pathogen (that the host has not been previously 
exposed to), the abundance of specific B and T cells is very low. The adaptive response 
delay is due to activation and clonal expansion stages, needed to generate high enough 
numbers of specific cells. During the adaptive immune response, naive B and T cells 
differentiate into effector cells, taking on different roles. These include antibody 
production by plasma cells, cell mediated cytotoxicity by cytotoxic T cells, and activation 
of multiple adaptive processes by T helper (Th) cells (Yatim and Lakkis, 2015). An 
important advantage of the adaptive response is that a proportion of highly specific B 
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and T cells are retained as memory cells, ready to initiate a recall response to a 
secondary pathogen challenge. 
The evolutionarily older innate immune system (Boehm, 2012) serves as the first line of 
defence against pathogens. Innate immune cells do not undergo somatic gene 
rearrangement; instead they rely on germline encoded receptors that recognise common 
patterns in pathogen structures or other danger signals. For example, the toll like 
receptors (TLRs) recognise a range of bacterial and viral components: such as TLR4, 
which recognises bacterial lipopolysaccharide (LPS) (Poltorak et al., 1998), and TLR3, 
which recognises viral double stranded RNA (dsRNA) (Alexopoulou et al., 2001). The 
innate immune system limits the spread of pathogens before the adaptive immune 
system can mount a response, but also plays an important role in initiating and shaping 
the adaptive response. The discovery of dendritic cells (DCs) in the 1970s proved this, 
as DCs became central in the current model of adaptive immunity. Those early 
experiments demonstrated that DCs were the “critical accessory cell” needed for the T 
cell response to progress (Nussenzweig et al., 1980). We now know that T cells can only 
recognise foreign antigen when it is processed and presented within host major 
histocompatibility complex (MHC) molecules, which is the system used to present 
endogenous cytosolic proteins on the cell surface. DCs are specialised antigen 
presenting cells, capable of presenting both endogenous and exogenous antigens, 
including bacterial protein fragments, viral antigens from other infected host cells, and 
also tumour cell antigens. DCs undergo maturation in the tissue, activated by stimulation 
of innate receptors such as the TLRs, take up antigens and present these molecules to 
potential antigen specific T cells in the lymph nodes, as well as providing co-stimulatory 
signals to enhance the initiation of adaptive immunity (Guermonprez et al., 2002). Other 
innate immune cells can directly kill infected host cells, providing a valuable defence 
against intracellular pathogens before the adaptive arm fully responds, as well as 
providing signals to T cells. These include large granular lymphocytes named natural 
killer (NK) cells.  
1.1.2 Immune cell classification 
All of the cell types discussed above originate from the haematopoietic stem cell (HSC) 
compartment, the source of all circulating immune cells.  HSCs give rise to two lineages: 
1) myeloid, which includes erythrocytes, platelets and several types of leukocytes, and 
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2) lymphoid, which gives rise to lymphocytes – the B, T and NK cells. Circulating 
leukocytes can also be divided into polymorphonuclear and mononuclear leukocytes. 
Named polymorphonuclear for the segmented appearance of their nuclei, this group 
includes neutrophils, basophils and eosinophils; short lived cells that respond rapidly to 
inflammatory stimuli (also known as granulocytes) (Geering et al., 2013). Mononuclear 
leukocytes in the blood consist of lymphocytes and also monocytes, large leukocytes 
that differentiate into antigen presenting cells when recruited to the tissue. Mononuclear 
leukocytes can be isolated by centrifugation, and are often used for in vitro 
immunological studies, as a convenient way to study lymphocyte biology. 
  
1.2 Natural Killer cells 
1.2.1 Identification 
As part of the innate immune system, natural killer (NK) cells play an important role in 
controlling viral infections and tumour growth. NK cells are cytotoxic lymphocytes but, 
unlike cytotoxic T cells, do not rely on prior sensitisation and they are not dependent 
upon somatically rearranged antigen receptors. Target killing without prior sensitisation 
was termed “natural killing” and led to the initial discovery of NK cells in 1975, within 
mouse splenic leukocytes (Kiessling et al., 1975).  Each NK cell is equipped with a 
diverse set of germline encoded receptors, which allow the recognition and killing of 
target cells. Cells that are dangerous to the host are recognised by NK cells, through the 
balance of activating and inhibitory ligands on the target cell surface. Along with their 
cytotoxic capability, NK cells also contribute to innate immunity by producing cytokines.  
Within human peripheral blood, NK cells range from 5.35–30.93 % of lymphocytes 
(Bisset et al., 2004). In humans, NK cells are defined as lymphocytes expressing CD56 
(also known as neural cell adhesion molecule, or NCAM1) but lacking expression of CD3 
(a component of the T cell receptor complex). Mouse NK cells do not express CD56, but 
do widely express the NK1.1 receptor. Alternatively, both species express NKp46 (also 
known as CD335; encoded by the NCR1 gene), which is sometimes used to identify NK 
cells (Morvan and Lanier, 2016).  
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1.2.2 Activating and inhibitory receptors 
NK cell recognition and killing of target cells depends on interactions between target cell 
ligands and NK cell activating or inhibitory receptors. The inhibitory receptors were 
discovered following the proposal of the “missing self” hypothesis in 1985. MHC 
molecules are assembled from a set of highly polymorphic genes, and are therefore 
highly variable across the population, making MHC a crucial marker of “self”. Tumour 
cell lines deficient for MHC class I were susceptible to NK cell killing in vivo  (Ljunggren 
and Karre, 1985). Karre proposed that the absence of MHC class I on target cells was a 
key determinant for NK cell killing. Following this discovery, a number of different 
molecules were identified that bind to MHC class I and have an inhibitory effect on NK 
cells. These included the first inhibitory killer cell immunoglobulin-like receptors (KIRs), 
initially known as p58 family molecules (Moretta et al., 1993)), and the CD94/NKG2A 
heterodimer (Carretero et al., 1998). The KIRs recognise the classical, highly 
polymorphic MHC class I molecules, coded by HLA-A, B and C, while the CD94/NKG2A 
receptor recognises the non-classical HLA-E. In addition to NKG2A, there are a group of 
related proteins that, similarly, dimerise with CD94. These include NKG2B and NKG2C, 
which were also found to recognise HLA-E (Braud et al., 1998). Surprisingly, a fraction 
of KIRs and CD94/NKG2 family receptors function as activating receptors, so MHC class 
I molecules presented on target cells can induce both inhibitory and activating signals in 
NK cells (Della Chiesa et al., 2015).    
Inhibitory receptors ensure that NK cell cytotoxicity is not unleashed upon normal healthy 
cells. Furthermore, this strategy maximises NK cell killing when T cell responses may be 
compromised. T cell activation relies on the presentation of antigen on MHC molecules, 
but sometimes transformed or infected cells downregulate expression of MHC. The 
herpesviruses in particular produce a number of viral proteins interfering with antigen 
presentation (VIPRs) (Yewdell and Hill, 2002). Downregulation of host MHC molecules 
allows viral evasion of the T cell response – but should enhance NK cell responses 
through the release of inhibitory receptor signalling. Small changes in target cell 
expression of MHC molecules can dramatically change the target’s susceptibility to NK 
cell killing. This has been demonstrated in vitro, with high MHC expressing cell lines 
proving much less susceptible to NK cell killing than lower expressers. Interestingly, a 
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threshold for target cell MHC expression was identified, with cell lines expressing MHC 
above this threshold appearing resistant to NK cell mediated killing (Holmes et al., 2011). 
NK cell activating receptors, on the other hand, stimulate NK cell cytotoxicity as well as 
cytokine release; generally in response to signs of stress on the target cell surface. 
NKG2D (CD314) is an important receptor found on NK cells and some T cell subsets, 
related to the CD94/NKG2 receptors, but structured differently and recognising different 
ligands. These include a number of cell surface molecules induced by infection, 
proliferation, DNA damage and other ‘stress’ conditions (Lanier, 2015). In particular, 
stressed cells can upregulate the MHC class I polypeptide-related sequence A/B 
(MICA/B) and the UL16 binding proteins (ULBPs). Several other NK cell activating 
receptors have been identified, including the natural cytotoxicity receptors (NCRs): 
NKp30, NKp44, and NKp46. The list of ligands for the NCRs is expanding every year as 
more are discovered, and includes many viral proteins as well as tumour expressed 
proteins. A common set of cellular ligands for the NCRs are heparin or heparan sulphate 
proteoglycans (Hecht et al., 2009), thought to direct NK cell recognition of tumour cells. 
The first viral ligands of the NCRs to be discovered were influenza virus haemagglutinin 
(HA) and sendai virus haemagglutinin–neuraminidase (HN), which, when expressed by 
infected cells, bind to NKp46 (Mandelboim et al., 2001). In addition to NKG2D and the 
NCRs, another important activating receptor is DNAX accessory molecule (DNAM-1).  
The principal ligands discovered for DNAM-1 are CD155 (poliovirus receptor, PVR) and 
CD122 (nectin-2) (Bottino et al., 2003). CD155 expression is upregulated in many 
cancers, with induction of the DNA-damage response pathway proposed as the trigger 
(de Andrade et al., 2014).  
The NK cell receptors mentioned here, and their major known ligands, are summarised 
in Table 1.1. The majority of the receptors discussed here are present in both humans 
and mice, except for the KIRs, which are only present in humans. Mice do possess a set 
of receptors that bind to murine MHC class I; these are the Ly49 family receptors, which 
also include both inhibitory and activating types (Pegram et al., 2011). 
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Human or mouse? Receptor Known ligands Activating/Inhibitory? 
Human Inhibitory KIRs: 
KIR2DL1,2,3 
and 4, KIR3DL1 
and 2 
MHC class I: HLA-
A,B and C  
Inhibitory 
Human Activating KIRs: 
KI2DS1,2,3,4 
and 5, KIR3DS1 
MHC class I: HLA-
A,B and C 
Activating 
Mouse Inhibitory Ly49: 
Ly49A,C,I and P 
MHC class I Inhibitory 





Both CD94/NKG2A,B MHC class I: HLA-
E 
Inhibitory 
Both CD94/NKG2C,E MHC class I: HLA-
E 
Activating 






Both NKp30 Heparan sulphate, 
BAT-3, B7-H6 
Activating 
Both NKp44 Viral HA Activating 
Both NKp46 Heparan sulphate, 
viral HA and HN 
Activating 
Both DNAM-1 CD155, CD122 Activating 
Table 1.1 NK cell activating and inhibitory receptors 
The human and mouse NK cell receptors discussed in this thesis are summarised here, 
with their known interacting ligands. Adapted from (Pegram et al., 2011). 
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The signalling pathways downstream of the main activating and inhibitory receptors are 
illustrated in Figure 1.1. The structures of the NK cell activating receptors vary, but the 
majority contain short intracellular domains that associate with adapter proteins, 
responsible for the initiation of activatory signalling pathways. Most adapter proteins, 
including DAP12, FcR-γ and CD3-ζ, contain an immunoreceptor-based activation motif 
(ITAM) (Vivier et al., 2004). Receptor engagement induces tyrosine phosphorylation of 
the ITAM sequence, leading to downstream activatory signalling. NKG2D is associated 
with DAP10, a different adapter protein, which contains the alternative tyrosine-
isoleucine-asparagine-methionine (YINM) motif rather than an ITAM motif, and so 
signals through slightly different pathways (Billadeau et al., 2003). DNAM-1 also does 
not signal through an ITAM motif; its own intracellular domain is phosphorylated instead 
(de Andrade et al., 2014). 
NK cell inhibitory receptors typically contain long intracellular domains containing an 
immunoreceptor tyrosine-based inhibition motif (ITIM). Engagement of inhibitory 
receptors induces phosphorylation of the ITIM sequence, leading to recruitment of SHP-
1 and SHP-2 tyrosine phosphatases. SHP-1 and 2 function to inhibit activatory signalling, 
by targeting activatory phosphorylated residues for dephosphorylation (Binstadt et al., 
1996; Yusa and Campbell, 2003). Interactions between NK cell receptors and target cell 
ligands, as well as adhesion molecules, lead to the formation of an immunological 
synapse. If the overriding signal received by the NK cell is activatory, this triggers a series 
of changes within the NK cell, leading to death of the target. Importantly, co-stimulation 
of multiple activatory receptors is necessary for the activation of target killing, although 
an exception is activation through the Fcγ receptor CD16, which recognises antibody 
bound target cells through the antibody Fc region (Bryceson et al., 2006). Engagement 
of CD16 by itself is sufficient to activate NK cell killing, termed antibody dependent 





- 24 - 
   
 
Figure 1.1 Activating and inhibitory receptor mechanisms 
Signalling downstream of NK cell activating and inhibitory receptors. Activating receptors 
are typically associated with adapter proteins containing an ITAM motif (or alternative 
motif in the case of NKG2D), which can recruit downstream signalling factors, including 
Syk kinase and phosphoinositide 3-kinase (PI3K), to trigger activation of the NK cell. 
Inhibitory receptors typically contain an ITIM motif, which can recruit the phosphatase 
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1.2.3 Target killing mechanisms 
NK cells kill target cells through two main mechanisms: granule dependent killing and 
death ligand mediated killing. These processes are summarised in figure 1.2.  
Granule dependent killing describes the exocytosis of cytotoxic granules from NK cells 
into target cells, a process shared with cytotoxic T cells. In NK cells, it is triggered 
following interactions between NK cell activating/inhibitory receptors and target cell 
ligands. NK cells form an immunological synapse with their target cells during this 
interaction. When the balance of signals is activatory (as described in section 1.2.2), 
intracellular signalling triggers mobilisation of calcium from the endoplasmic reticulum 
and actin cytoskeleton reorganisation, leading to granule polarisation at the 
immunological synapse. Finally, cytotoxic granules fuse with the NK cell plasma 
membrane and granule contents are exocytosed towards the target,  also known as 
degranulation (Stinchcombe and Griffiths, 2007).   During degranulation, proteins such 
as CD107a, which are normally present inside the cytotoxic granules, are externalised 
on the cell surface. This provides the basis of a useful assay for detecting degranulated 
NK cells (Alter et al., 2004).   
NK cell cytotoxic granules contain perforin and granzyme B. Perforin release triggers 
pore formation in the target cell membrane, in order to deliver granzyme directly into the 
target cytoplasm. When perforin deficient mice were generated, their NK cells and T cells 
could not lyse targets in vitro (Kagi et al., 1994), demonstrating that cytotoxic 
lymphocytes are completely reliant on perforin for granule dependent killing. Cytotoxic 
cells themselves are relatively resistant to the effects of perforin, in comparison to other 
cell types (Liu et al., 1989). The granzymes are serine proteases, capable of cleaving 
specific intracellular proteins. There are five types of granzyme known in humans: 
granzyme A, B, H, K and M (Trapani, 2001). Granzyme B induces apoptosis through 
cleavage of the pro-apoptotic protein Bid in the target cell cytosol (Sutton et al., 2000). It 
is the main granzyme used in granule dependent killing by NK cells and T cells. This was 
demonstrated in granzyme B deficient mice; NK cells from these animals lost the ability 
to rapidly kill targets in vitro, requiring dramatically longer incubation times (Heusel et al., 
1994). The fact that cytotoxic killing can still progress (although very slowly) in granzyme 
B deficient NK cells suggests that the other granzymes may partly contribute to granule 
dependent killing. Granzyme K and M have also been implicated in the processing of 
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cytokines and the cleavage of some target cell proteins required for viral replication 
(Voskoboinik et al., 2015). 
Alternatively, NK cells can induce target cell apoptosis through expression of death 
receptor ligands. These include TNF-related apoptosis-inducing ligand (TRAIL) and FAS 
ligand (FasL), which engage with TRAIL receptors and Fas on target cells, respectively. 
Engagement of death receptors on target cells recruits caspases, initiating apoptosis 
(Warren and Smyth, 1999). Studies in humans and mice have shown that immature NK 
cells preferentially use TRAIL dependent killing (Zamai et al., 1998) and TRAIL 
expression is lost as NK cells mature, although cytokine stimulation can upregulate its 
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Figure 1.2 Target killing mechanisms 
NK cells kill their targets through two distinct mechanisms: granule dependent or death 
ligand dependent killing. Granule dependent killing involves the release of cytotoxic 
granules from NK cells into targets to induce apoptosis, while death ligands on NK cells 
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1.2.4 NK cell classification and subsets 
Since the discovery of NK cells, several other types of innate lymphocyte like cells, also 
lacking somatically rearranged antigen receptors, have been described. A new category 
of innate lymphoid cells (ILCs) was proposed, to include both NK cells and this new set 
of cell types. A common feature of this family is the production of immune modulating 
cytokines; NK cells are classified as group 1 ILCs based on their capacity to produce 
interferon γ (IFN-γ), a crucial cytokine for immunity against intracellular pathogens. 
However, NK cells are the only cytotoxic ILCs (Cortez and Colonna, 2016).  
In humans, NK cells can be further divided into two main subtypes, which differ in their 
ability to produce IFN-γ.  These distinct populations are categorised by their levels of cell 
surface CD56.  CD56dim NK cells express lower levels of this marker and are able to lyse 
target cells more effectively, whereas CD56bright cells are more efficient cytokine 
producers (Jacobs et al., 2001) (Cooper et al., 2001). CD56dim NK cells also express 
higher levels of CD16 (Cooper et al., 2001), the activating receptor responsible for 
ADCC. CD56bright NK cells are abundant in the lymph nodes (Fehniger et al., 2003), 
where they can receive signals from antigen presenting cells (APCs), and release 
cytokines to signal to other immune cell types. Therefore, they can participate in crosstalk 
between different cell types, helping to drive the innate and adaptive immune response. 
In peripheral blood, CD56dim cells make up the majority of the population (Cooper et al., 
2001). Thought to be the effector subtype, it has been suggested that CD56dim NK cells 
differentiate from CD56bright NK cells, with maturation occurring in the periphery (Chan et 
al., 2007).  
Mouse NK cells do not express CD56, however similar subsets do exist in mice. 
CD27highCD11bdull are immature mouse NK cells, analogous to CD56bright human NK 
cells, while CD11bhigh CD27dull are the most mature subset, displaying stronger effector 
functions (Gregoire et al., 2007). One study demonstrated similarities between human 
CD56bright NK cells and CXCR3+CD27bright cells in mice, and proposed this subset of 
CD27+ NK cells as the mouse equivalent (Marquardt et al., 2010). On the other hand, a 
recent transcriptomic study showed that human CD56bright NK cells expressed a strikingly 
similar gene expression signature to mouse CD127+ innate lymphoid cells (Allan et al., 
2017). Therefore, in order to specifically study CD56dim and CD56bright NK cells, human 
samples are required.  
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1.2.5 Tumour Killing 
There is a growing interest in the immune response against tumours, with recent 
approvals of a number of cancer immunotherapies. NK cells, like cytotoxic T cells, are 
known to participate in tumour immunosurveillance, eliminating transformed cells that 
may form tumours. The evidence for this comes from in vivo models in which NK cells 
were selectively depleted. Treatment with specific anti-NK cell antibodies is one strategy, 
although selection of appropriate antibodies that do not deplete other cell types is crucial. 
Treatment with anti-asialo-GM1 successfully depleted NK cells but not NKT cells (which 
display similar markers) in mice, and as a result increased susceptibility to 
methylcholanthrene induced sarcomas (Smyth et al., 2001). In another approach, 
depletion of NK cells in a transgenic mouse model resulted in a higher number of lung 
metastases following tumour cell injection (Kim, S. et al., 2000). NKG2D may be 
particularly important for innate anti-tumour immunity, as ligands for this receptor are 
expressed on a number of different tumour cell lines (Pende et al., 2002) and on freshly 
isolated tumours (Groh et al., 1999). Furthermore, mice lacking NKG2D are more prone 
to spontaneous tumour growth (Guerra et al., 2008). Human studies also offer strong 
evidence for NK cell immunosurveillance. In an eleven year follow up study of a 
Japanese general population, higher natural cytotoxicity levels at baseline (tested by 
measuring peripheral blood cell mediated killing of K562 cells, the prototypical NK cell 
target line) was associated with reduced cancer risk (Imai et al., 2000).  
Although activating receptor ligands may be upregulated during transformation, 
developed tumours can evade the immune system in many ways. For example, tumours 
may release immunosuppressive cytokines to dampen down the immune response, or 
the cancer may develop ‘immune privilege’ by expressing FasL, inducing apoptosis in 
cytotoxic lymphocytes (OConnell et al., 1996). Some cancers may even cause 
downregulation of activating receptors at the NK cell surface. Transforming Growth 
Factor β (TGF-β) is an immunosuppressive cytokine implicated in NK cell inhibition by 
tumours. Ex vivo exposure to a number of different cancer cell lines triggered the 
downregulation of NK cell activating receptors at the cell surface and reduced expression 
of cytotoxic molecules, in a TGF-β dependent manner (Wilson et al., 2011).  
The combination of immune evasion strategies employed by many cancers creates an 
immunosuppressive tumour microenvironment, which effectively protects the tumour 
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from natural killing. Indeed, immune evasion is now recognised as a hallmark of cancer 
(Hanahan and Weinberg, 2011). Recent immunotherapy strategies aim to re-activate the 
cytotoxic lymphocytes of the patient, or to release these cells from the 
immunosuppressive block created by the tumour. 
 
1.2.6 Anti-viral Response 
The other key role of NK cells is in the control of viral infections. NK cell activity is thought 
to be crucial during the first few days of a viral infection, when the adaptive immune 
response is still developing. NK cells can recognise markers on the surface of a target 
cell, which are indicative of viral infection. This is co-ordinated through activating and 
inhibitory receptors, similar to tumour cell recognition. As discussed in section 1.2.2, the 
activating natural cytotoxicity receptors (NCRs) are thought to bind certain viral ligands 
including haemagglutinin (HA) and haemagglutinin–neuraminidase (HN), presented on 
infected cells. Furthermore, virally infected cells display additional signs of stress on the 
surface, such as downregulation of MHC class I due to viral interference with MHC 
presentation. The adenovirus E19 protein is one example; E19 interference with MHC 
class I processing was some of the first evidence for this viral immune evasion strategy 
(Andersson et al., 1985). Other viral proteins that interfere with MHC processing are 
commonly found in the herpesviruses. Human cytomegalovirus (HCMV) is a herpesvirus 
with a particularly large genome, encoding numerous proteins capable of downregulating 
MHC class I expression: US2, US3, US6 and US11 (Roder et al., 2008). MHC class I 
downregulation on HCMV infected cells should increase susceptibility to NK cell killing 
and, indeed, NK cells are crucial for defence against herpesviruses. Early studies to 
support this include depletion of NK cells in mice using the anti-asialo GM1 antibody, 
which increased susceptibility to herpes simplex virus (HSV) (Habu et al., 1984) and to 
murine CMV (MCMV) (Bukowski et al., 1983). In fact, the latter study found that NK cell 
depletion increased susceptibility to disease in a range of murine viral infections, except 
for lymphocytic choriomeningitis virus (LCMV). Therefore, NK cell contribution to the anti-
viral immune response may vary across species of virus.  
In humans, immune deficiencies observed in the clinic emphasise the importance of NK 
cells in the control of viral infections. In the first case reported, a patient with a specific 
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NK cell deficiency had a severe susceptibility to herpesvirus infections (Biron et al., 
1989). Subsequent studies have identified numerous types of human NK cell deficiencies 
(either lacking NK cells or possessing functionally deficient NK cells) with a common 
feature being susceptibility to herpesviruses and papillomavirus infections, and virus 
driven cancers (Orange, 2013). 
Cytokine release during a viral infection is a powerful activating stimulus for NK cells. 
Type I interferons (IFN-I) can be produced by most (if not all) cell types, especially by 
antigen presenting cells, as a response to viral infection. Viral detection by toll like 
receptors (TLRs) in the endosome or retinoic acid-inducible gene 1 (RIG-I) activation in 
the cytosol leads to IFN-I production, shown in Figure 1.3. The ability of IFN-I to 
upregulate NK cell cytotoxicity was discovered over four decades ago (Santoli et al., 
1978), but the precise mechanism of gene induction and the contribution of other 
cytokines are not well understood. IFN-I includes IFN-α, of which there are 13 types 
(encoded by 13 genes) , and IFN-β (encoded by a single gene) (Honda et al., 2006). 
IFN-I signals through the Janus kinase and Signal transducer and activator of 
transcription (JAK/STAT) family of signalling pathways; the basic pathway is shown in 
Figure 1.4.  
The IFN-I receptor, also known as the IFNαβ receptor, consists of the IFNAR1 and 
IFNAR2 subunits. Binding of IFN-I to either IFNAR1 or IFNAR2 recruits the second 
subunit and triggers the signalling cascade. JAK family kinases phosphorylate each other 
and phosphorylate the receptor, which induces the recruitment, phosphorylation and 
dimerisation of STAT1 and STAT2 molecules. The STAT heterodimer subsequently 
binds Interferon regulatory factor 9 (IRF9) to form the interferon stimulated gene factor 3 
(ISGF3) transcription factor complex (Platanias, 2005). A consensus DNA sequence 
known as the interferon stimulated response element (ISRE) is able to bind ISGF3 
(Platanias, 2005), providing a direct pathway from interferon binding to gene induction in 
the same cell. The other major type of interferon that acts during viral infection is IFN-γ, 
but this is a type II interferon and therefore acts through the separate IFN-II receptor, 
using slightly different JAK and STAT pathway components. IFN-γ predominantly 
activates a homodimer of STAT1, forming a transcription factor that binds to the gamma 
interferon activation site (GAS) consensus sequence, rather than ISRE (Schneider et al., 
2014). Interferon stimulated genes often contain both ISRE and GAS sequences in their 
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promoter regions, but some genes are regulated by only one or the other. Consequently, 
IFN-I and IFN-II induce different transcriptional responses with many overlapping genes, 
as shown in microarray studies (Der et al., 1998). 
Interferon stimulated gene (ISG) expression in virally infected cells is essential for 
restricting viral replication. ISG encoded proteins have a wide array of functions, 
including shutting down protein translation (achieved by protein kinase R (PKR)), acting 
directly on viral particles (such as the Myxovirus resistance (Mx) proteins) and 
potentiating the IFN response (components of IFN signalling such as STAT1) (Schneider 
et al., 2014). In addition, IFN-I acts upon immune cells to promote anti-viral responses, 
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Figure 1.3 Type I Interferon (IFN-I) induction by viruses 
When a virus gains entry to a host cell, its genome may be exposed to molecular sensors 
inside the cell. Intracellular toll like receptors (TLRs), positioned on the endosome 
membrane, are able to recognise the RNA or DNA of viruses which have been 
endocytosed into the cell. The retinoic acid-inducible gene 1 (RIG-I) like helicases, 
including RIG-I and melanoma differentiation-associated 5 (MDA5) are able to sense 
uncapped 5′-triphosphate RNA or cytoplasmic double stranded RNA (dsRNA) from 
replicating viruses. Sensing of viral RNA or DNA activates downstream signalling 
pathways, leading to the expression of IFN-I such as interferon α (IFNα) and interferon 
β (IFNβ). Adapted from (Heim, 2012). 
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Figure 1.4 JAK/STAT signalling 
The canonical Janus kinase and Signal transducer and activator of transcription 
(JAK/STAT) pathway, and the specific molecules involved in type I interferon signalling. 
JAK molecules associated with the cytokine receptor are activated to phosphorylate the 
receptor when bound to ligand.  The receptor then phosphorylates the relevant Signal 
Transducer and Activator of Transcription (STAT) molecules, which are recruited through 
their Src homology-2 (SH2) domains. Phosphorylation induces STAT dimerisation and 
translocation to the nucleus, where modulation of gene expression occurs. In the case 
of IFN-I, the activated receptor primarily phosphorylates STAT1 and STAT2, leading to 
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 Regulation by additional cytokines 
IFN-I is a crucial anti-viral cytokine, but additional cytokines also play a role in the NK 
cell response against viruses. Murine models of viral infection have proven to be useful 
tools in this field of research. Using a murine model of CMV (MCMV) infection, Nguyen 
et al., (2002) argued that anti-viral response functions in NK cells, including target cell 
killing and the release of interferon γ (IFN-γ), are actually separately regulated by 
different cytokines (Nguyen, K.B. et al., 2002a). They showed that NK effector functions 
are regulated by independent JAK/STAT pathways; cytotoxicity via the IFN-I receptor/ 
STAT1 pathway, and IFN-γ release via the interleukin 12 (IL-12) receptor and STAT4.   
Additionally, the importance of another cytokine, interleukin 15 (IL-15), was 
demonstrated in the regulation of NK cells during viral infection. IL-15 signals primarily 
through STAT5 and also through non JAK/STAT pathways including phosphoinositide 
3-kinase (PI3K) signalling (Mishra et al., 2014). Experiments using neutralising 
antibodies showed that IL-15 was required for NK cell proliferation and survival during 
infection, but not involved in NK cell cytotoxicity or IFN-γ induction (Nguyen, K.B. et al., 
2002a). However, this finding is not consistent with what others have observed. In 
another MCMV infection model, Baranek et al., (2012) showed that IL-15 was in fact 
necessary for activation of NK cell cytotoxicity. In their IL-15 neutralisation model, there 
was a reduction in the number of NK cells positive for granzyme B, a serine protease 
required for cytotoxic activity (Baranek et al., 2012). They also showed that many NK cell 
genes upregulated during viral infection did not contain interferon response elements, 
but did contain response elements for IL-15 activated transcription factors, suggesting a 
more important role for IL-15 in the activation of NK cells. Despite differences, the studies 
of Nguyen et al (2002) and Baranek et al (2012) do agree that IL-15 is upregulated in an 
IFN dependent manner during viral infection.  
In another contrasting viral infection model, the direct action of IFN-I on NK cells was 
sufficient for NK cell activation in response to vaccinia virus in vivo (Martinez et al., 2008). 
It is unclear whether the differences in reported mechanisms are due to the type of virus, 
or can be explained by the experimental model used. It could be the case that different 
viruses trigger varying combinations of cytokines in the host, due to differences in viral 
structures. For example, DNA viruses and RNA viruses are detected via different 
mechanisms (figure 1.3). Figure 1.5 summarises the main cytokines thought to be 
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involved in virus induced NK cell activation. However, the inconsistencies in the literature 
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Figure 1.5 Cytokines involved in NK cell activation 
The cytokines interleukin 12 (IL-12), interleukin 15 (IL-15) and type I interferon (IFN-I) 
are able to activate NK cell effector functions. Exactly how they function during a viral 
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1.2.7 Migration 
NK cells are widely distributed throughout the body, in the blood, lymphoid tissues and 
other organs. Mouse studies have demonstrated the presence of NK cells in a wide 
range of tissues, with the highest proportions found in the lungs, liver and peripheral 
blood (Gregoire et al., 2007). Therefore NK cells are well adapted for immune 
surveillance. However, during an acute viral infection, rapid recruitment of NK cells to 
the affected area may be necessary. One mechanism for NK cell recruitment is the 
release of chemokines from infected tissues, triggering chemotaxis of NK cells.  
In the MCMV model, macrophage inflammatory protein 1 alpha (MIP-1alpha, also known 
as CCL3) is critical for recruitment of NK cells to infected liver (Salazar-Mather et al., 
1998), as is monocyte chemoattractant protein-1 (MCP-1/ CCL2), interacting with the 
chemokine receptor CCR2 (Hokeness et al., 2005). Another cytokine receptor, CCR1, 
has also been implicated in NK cell recruitment to the inflamed liver, in a model of 
hepatitis (Gregoire et al., 2007). Recruitment of NK cells to lymph nodes has also been 
demonstrated in mice, following injection of mature dendritic cells (simulating 
inflammatory events). This was dependent on expression of the chemokine receptor 
CXCR3 (Martin-Fontecha et al., 2004). Chemotaxis mechanisms are also likely 
responsible for NK cell recruitment to tumour sites. In mice, NK cells can migrate towards 
implanted tumours, in a CX3CR1 dependent manner (Gregoire et al., 2007). 
Much less is known about the migration of human NK cells. Studies comparing the 
CD56dim and CD56bright NK subsets have revealed differences in migratory receptor 
expression. Expression of CD62L (L-selectin) on leukocytes is required for binding and 
rolling on endothelial cells, a process crucial for recruitment into lymph nodes (Arbones 
et al., 1994), and this molecule is expressed selectively on the CD56bright subset (Frey et 
al., 1998). Furthermore, CD56bright NK cells express much higher levels of CCR7 than 
the CD56dim subset (Campbell et al., 2001; Berahovich et al., 2006); CCR7 is a 
chemokine receptor usually expressed on lymphocytes homing to the lymph nodes. This 
is also a key difference between human and mouse NK cells, which do not express CCR7 
(Gregoire et al., 2007). The selective expression of key lymph node homing receptors on 
CD56bright NK cells explains why it is the dominant NK cell subset in human lymph nodes. 
Figure 1.6 summarises the important functional differences between the two human NK 
cell subsets.  
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Finally, another important system controlling lymph node trafficking is the gradient of 
sphingosine-1-phosphate (S1P) between lymph node and blood. S1P concentrations are 
much higher in the blood, so lymphocyte expression of the receptors for S1P are crucial 
for lymph node egress (Matloubian et al., 2004; Walzer et al., 2007). Changes in 




Figure 1.6 Functional differences between CD56dim and CD56bright NK cells 
Although CD56bright NK cells are less efficient killers, this subset displays high expression 
of lymph node homing receptors and strong capability for cytokine production. CD56dim 
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1.2.8 Proliferation 
Research into NK cell proliferation began by defining the signals required for NK cell 
division in vitro. These studies agreed that interleukin 2 (IL-2) was the most potent 
inducer of NK cell proliferation (Robertson et al., 1993; Ythier et al., 1985), and that 
mitogenic signals delivered by IL-2 could be enhanced by co-culture with target cell lines 
such as K562, the prototypical NK-susceptible cell line (Ythier et al., 1985; Baume et al., 
1992). However, mice deficient in IL-2 have a normal complement of NK cells (Kundig et 
al., 1993) and this suggested that a distinct cytokine regulated NK cell development and 
proliferation in vivo. 
Later, IL-15 was identified as an inducer of NK cell proliferation (Carson et al., 1994). 
The receptors for IL-2 and IL-15 share 2 out of 3 subunits: common γ chain (also shared 
with a number of other cytokine receptors), as well as the β subunit. As expected, IL-2 
and IL-15 consequently share downstream signalling pathways, including STAT5 
activation and phosphoinositide 3-kinase (PI3K) signalling, which promote survival and 
proliferation (Waldmann, 2015). A third subunit, the α chain, is unique to each cytokine. 
IL-2Rα (CD25) is expressed on activated T cells, and on the CD56bright NK cell subset. 
When IL-2Rα is associated with the γ and β subunits, the high affinity IL-2 receptor is 
formed, allowing CD56bright NK cells to respond to picomolar concentrations of IL-2 
(Cooper et al., 2001). IL-15Rα is thought to function differently; it binds to IL-15 and 
presents the cytokine on the surface of monocytes or dendritic cells, where NK cells can 
interact through IL-15Rβγ, in a process termed IL-15 trans presentation (Burkett et al., 
2004). In vivo, IL-15 promotes homeostatic proliferation of NK cells (Burkett et al., 2004), 
as well as NK cell differentiation from HSCs in a humanised mouse model (Huntington 
et al., 2009).  
In some cases, expansion of NK cells has been reported during infection. In the mouse 
MCMV model, there is a characteristic expansion of NK cells which follows two phases 
of proliferation: the first is dependent on cytokines, while the later phase is dependent on 
a specific interaction between the MCMV glycoprotein m157 (expressed on the surface 
of infected cells) and the mouse NK cell activatory receptor Ly49H (Dokun et al., 2001). 
In this model, Ly49H+ NK cells expand and persist in infected mice, providing a “memory 
pool” of NK cells. Following this discovery, it was initially unclear whether “memory” NK 
cells were unique to MCMV infection. Interestingly, evidence of NK cell memory like 
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behaviour has been observed in human HCMV infection, with expansion of 
CD94/NKG2C+ NK cells detected in response to co-culture with HCMV infected 
fibroblasts (Guma et al., 2006) and expansion of this subset observed in CMV(+) donors 
(Lopez-Verges et al., 2011).  
In humans, controlled studies of NK cell proliferation during infection are generally not 
possible, but clinical case studies offer some insight. In the case of hantavirus, infected 
patients experience NK cell expansion in the blood, which has been linked to expression 
of IL-15 and IL-15Rα on infected endothelial cells, with the IL-15 trans presented to NK 
cells (Bjorkstrom et al., 2011; Braun et al., 2014).  
Vaccination studies are also valuable sources of human in vivo data. In individuals 
vaccinated with heat-inactivated rabies virus, ex vivo re-stimulation of their PBMC with 
rabies virus induced high levels of NK cell proliferation. The proliferative response was 
not observed in pre-vaccination PBMC, suggesting that NK cell proliferation may occur 
during the recall response – the authors suggest that NK cells proliferate in response to 
effector T cell derived IL-2 (Horowitz et al., 2010). Overall, there have been a number of 
diverse mechanisms proposed for infection induced NK cell proliferation, which might be 
determined by the type of virus or infection model. However, the mechanisms controlling 
NK cell proliferation are not well defined. 
 
1.2.9 Markers of NK cell activation 
When examining NK cell responses to various stimuli, the use of an activation marker, 
detectable by flow cytometry, can be a convenient and quick way to assay NK cell 
activation. CD69 is a transmembrane protein, used widely as a lymphocyte activation 
marker ever since it was linked to early activation of T cells (Ziegler et al., 1994). NK 
cells upregulate CD69 when exposed to activating cytokines in vitro, and high CD69 
expression predicts increased NK cell cytotoxicity (Clausen et al., 2003). CD69 is also 
highly expressed on tissue resident memory T cells (Cibrian and Sanchez-Madrid, 2017). 
Furthermore, CD69 expression by B cells and T cells is known to inactivate the S1P 
receptor, thereby preventing lymph node egress (Shiow et al., 2006), implying that CD69 
may function as a regulator of lymphocyte trafficking.  
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1.3 Oncolytic Viruses 
1.3.1 Replication in cancer cells 
Oncolytic viruses (OVs) are viruses which preferentially replicate in cancer cells 
compared to healthy human cells. A link between viral infection and tumour regression 
was observed more than 100 years ago, but initial trials of pathogenic viruses were often 
risky for the patients (Kelly and Russell, 2007). Recent developments, both in the 
identification of new viruses and engineering of existing ones, have reduced those risks 
and enhanced the efficacy of OVs.  
Many cancer cell types are more susceptible to viral infection than non-transformed cells. 
Several mechanisms have been proposed to explain this. Firstly, selective entry of OVs 
into tumour cells can occur due to upregulated expression of viral entry receptors; for 
example oncolytic Coxsackie virus preferentially infects cells with high intracellular 
adhesion molecule 1 (ICAM) expression (Au et al., 2007). Secondly, cancer cells have 
high metabolic activity and hence larger pools of nucleotides and amino acids, which 
may enhance viral replication. Common cancer mutations can also enhance 
susceptibility to OVs, for example constitutive Ras activation increases replication of 
reovirus (Strong et al., 1998). A recent study demonstrated that phosphatase and tensin 
homolog (PTEN) depletion inhibited host cell interferon production in response to viral 
infection (Li et al., 2016). PTEN is a frequently mutated tumour suppressor, so this finding 
may explain why so many cancers are vulnerable to viral infection. It is now generally 
accepted that the spectrum of genetic and biochemical changes observed in cancer cells 
makes them attractive targets for viral infection, not least because they frequently 
suppress interferon responses and the resultant cell intrinsic mechanisms of preventing 
viral infection (Chen et al., 2009). 
Additionally, many OVs are genetically engineered to increase selectivity for cancer cells 
over healthy cells. DNA viruses such as adenovirus are ideal for genetic manipulation 
strategies. One of the first was an adenovirus with a mutated E1B region, which was 
unable to produce the viral E1B 55K protein. In the wild type adenovirus, this protein 
binds to and inactivates host cell p53, allowing viral replication. The mutated adenovirus 
(which was named ONYX-015 later in clinical development) showed selectivity for cancer 
cells with deficient p53 (Bischoff et al., 1996). Alternatively, oncolytic adenoviruses have 
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been engineered to express “tumour directing antigens”; peptides expressed within viral 
surface proteins that are specific for receptors overexpressed in cancers. For example, 
the epithelial integrin αvβ6 is often overexpressed in carcinoma, so an adenovirus 
expressing an αvβ6-selective peptide in its outer structure was engineered. The 
retargeted virus showed enhanced uptake into carcinoma tumours in vitro and in vivo 
(Coughlan et al., 2009). 
An initial focus of OV research was on the mechanism of direct tumour cell lysis. Host 
tumour cells can be killed through lytic viral replication, or even toxicity from viral proteins 
(Kuruppu and Tanabe, 2005), and numerous in vitro studies demonstrated virus induced 
killing of cancer cell lines but not non-transformed cells. In early studies, successful 
delivery of OVs and subsequent tumour regression was shown in immune deficient mice 
engrafted with human tumours (known as xenograft models) (Fueyo et al., 2000; Walker 
et al., 1999). These earlier studies generally did not consider the contribution of the 
immune system, and used nude mice lacking T cells. Even in these models, the response 
of NK cells and other immune cells cannot be ruled out as a contributing mechanism to 
tumour regression, other than direct lytic viral replication.  
Initially the immune response was seen as a barrier to effective therapy, as a specific 
anti-viral immune response can trigger clearance of the virus before it reaches the 
tumour. This is especially problematic for systemic delivery of OVs.  Strategies to shield 
oncolytic viruses from this initial anti-viral response have been encouraging.  In the case 
of oncolytic measles virus (MV), loading of virus onto bone marrow-derived 
mesenchymal stromal cells (BM-MSCs) ex vivo enabled the successful delivery of MV 
to acute lymphoblastic leukemia (ALL) targets in a xenograft mouse model (Castleton et 
al., 2014). Enhanced delivery of virus was observed despite the presence of injected 
anti-MV antibodies. 
During a clinical trial of reovirus, intravenous delivery of the virus to tumour tissue was 
demonstrated despite the presence of neutralising antibodies from previous natural 
exposure, and virus was detected within blood immune cells, suggesting cellular carriage 
of the virus (Adair et al., 2012). These approaches increase the chance of the OV 
reaching the tumour to replicate there. Once viral replication is taking place, ideally the 
patient immune response can be directed against the tumour rather than solely against 
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the virus. More recently, OV research has changed focus towards the immune response, 
as increasing numbers of studies support the use of OVs as immunotherapies. 
 
1.3.2 Immune activation 
Given that many viruses are efficient activators of NK cells and other immune cells during 
an infection, it is not surprising that OVs stimulate immune responses. Interest in the 
immunotherapeutic potential of OVs increased when several preclinical studies 
highlighted the beneficial role of the host immune system during OV therapy. In one 
study, treatment with vesicular stomatitis virus enhanced the survival of tumour bearing 
mice, and actually required both NK cells and CD8 T cells for this effect (Diaz et al., 
2007).  
Specific anti-tumour immunity was also observed following intratumoural oncolytic 
herpes simplex virus (HSV) treatment in a neuroblastoma model (Li, H. et al., 2007) and 
in a mouse breast tumour model (Li, H.T. et al., 2007), which was enhanced by multiple 
doses of virus. Intratumoural OV injection even resulted in growth inhibition of secondary 
implanted tumours, which were not exposed to virus. This secondary effect was only 
observed in immune competent mice, and not in nude mice (which lack T cells), so the 
adaptive immune response was crucial (Li, H.T. et al., 2007).  
In a mouse model of melanoma metastases, priming of anti-tumour immunity was 
demonstrated after intravenous delivery of another OV, reovirus (Prestwich et al., 2008). 
In particular, dendritic cell (DC) maturation was demonstrated following OV infection of 
cancer cell lines; this is important as activated mature DCs are thought to cross present 
tumour antigens to prime the adaptive immune response. Many of these studies used 
whole splenocytes from treated mice, in order to study cytotoxic T cells. However, NK 
cells are also likely to play an important role; in fact cytotoxic killing measured within 
whole splenocytes would probably include killing mediated by NK cells.   
In 2015 a milestone was reached, as the first OV was approved for treatment by the US 
Food and Drug Administration (FDA) in the United States. Named talimogene 
laherparepvec (T-VEC), it is a modified herpes simplex virus type 1 (HSV-1) expressing 
granulocyte–macrophage colony stimulating factor (GM-CSF). The inclusion of the GM-
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CSF gene, encoding a cytokine that promotes immune cell infiltration, demonstrates the 
importance of immune stimulation in the context of OV therapy. 
 
1.4 Reovirus 
Mammalian orthoreovirus (referred to as reovirus) is a non-enveloped, double stranded 
RNA (dsRNA) virus in the Reoviridae family, which infects mammals, including humans. 
In fact, most of us have been exposed to this virus during childhood (as evidenced by 
the widespread occurrence of neutralising antibodies). The reovirus structure is 
illustrated in Figure 1.7. Its genome is composed of 10 separate dsRNA segments, 
termed either large (L), medium (M), or small (S), according to size of the strands. The 
proteins encoded on these segments are labelled either lambda (λ), mu (μ) or sigma (σ) 
respectively (Danthi et al., 2013). Reovirus proteins form two concentric shells, the outer 
capsid and core. The outer capsid contains the attachment protein σ1, which binds 
junctional adhesion molecule-A (JAM-A) on host cell membranes (Barton et al., 2001). 
Other reovirus proteins facilitate internalisation of the virus by endocytosis and 
penetration of the endosome membrane to release disassembled virus into the 
cytoplasm, and the core contains RNA dependent RNA polymerase (protein λ3), for 
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Figure 1.7 Reovirus structure 
Diagram showing the structure of mammalian reovirus. The dsRNA genome is 
segmented, with 3 large (L) strands, 3 medium (M) strands and 4 small (S) strands. Key 
reovirus proteins are shown, making up two concentric shells, the outer capsid and core. 
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1.4.1 Cancer cell selectivity  
Reovirus is not a significant human pathogen. In 1977, Hashiro et al. discovered that 
reovirus could replicate in a number of transformed mammalian cell lines, but not in 
normal human cells (Hashiro et al., 1977). Since this important discovery, reovirus 
specificity for cancer cells has been exploited for the development of OV therapy. The 
type 3 Dearing strain of reovirus was selected to develop as a therapeutic (Reolysin). 
Unlike many oncolytic viruses, which are genetically engineered to selectively replicate 
in cancer cells, reovirus is naturally oncolytic. This is a great advantage in terms of cost 
and safety. 
 
What is the basis for the cancer cell selectivity of reovirus? There is strong evidence that 
host cell activation of the Ras signalling pathway enhances the production of reovirus 
(Strong et al., 1998), specifically constitutive activation of RalGEF and p38 (Norman et 
al., 2004), downstream of Ras. In those studies, cell lines were artificially transformed 
with constitutively active forms of Ras pathway genes, which led to increased reovirus 
protein production. Based on this data, many speculated that Ras transformation in 
human cancers was the reason for the oncolytic properties of reovirus. In more recent 
studies, others have demonstrated that Ras pathway activation in cancer cell lines does 
not correlate with reovirus induced killing (Twigger et al., 2012). It is likely that reovirus 
oncolysis is not solely dependent on Ras transformation, and may be explained by a 
number of contributing mechanisms. One study showed that cell cycle phase influenced 
the selectivity of reovirus, as host cells induced to accumulate in S phase were more 
sensitive to reovirus mediated killing (Heinemann et al., 2010). Therefore, rapidly cycling 
cancer cells may be more vulnerable to reovirus infection. Other mechanisms may 
include the more general downregulation of anti-viral defence machinery observed in 
many cancers, as discussed in section 1.3.1.   
 
1.4.2 Clinical trials  
To date, there have been a number of phase I and phase II clinical trials of reovirus, 
recruiting patients with many different types of solid tumours. In these trials, reovirus was 
well tolerated, and maximum tolerated doses were not reached in most cases (Gong et 
al., 2016). The most common adverse effects were flu like toxicities, which is not 
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surprising given the high doses of replicating virus. Phase I trials have tested both 
intratumoural and intravenous delivery of reovirus, with most phase II trials continuing 
with intravenous delivery (which is more amenable to the clinic than intratumoral 
injection).  
 
Currently, there has been one phase III trial of reovirus, to test the efficacy of intravenous 
reovirus for the treatment of advanced head and neck cancer. This was a randomised, 
double-arm, double-blinded trial of reovirus in combination with the chemotherapy 
agents paclitaxel and carboplatin. Oncolytics Biotech, the developer of Reolysin, 
reported a higher median progression-free survival in the reovirus test group compared 
with the placebo group, in preliminary data from 2013 (Gong et al., 2016).  
 
1.4.3 NK cell activation 
A number of studies have demonstrated reovirus induced activation of NK cells, both in 
vitro and in vivo. In cell culture, the virus can activate DCs through soluble factors. ‘Reo 
activated’ DCs can activate NK cells in vitro, as might be the case in patient lymph nodes 
(Errington et al., 2008). Further studies have shown that NK cells can be activated 
directly by the conditioned media from reovirus infected tumour cells (Steele et al., 2011) 
and also by monocytes in peripheral blood when exposed to reovirus (Parrish et al., 
2015). This suggests that NK cells may be activated both systemically and at the local 
tumour site in patients. A recent study showed that reovirus was effective as a combined 
anti-tumour and anti-viral therapy, against HCV and liver cancer (Samson et al., 2016). 
Interestingly, UV inactivated virus was able to inhibit tumour growth and activate NK cells 
just as well as replication competent virus, indicating that direct lysis of tumour cells was 
probably not important in this model - instead recognition of virus by the immune system 
was sufficient (for example by detection of the dsRNA genome). The activation of NK 
cells has also been studied in patients, receiving intravenous infusions of reovirus during 
a clinical trial. Following viral treatment, a number of interferon induced genes and 
activatory markers were upregulated on peripheral blood NK cells from these patients 
(El-Sherbiny et al., 2015).  Blocking IFN-I in vitro completely inhibited reovirus induced 
cytotoxic granule release in peripheral blood NK cells (Parrish et al., 2015). The evidence 
suggests that, at least in peripheral blood, NK response to reovirus is dependent on the 
release of IFN-I, as is the case in natural viral infections. In order to improve on this 
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treatment, it will be important to understand the molecular mechanisms of OV induced 
immune activation in more detail. 
1.5 Aims of the PhD project 
Reovirus is an oncolytic virus (OV) which shows evidence of anti-tumour immunity 
induction in several in vitro and in vivo studies, particularly with the involvement of NK 
cells. Reovirus therapy is likely to activate NK cells by the release of cytokines, triggering 
activation of a number of signalling pathways that lead to upregulation of NK cell effector 
functions.  
The broad aim of this project was to increase our understanding of NK cell activation in 
the context of viral infection, as there is conflicting evidence in the literature concerning 
the role of different cytokines and signalling pathways. The work focuses specifically on 
reovirus, as there is a need to better understand the molecular mechanisms that drive 
the induction of anti-tumour immunity seen in pre-clinical trials with this OV.  
I have used an in vitro model of reovirus treatment, to study the response of human NK 
cells, and in particular the two major subsets, CD56dim and CD56bright NK cells. The main 
aims were: 
• To define the reovirus induced mechanism of NK cell activation through IFN-I, 
and the signalling events leading to activation. In particular, to test the 
hypothesis that reovirus triggers NK cell activation directly through the IFN-I 
receptor. 
• To determine the wider effects of reovirus treatment on human NK cells, by 
performing a gene expression screen. Studies to date have focussed largely on 
granule dependent cytotoxicity mechanisms. I hypothesised that other NK cell 
functions will be enhanced by viral therapy, such as proliferation and migration, 
which are altered during some viral infections. 
• To further investigate NK cell pathways highlighted by the gene expression 
screen, and to determine the consequences of pathway activation on NK cell 
function.   
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A better knowledge of the cytokines and pathways involved should lead to improvements 
in OV therapy, for example it may inform the choice to combine OV treatment with other 
immunotherapies. 
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Chapter 2. Materials and Methods 
2.1 Cells 
2.1.1 Isolation of peripheral blood mononuclear cells (PBMC) 
Apheresis cones containing platelet depleted peripheral blood from healthy donors were 
obtained from NHS Blood and Transplant (Leeds) and separated by density gradient 
centrifugation on the day of donation. Briefly, donor blood was diluted with 50 ml of 
phosphate buffered saline (PBS), giving a final volume of 60 ml. Each 30 ml of eluate 
was carefully layered onto 15 ml of room temperature Lymphoprep (Axis-Shield) and 
centrifuged at 800 x g for 20 minutes, with no brake. Post-centrifugation the PBMC collect 
in a layer at the interface of the Lymphoprep and plasma as shown in Figure 2.1. This 
layer was collected using a 5 ml pastette and washed with PBS before centrifugation at 
200 x g for 15 minutes (brake on). The supernatant was discarded and the pelleted 
PBMC were pooled and washed again in 20 ml PBS before centrifugation at 300 x g for 
10 minutes. The supernatant was discarded and the pellet was resuspended in Roswell 
Park Memorial Institute medium (RPMI) 1640 (Sigma) + 10 % foetal calf serum (FCS) 
(Sigma) at a concentration of 2 x 106 cells/ml and cultured at 37 °C with 5 % CO2.  
 
Figure 2.1 Isolation of PBMC by density gradient centrifugation 
Left – blood layered over Lymphoprep pre-centrifugation. Right – Post centrifugation, 
PBMC collect in the interface of the plasma and Lymphoprep layers. 
- 52 - 
   
 Isolation of PBMC from patients with systemic lupus 
erythematosus (SLE) 
Ethical approval to collect blood samples after informed consent was obtained from 
the ethics committee at the Leeds Teaching Hospitals NHS Trust (REC number 
10/H1306/88). Blood was collected from consenting patients, and from consenting 
healthy donors, into EDTA treated tubes, to be processed the same day. PBMC were 
isolated as in section 2.1.1, except blood was diluted 1 in 2 with PBS in the first stage.  
2.1.2 Isolation of NK cells from PBMC 
NK cells were purified from whole PBMC, either on the day of donation or after culturing 
for the specified number of hours/days. NK cell isolation was performed by untouched, 
negative selection using a bead-based human NK cell isolation kit (Miltenyi), according 
to the manufacturer’s instructions. PBMC (isolated as in 2.1.1) were centrifuged at 
300 x g for 10 minutes at 4 °C and resuspended in MACS buffer (PBS with 0.5 % bovine 
serum albumin (BSA) and 2 mM EDTA) and biotin antibody cocktail (Miltenyi). ‘Non NK’ 
cells were labelled with the biotin conjugated antibodies. After incubating for 5 minutes 
at 4 °C, MACS buffer and anti-biotin magnetic beads (Miltenyi) were added to the cell 
suspension. After a further incubation of 10 minutes at 4 °C, the cell suspension was 
passed through an LS magnetic column in a strong magnetic field (Miltenyi). The column 
was flushed through with 9 ml of cold MACS buffer, to elute the non labelled cells. Eluted 
NK cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma), 
supplemented with 10 % human AB serum (Gemini Bio-Products) at 37 °C, 5 % CO2, 
unless otherwise specified. 
2.1.3 Cell lines 
The NK sensitive leukaemia cell line, K562, was cultured in RPMI 1640 medium (Sigma), 
supplemented with 10 % FCS, at 37 °C, 5 % CO2. Cells were subcultured according to 
ATCC guidelines.  
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2.2 Treatment of primary cells 
2.2.1 Reovirus treatment 
Commercial reovirus (Reolysin®) was provided by Oncolytics Inc. (Canada). Viral titre of 
reovirus stocks were determined by routine plaque assays performed by members of 
Prof Alan Melcher’s group. After culturing overnight, PBMC were seeded into cell culture 
plates (Corning) at 2 x 106 cells per ml (NK cells at 1 x 106 cells per ml) and reovirus was 
added at a multiplicity of infection (MOI) of 1 (unless otherwise stated). Plates were 
returned to standard cell culture conditions, as described in section 2.1. 
2.2.2 Cytokine treatment 
PBMC or NK cells were cultured overnight before seeding into plates (as above). 
Cytokines from Table 2.2 were added to the plate at the specified concentrations, then 
cells were returned to standard cell culture conditions (section 2.1). In chapter 3, human 
purified IFN-α from Sigma was used, however this product was discontinued so 
recombinant IFN-α from Miltenyi was used in chapter 5. IL-12 from R&D Systems was 
used in chapter 3, but IL-12 from Peprotech was used in chapter 5.  
Cytokine Source 
Human Interferon α (IFN-α) Sigma, purified from human leukocytes 
Human Interferon α2 Miltenyi, recombinant 
Human Interleukin 12 (IL-12) R&D systems, recombinant 
Human Interleukin 12 Peprotech, recombinant 
Human Interleukin 15 (IL-15) Miltenyi, recombinant 
Table 2.1 Details of cytokines 
 
2.2.3 Polyinosinic:polycytidylic acid (Poly(I:C)) treatment 
PBMC were seeded into a 12 well cell culture plate (Corning) at 2 x 106 cells per ml and 
transfected with 1 µg Poly(I:C) (high molecular weight, Invivogen) according to 
instructions in the Effectene transfection kit (Qiagen). Briefly, 1 µg Poly(I:C) was diluted 
with DNA-condensation buffer and incubated with Enhancer solution. Effectene 
transfection reagent was added to the Poly(I:C)–Enhancer solution to allow complexes 
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to form. Finally, growth medium (RPMI 1640 + 10% FCS) was mixed with the complexes 
and the mixture was added, drop wise, to cells in the plate. Mock treated cells were 
treated in exactly the same way, except PBS rather than Poly(I:C) was added.  
2.2.4 Type I interferon neutralisation 
To neutralise type I interferons during culture of PBMC or NK cells, a cocktail of 
antibodies, including a monoclonal mouse antibody and sheep serum polyclonal 
antibodies, was added at the start of the culture. As a control, mouse isotype control 
antibody plus heat inactivated sheep serum were used: 




Anti-human interferon α/β 
receptor chain 2 (mouse 
IgG2a). Clone MMHAR-2. 
PBL Assay 
Science 
0.5 mg/ml 2.5 % v/v 
Anti-human interferon α, 





1.5 % v/v 
Anti-human interferon β, 





1.5 % v/v 
Mouse IgG2a. BioLegend 0.5 mg/ml 2.5 % v/v 
Heat inactivated sheep 
serum 
Sigma  3 % v/v 
Table 2.2 Antibodies and controls for type I interferon neutralisation experiments 
 
2.2.5 IL-15 neutralisation 
For IL-15 neutralisation, an antibody against human IL-15 (R&D systems, clone 34593, 
mouse IgG1) was added at the start of the culture, at 1 µg/ml. As a control, 1 µg/ml of 
mouse IgG1 antibody (R&D systems, clone 11711) was used.  
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2.3 Flow cytometry 
For all flow cytometry experiments, staining buffer (PBS + 2 % FCS + 0.09 % sodium 
azide) was used for washing and staining steps. Cells were centrifuged at 300 x g for 5 
minutes, unless otherwise stated. For staining of NK cells within PBMC, antibodies 
against CD56 and CD3 were routinely added (for gating of CD3- CD56+ NK cells). To 
assess background staining levels for markers of interest, cells were stained with isotype 
matched control antibodies. Where % positive values are reported, a gate was set 
whereby 2 % of isotype control stained cells were positive. For multicolour experiments, 
single stain controls (using PBMC) were included, for compensation calculations. For a 
list of antibodies used in this thesis, see table 2.3. 
2.3.1 Surface staining 
Cells were collected into 5 ml polystyrene tubes (Falcon) and centrifuged, then washed 
with 2 ml of staining buffer. Samples were resuspended at 1 x 106 cells/100µl staining 
buffer, in a mixture of antibodies specific to the experiment and incubated for 15 minutes 
at room temperature, protected from light. Cells were washed once more in staining 
buffer and resuspended in staining buffer. For virus containing samples, cells were fixed 
in Cytofix fixation buffer (BD Biosciences) on ice for 15 minutes, before the final wash 
and resuspension. Samples were analysed by flow cytometry, either on an LSRII flow 
cytometer (BD Biosciences) or a Cytoflex cytometer (Beckman Coulter). 
2.3.2 Viability staining 
Cells were collected into 5 ml polystyrene tubes (Falcon), centrifuged and washed with 
PBS, then resuspended at 1 x 106 cells/100 µl, in PBS + 0.5 % v/v zombie NIR dye 
(BioLegend). Samples were incubated for 10 minutes at room temperature, protected 
from light, then cells were washed with staining buffer and finally surface stained (section 
2.3.1).  
2.3.3 Fluorescence activated cell sorting of NK cells into CD56dim 
and CD56bright subsets 
In this case, cells were centrifuged for 10 minutes for wash steps, rather than 5 minutes. 
NK cells were first magnetically isolated from cultured PBMC (section 2.1.2). Then, NK 
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cells were collected into 5 ml polypropylene tubes (Falcon) and resuspended at 1 x 107 
cells/ml, in staining buffer plus antibodies against CD3, CD56 and CD16. Samples were 
incubated at room temperature for 15 minutes, protected from light, then washed and 
resuspended in RPMI + 10 % FCS (at the same density). Stained NK cells were sorted 
into CD56dim CD16+ and CD56bright CD16- subsets using a BD Influx cell sorter (BD 
Biosciences). NK cells were collected into tubes containing RNAprotect reagent (Qiagen) 
for stabilisation of RNA, then stored at -20 °C until RNA extraction.  
2.3.4 CD107a degranulation assay 
PBMC were co-cultured with K562 cells in a 96 well, round bottomed cell culture plate 
(Corning), at a 10:1 effector:target ratio (1:1 NK:target assuming NK cells are 10 % of 
PBMC). After 1 hour of culture, GolgiStop (containing monensin, BD Biosciences) was 
added to each well at 1 in 1000, to prevent the internalisation of CD107a after 
degranulation. After a further 5 hours, cells were collected into 5ml polystyrene tubes 
(Falcon), centrifuged and washed with staining buffer. Samples were resuspended in 
staining buffer plus antibodies against CD3, CD56 and CD107a (or matched isotype 
control), and incubated at room temperature for 15 minutes. Cells were fixed in Cytofix 
fixation buffer (BD Biosciences) on ice for 15 minutes, then washed and resuspended in 
staining buffer. Staining was analysed on an LSRII flow cytometer (BD Biosciences).  
2.3.5 Intracellular phosphorylated protein staining 
After incubation with reovirus or cytokine for the specified time, cells were fixed in Cytofix 
fixation buffer (BD Biosciences). Briefly, Cytofix buffer was warmed to 37 °C and treated 
cells were harvested into 15 ml falcon tubes. An equal volume of Cytofix buffer was 
added to the cells, which were then incubated at 37 °C for 10 minutes. Fixed cells were 
centrifuged at 600 x g for 5 minutes and resuspended in 1 ml staining buffer. For time-
course experiments, fixed cells were stored at 4 °C and all cells within an experiment 
were stained at the same time. On the day of staining, cells were centrifuged at 600 x g 
for 5 minutes, and the remaining centrifugation steps were all at 600 x g. Samples were 
vortexed to disrupt the pellet and resuspended in 1 ml of ice cold Permeabilisation Buffer 
III (BD Biosciences, contains methanol), then permeabilised on ice for 30 minutes. This 
was followed by washing with staining buffer three times.  
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Cells were stained at 1 x 106 cells per 100 μl stain buffer with the appropriate antibodies, 
against phosphorylated proteins or isotype controls, for 1 hour at room temperature, 
protected from light. Antibodies against CD3 and CD56 were added together with 
phosphoprotein antibodies. Finally, cells were washed in stain buffer twice more, then 
resuspended in staining buffer. Samples were analysed on an LSRII flow cytometer (BD 
Biosciences) or a Cytoflex cytometer (Beckman Coulter). 
2.3.6 Intracellular staining for Ki67 and PCNA 
Cells were fixed, permeabilised and stained as in section, 2.3.5, except cells were 
stained for 30 minutes.  Antibodies against CD3 and CD56 were added together with 
Ki67 or PCNA antibodies.  
2.3.7 Intracellular staining for Granzyme B (saponin method) 
Cells were collected into 5 ml polystyrene tubes (Falcon) and surface stained, as in 
section 2.3.1. Following this, samples were washed with 2 ml staining buffer and fixed in 
Cytofix fixation buffer (BD Biosciences) for 15 minutes on ice. Samples were washed 
again in staining buffer, then resuspended in saponin buffer (staining buffer + 0.1 % 
saponin) at 1 x 106 cells per 100 µl. Samples were incubated for 15 minutes at room 
temperature, then resuspended in saponin buffer + anti Granzyme B (or a matched 
isotype control), at 1 x 106 cells per 100 µl. Samples were stained for 30 minutes at room 
temperature, then washed in 2 ml saponin buffer. Finally, cells were resuspended in 0.5 
% paraformaldehyde in staining buffer, and analysed on a Cytoflex flow cytometer 
(Beckman Coulter).  
2.3.8 Carboxyfluorescein Diacetate, Succinimidyl Ester (CFDA-SE) 
labelling assay 
Firstly, PBS, FCS and RPMI 1640 (Sigma) + 10% FCS were pre-warmed in a 37 °C 
water bath. After culturing overnight, PBMC were centrifuged for 10 minutes then 
resuspended in warm PBS + 2 μM CFDA-SE (Invitrogen) at 107 cells/ml. Cells were 
incubated for 10 minutes at 37 °C, then the labelling reaction was quenched with an 
equal volume of warm FCS. Cells were washed twice with warm RPMI 1640 + 10 % 
FCS, centrifuging for 10 minutes each time. Finally, PBMC were resuspended in RMPI 
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+ 10 % FCS, at 2 x 106 cells/ml and cultured with or without virus/cytokine for the 
specified time. 
After culturing, cells were collected into 5 ml polystyrene tubes (Falcon), then stained 
with viability dye (section 2.3.2) followed by surface staining with antibodies against 
CD56, CD3 and CD16 (section 2.3.1). Finally, cells were fixed in Cytofix fixation buffer 
(BD Biosciences) on ice for 15 minutes, then washed and resuspended in staining buffer. 
Staining was analysed on an LSRII flow cytometer (BD Biosciences), on the lowest 
speed setting.  
2.3.9 Propidium iodide staining for cell cycle analysis 
Cells were collected into 15 ml falcon tubes and centrifuged for 10 minutes, then washed 
once in PBS. Next, cells were resuspended in ice cold 70 % ethanol, at 1 x 106 cells/ml, 
while vortexing to avoid cell clumping. Samples were fixed on ice for 30 minutes, then 
stored at -20 °C until staining.  
Fixed cells were transferred into FACS tubes and washed with 2ml stain buffer, 
centrifuging at 600 x g. Next, each sample (between 0.5 – 1 x 106 cells) was resuspended 
in 50 μl of 100 μg/ml RNase A (Qiagen). Next, DNA staining solution was prepared by 
diluting propidium iodide (PI) (Life Technologies) to a working concentration of 16.6 µg/ml 
in staining buffer. DNA staining solution was added directly to cells resuspended in 
RNase A, so the final concentration of cells was 1 x 106/650 µl.  Samples were incubated 
at room temperature for 10 minutes, then analysed on an LSRII flow cytometer (BD 
Biosciences), on the lowest speed setting. 
2.3.10 List of antibodies 
Table 2.3 details all antibodies used in flow cytometry experiments, including antibody 
clone number, isotype and experimental concentration.  
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Target Conjugate Clone  Isotype Manufacturer Experimental 
concentration 





Miltenyi 1 µl / 8.25 ng 
CD56 APC AF12-7H3 IgG1 Miltenyi 2 µl / 16.5 ng 
CD3 FITC UCHT1 IgG1 BD Biosciences 5 µl / 62.5 ng 
CD3 BV421 UCHT1 IgG1 BD Biosciences 2 µl / 100 ng 
CD69 BV421 FN50 IgG1 BioLegend 2 µl / 50 ng 
CD69 FITC FN50 IgG1 BioLegend 5 µl / 500 ng 
CD69 PE FN50 IgG1 BioLegend 2 µl / 20 ng 
CD317 
(Tetherin) 
PE REA202 Human 
IgG1 
Miltenyi 5 µl / 550 ng 
pY701 
STAT1 
APC REA345 Human 
IgG1 
Miltenyi 10 µl / 20 ng 
pY693 
STAT4 





47/Stat5(pY694)   IgG1 BD Biosciences 10 µl / 15 ng 
Granzyme 
B 
PE GB11 IgG1 Thermo Fisher 
Scientific 




APC RIK-2.1 IgG1 Miltenyi 10 µl / 550 ng 
CD16 BV421 3G8 IgG1 BioLegend 2 µl  




- 3D12 Rat 
IgG2a 
BD Biosciences 0.5 µl / 250 ng 










VioBlue REA546 Human 
IgG1 
Miltenyi 10 µl / 1.65 µg 
PCNA PE PC10 IgG2a BD Biosciences 20 µl / 125 ng 
Ki67 PE REA183 Human 
IgG1 
Miltenyi 10 µl / 220 ng 
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pY694 
STAT5 
BV421 47/Stat5(pY694) IgG1 BD Biosciences 3 µl / 150 ng 
pS2448 
mTOR 
PE O21-404 IgG1 BD Biosciences 5 µl / 16 ng 
pS473 Akt  Alexa 
Fluor 488 
M89-61 IgG1 BD Biosciences 15 µl / 45 ng 
Controls 
 BV421 MOPC-21 IgG1 BioLegend  
 FITC MOPC-21 IgG1 BD Biosciences  
 PE REA293 Human 
IgG1 
Miltenyi  
 APC REA293 Human 
IgG1 
Miltenyi  
 PE 27-35 IgG2b BD Biosciences  
 PerCP-
Cy5.5 
MOPC-21 IgG1 BD Biosciences  
 PE MOPC-31C IgG1 BD Biosciences  
 VioBlue REA293 Human 
IgG1 
Miltenyi  
 PE MOPC-173 IgG2a BD Biosciences  
 BV421 X40 IgG1 BD Biosciences  
 Akt MOPC-21 IgG1 BD Biosciences  
Table 2.3 List of flow cytometry antibodies 
All antibodies are mouse monoclonal, unless otherwise specified.  
 
2.4 Enzyme-linked immunosorbent assay (ELISA)  
The sandwich ELISA assay was carried out in 96 well protein binding plates (Thermo 
Fisher Scientific, Nunc MaxiSorp) and washing buffer (PBS + 0.05 % Tween) was used 
for wash steps. 
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2.4.1 ELISA for interferon α 
Firstly, a mixture of coating antibodies against IFN-α (Mabtech, MT1/3/5) was diluted in 
PBS, to a final concentration of 4 µg/ml, and added to the plate at 100 µl per well. The 
plate was coated overnight at 4 °C. Next, the plate was washed 3 times with washing 
buffer. To block the plate, 200 µl of PBS + 10 % FCS was added to each well and the 
plate was incubated for 2 hours at room temperature. After washing 3 more times, PBMC 
supernatant samples were added to the plate. At the same time, recombinant IFN-α2 
(Miltenyi) of known increasing concentration was added to the plate, to generate a 
standard curve. IFN-α was diluted in RPMI 1640 (Sigma) + 10 % FCS, starting at 2500 
pg/ml, with 6 sequential 1 in 2 dilutions. A blank sample, with only RPMI + 10 % FCS, 
was also added. All samples were added in triplicate, at 100 µl per well. The plate loaded 
with samples was incubated overnight at 4 °C, then washed 6 times. A mixture of 
biotinylated detection antibodies against IFN-α (Mabtech, MT2/4/6) was diluted in PBS 
+ 10% FCS to a final concentration of 1 µg/ml, and added to the plate at 100 µl per well. 
The plate was incubated for 2 hours at room temperature, then washed another 6 times. 
Avidin conjugated alkaline phosphatase (Sigma, ExtrAvidin) was diluted 1 in 5000, in 
washing buffer, and added to the plate at 100 µl per well. After incubating at room 
temperature for 1 hour, the plate was washed 3 times with distilled water. Finally, p-
Nitrophenyl phosphate substrate was prepared according to manufacturer instructions 
(Sigma, SigmaFast tablets) and added to the plate at 100 µl per well. The plate was 
incubated at room temperature for 10 to 30 minutes to develop, protected from light, then 
absorbance was read at 405 nm on a Multiskan EX plate reader (Thermo Fisher). A 
standard curve was fitted using Excel. The limit of detection (LoD) was calculated as 
follows (LoB = Limit of blank): 
LoD = LoB + 1.645(Standard deviation of low concentration sample) 
LoB = meanblank + 1.645(SDblank) 
Low concentration sample = bottom of standard curve.  
2.4.2 ELISA for interferon β 
ELISA was carried out as in section 2.4.1, except for the following changes: 
- 62 - 
   
The plate was initially coated with an antibody against IFN-β (Peprotech, 500-P32B, 
rabbit polyclonal), diluted 1 in 1000 in coating buffer (100 mM NaHCO3). A biotinylated 
antibody against IFN-β (Peprotech, 500-P32BBT, rabbit polyclonal), diluted 1 in 1000 in 
PBS + 10 % FCS, was used as the detection antibody.  
2.5 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blotting  
2.5.1 Preparation of cell lysates for SDS-PAGE  
Cells were collected into Eppendorf tubes, centrifuged at 300 x g for 5 minutes, then 
washed with 1 ml ice cold PBS. Next, cells were lysed with ice cold RIPA buffer (150mM 
NaCl, 10mM Tris pH7.2, 0.1% SDS, 0.1% Triton-X, 1% deoxycholic acid, 5mM EDTA) 
with added cOmplete™ Mini EDTA-free protease inhibitor cocktail and PhosStop 
phosphatase inhibitors (both Roche), at 1 x 106 cells/50µl, for 20 minutes on ice. Samples 
were sonicated in 2 x 2 second pulses, in order to shear DNA. At this point, samples 
could be stored at -80 °C until the next step. Protein sample buffer (5x) (250 mM Tris 
pH 6.8, 50 % glycerol, 10 % sodium dodecyl sulphate (SDS), 0.1 % bromophenol blue, 
1 % β-mercaptoethanol) was added to each sample at 1 part to 4 parts lysate, and 
samples were boiled at 95 °C for 10 minutes, to denature and reduce protein.  
2.5.2 SDS-PAGE 
A 10% Tris Glycine resolving gel (10 % acrylamide, 380 mM Tris pH 8.8, 0.1 % SDS, 
0.1 % APS , 0.1 % TEMED) with  4 % stacking gel (4 % acrylamide, 120 mM Tris pH 6.8, 
0.1 % SDS, 0.1 % APS, 0.1 % TEMED) was prepared and immersed in 1x SDS-PAGE 
buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS) in a miniPROTEAN Tetra Cell gel 
electrophoresis tank (Bio-Rad). Protein samples were loaded into the gel, along with 
10 µl of SeeBlue Plus 2 pre-stained protein standard (Invitrogen) in the first well. A 
potential difference of 150 V was applied across the gel for 1 hour.  
2.5.3 Western Blot 
A 6 x 8 cm2 piece of Hybond-P polyvinylidene fluoride (PVDF) membrane (GE Healthcare 
Life Sciences) was activated in methanol for 20 seconds, then immersed in 1 x Towbin 
buffer (25 mM Tris, 192 mM glycine, 20 % methanol). Two filters (BioRad) were also 
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immersed in 1 x Towbin buffer. The SDS-PAGE gel was then placed on top of the 
membrane, between the two filters, in a semi dry transfer machine (Bio-Rad). A potential 
difference of 15 V was applied for 1 hour. 
For probing of the PVDF membrane, antibody details are specified in Table 2.4. The 
PVDF membrane with transferred protein was blocked in 1 x Tris Buffered Saline with 
0.1% Tween (TBST) and 5% skimmed milk, for 1 hour at room temperature, with 
continuous agitaton. The skimmed milk solution was removed and replaced with primary 
antibody at the specified dilution (see Table 2.4), and incubated overnight at 4 °C, with 
continuous agitation. The primary antibody solution was removed and the membrane 
was washed in TBST for 5 minutes, a total of 3 times. Secondary antibody was added at 
the specified dilution and the blot was incubated for 1 hour at room temperature, with 
continuous agitation. The membrane was washed another 3 times in TBST before 
enhanced chemiluminescence (ECL) solution 1 (0.4 mM p-coumaric acid, 2.5 mM 
Luminol, 0.1 M Tris pH 8.5) and ECL solution 2 (0.02 % hydrogen peroxide, 0.1 M Tris 
pH 8.5) were added at a 1:1 ratio, and mixed by pipetting over the membrane. The blot 
was transferred to a light proof cassette and developed using a Konica SRX-101A 
Tabletop X-ray Film Processor (Konica, UK). The expression of β-actin was used to 









- 64 - 
   
Target Clone Manufacturer Dilution Buffer 
MCM4 Rabbit 
polyclonal 
Abcam 1 in 5000/ 
200 ng/ml 
2.5 % BSA in TBST 




1 in 1000/ 
250 ng/ml 
2 % BSA in TBST 




1 in 1000/ 
250 ng/ml 
2 % BSA in TBST 
β actin IgG2a, clone 
AC-74 
Sigma 1 in 10,000 2 % BSA in TBST 
Rabbit IgG Goat polyclonal, 
HRP conjugated 
Sigma 1 in 5000 2 % BSA in TBST 
Mouse Ig Rat IgG, clone 
eB144, HRP 
conjugated 






Sigma 1 in 5000 2 % BSA in TBST 
Table 2.4 List of Western Blotting antibodies 
 
2.6 Transcriptome microarray 
2.6.1 Sample preparation 
PBMC cultured with or without reovirus at an MOI of 1 were magnetically labelled to 
isolate PB-NK cells (section 2.1.2). Helen Close provided purified NK cell samples, 
cultured with or without 100 international units/ml of IL-15 (Miltenyi). After the last wash 
step, NK cells were resuspended in RNAprotect Cell Reagent (Qiagen), to stabilise RNA, 
and tubes were vortexed to resuspend the pellet completely. Cells in RNAprotect were 
stored at -20 °C until samples from 5 separate donors were collected. Samples were 
sent to an external service provider (Hologic, Manchester, UK). Staff at Hologic 
isolated RNA from the samples with the RNeasy mini kit (Qiagen), according to 
manufacturer instructions. Contaminating DNA was removed by on column DNase 
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digestion and RNA integrity was checked using an Agilent 2100 Bioanalyzer (Agilent 
Technologies).  
2.6.2 Microarray 
Hologic also carried out all microarray steps: First, total RNA was amplified, then sense 
strand cDNA was synthesised and labelled using the GeneChip™ WT PLUS Reagent 
Kit, according to manufacturer instructions (Applied Biosystems, Thermo Fisher 
Scientific). Labelled cDNA was hybridised to a GeneChip® Human Transcriptome Array 
2.0 (Applied Biosystems, Thermo Fisher Scientific), according to manufacturer 
instructions.  
2.6.3 Differentially expressed genes 
Raw intensity files for each microarray chip were received from Hologic. Raw data (CEL 
files) for all conditions were processed with the Expression Console software (Affymetrix) 
which performed background correction, normalisation and summarisation steps, using 
the Signal Space Transformation-Robust Multi-Chip Analysis (SST-RMA) algorithm. All 
chip intensity data passed quality control steps. Then, normalised signal values were 
analysed with the Transcriptome Analysis Console (TAC, Affymetrix) software, to identify 
statistically significant differences between conditions. Following manufacturer 
guidelines, TAC software was used to run paired ANOVA tests and false discovery rate 
(FDR) prediction. Differentially expressed genes were defined as at least 1.5 fold 
up/downregulated and FDR p value < 0.05 (unless otherwise stated).  
2.6.4 Pathway enrichment analysis 
Pathway enrichment analysis was performed with MetaCore GeneGo (Thomson 
Reuters).  
2.7 Real time PCR 
2.7.1 Sample preparation 
Cells were resuspended and stored in RNAprotect cell reagent (Qiagen), as in section 
2.6.1. For time-course experiments, samples were stored until all time-points could be 
processed together. Then, RNA was extracted with the RNeasy mini kit (Qiagen), 
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according to manufacturer instructions (following specific instructions for RNAprotect 
stored cells). Contaminating DNA was removed by on column DNase digestion, with the 
RNase-Free DNase Set (Qiagen). RNA was eluted from the column in nuclease free 
water. 
RNA concentration was measured using a Nanodrop spectrophotometer (Thermo Fisher 
Scientific). Next, complementary DNA (cDNA) was synthesised from the extracted RNA. 
In a 13 μl reaction volume, random primers (New England Biolabs) to a final 
concentration of 4.6 μM and dNTP mix (New England Biolabs) to a final concentration of 
800 nM were combined with 30-100 ng RNA. This was incubated at 65 °C for 5 minutes 
and cooled on ice for 1 minute. To a final volume of 20 μl, the following components were 
added: 1x First strand buffer (Invitrogen), 5 nM DTT, 40 units RNase OUT (Invitrogen) 
and 200 units of Superscript III reverse transcriptase (Invitrogen). This mixture was 
incubated at 25 °C for 5 minutes, followed by incubation at 50 °C for 1 hour and 
inactivation at 15 °C for 15 minutes. cDNA samples were stored at -20 °C. 
2.7.2 Taqman method 
In a MicroAmp fast optical 96 well reaction plate (Applied Biosystems), 1x Taqman gene 
expression master mix (Applied Biosystems) was combined with 10ng cDNA, 1x Taqman 
gene expression assay probe (see section 2.7.5) and nuclease free water to a final 
volume of 20 μl.  
Amplification was carried out in a 7500 Real Time PCR machine (Applied Biosystems) 
or a QuantStudio 5 machine (Applied Biosystems), using the following thermal cycling 
conditions: 50 °C for 2 minutes, 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 
15 seconds/ 60 °C for 1 minute. Reactions were performed in triplicate and all replicate 
values were within 0.5 cycles. Cycle threshold (Ct) values were calculated using Applied 
Biosystems software. 
2.7.3 SYBR Green method 
For targets with standard primers already available, the SYBR Green method was used 
instead. Reactions were prepared in plates as in section 2.7.2, except for the following 
changes: 
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• PowerUp™ SYBR™ Green Master Mix (Applied Biosystems) was used instead 
of Taqman gene expression master mix. 
• Primers (section 2.7.5) were used instead of Taqman gene expression assay 
probes. Primers were included at a final reaction volume of 500 nM.  
• Identical cycling conditions to section 2.7.3 were used, plus melt curve analysis 
was included to test for specific product amplification.  
2.7.4 Analysis 
Fold change gene expression over resting was calculated by the ΔCt method (below). 
ABL1 was used as the housekeeping gene. 
∆𝐶𝑡 = 𝑇𝑎𝑟𝑔𝑒𝑡 𝐶𝑡 𝑚𝑒𝑎𝑛 − 𝐻𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝐶𝑡 𝑚𝑒𝑎𝑛 
∆∆𝐶𝑡 =  ∆𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −  ∆𝐶𝑡 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 𝑟𝑒𝑠𝑡𝑖𝑛𝑔 =  2∆∆𝐶𝑡 
2.7.5 Primers 
 Target Probe/Sequence 
Taqman probes 
(Taqman method) 
ABL1 Applied Biosystems Hs01104728_m1 
CCR7 Applied Biosystems Hs01013469_m1 
S1PR1 Applied Biosystems Hs01922614_s1 




CDK2 F ATGGATGCCTCTGCTCTCACTG 
R CCCGATGAGAATGGCAGAAAGC 
CCNA2 F         CTCTACACAGTCACGGGACAAAG 
R CTGTGGTGCTTTGAGGTAGGTC 
CCNB1 F GACCTGTGTCAGGCTTTCTCTG 
R GGTATTTTGGTCTGACTGCTTGC 
Table 2.5 List of probes and primers for Real Time PCR 
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2.8 Statistics 
Statistical tests were performed using Graphpad Prism (Graphpad Software).  
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Chapter 3. Interferon dependent activation of NK cells during 
reovirus treatment 
3.1  Introduction 
Oncolytic virus therapy has the potential to enhance the patient’s innate immune 
response against tumour cells. Evidence of human NK cell activation was observed 
during a clinical trial of intravenous reovirus (EUDRACT number 2007/000258-29) (El-
Sherbiny et al., 2015), and recent studies have demonstrated enhanced NK cell killing 
of targets following in vitro treatment of PBMC (Parrish et al., 2015) or liver mononuclear 
cells (Samson et al., 2016) with reovirus. However, the precise mechanism of NK cell 
activation is not well understood. Type I interferons (IFN-I), released during viral 
infection, are important for NK cell responses in vivo, but studies disagree on the 
mechanistic details, in particular, whether IFNs act directly on NK cells or indirectly 
through a secondary cytokine. In this chapter, I have attempted to answer this question 
using a simple in vitro model of reovirus therapy.  
 
3.2 Results 
3.2.1 Reovirus treatment activates NK Cells within PBMC 
Blood from healthy donors was used as a source of immune cells, from which peripheral 
blood mononuclear cells (PBMC) were isolated by density gradient separation (section 
2.1.1).  Human NK cells are defined as CD56+CD3- lymphocytes, and antibody staining 
and flow cytometry can be used to identify NK cells within PBMC, where NK cells 
represent approximately 10% of lymphocytes (PBMC; Figure 3.1a). Furthermore, this 
staining can be used to assess the purity of NK cells enriched via immunomagnetic 
selection from PBMC, with purity exceeding 95% routinely obtained (Purified NK; Figure 
3.1a).  
 
Human NK cell activation can be assessed via expression of the lymphocyte activation 
marker CD69, via flow cytometry. In the clinical study referred to above (EUDRACT 
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number 2007/000258-29), CD69 expression by NK cells peaked approximately 48 hrs 
post-intravenous delivery  at a multiplicity of infection estimated at approximately 1 (El-
Sherbiny et al., 2015). This time point was therefore chosen for the in vitro model used 
here, together with MOIs of 1 and 10. The effect of reovirus on NK cells was analysed in 
two ways. First, PBMC were treated with reovirus and the activation of NK cells within 
PBMC was analysed. Secondly, NK cells were purified from PBMC and treated directly 
with reovirus. Figure 3a (bottom) shows that reovirus treatment induced CD69 
expression on ~90 % of NK cells within PBMC, compared to ~10 % in untreated cells 
(figure 3.ab). CD69 expression was also induced by reovirus on purified NK cells, 
although the response was lower in magnitude and showed more donor variability. Most 
importantly, use of PBMC (containing multiple blood cell types) for in vitro studies more 
closely mimics the intravenous delivery of reovirus into patients. Therefore, PBMC based 
assays were used for the majority of experiments in this thesis. 
 
Several studies have shown that reovirus treatment enhances the anti tumour response 
of NK cells in vitro by enhancing granule dependent killing. (Parrish et al., 2015; Samson 
et al., 2016; Errington et al., 2008; Steele et al., 2011; El-Sherbiny et al., 2015). To 
confirm this, PBMC were treated with reovirus and exposed  to the NK sensitive 
leukaemia cell line, K562). Display of CD107a (a marker of degranulation) on the surface 
of NK within PBMC, was analysed using flow cytometry. NK cells from reovirus treated 
PBMC exhibited greater levels of degranulation than their untreated counterparts (Figure 
3.1b). These results confirm that reovirus treatment of PBMC initiates a pathway that 
induces the anti-tumour activity of NK cells. Subsequent experiments were aimed at 
determining the nature of this activation step. 
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Figure 3.1 Effect of reovirus on CD69 expression and NK degranulation 
a) Top: NK cells were identified as a CD3-CD56+ population within the whole PBMC 
population (left panel). The purity of isolated NK cells was confirmed using the same 
antibody panel (right panel). Bottom: Flow cytometric data to show the mean percentage 
of NK cells expressing CD69, either within PBMC (PBNK) or isolated from PBMC 
(purified NK), 48 hours post reovirus treatment (MOI of 1 or 10) or resting (unstimulated 
cells). Four donors were analysed, error bars represent the standard deviation for each 
condition. b) PBMC were cultured without (untreated) or with reovirus at an MOI of 1 for 
48 hours, followed by co-culture with K562 target cells.  Degranulation of PBMC-NK cells 
was examined by measuring expression of surface CD107a, by flow cytometry. CD107a 
display was analysed on unstimulated cells (Resting), or cells treated with reovirus in the 
presence or absence of K562 target cells. The experiment was repeated with 2 separate 
donors.  
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3.2.2 PBMC derived IFN-I activates NK cells 
One clear candidate for the activation of NK cells by reovirus is IFN-I. Previous studies 
showed that IFN-I was necessary for the upregulation of CD69 and degranulation 
induced by reovirus (El-Sherbiny et al., 2015; Parrish et al., 2015). However, these 
studies did not address whether IFNs induced NK cell activation directly, or indirectly 
through other cell types. One possible indirect mechanism could be the IFN dependent 
induction of monokines such as IL-12 and/or IL-15.  
I first tested whether soluble factors, released into the media during culture of PBMC with 
reovirus, were sufficient to activate purified NK cells. Conditioned media was collected 
from both untreated and reovirus treated PBMC, and filtered (using Viresolve®) to 
remove reovirus. The remaining media was predicted to contain extracellular factors but 
lack cells or virus (Figure 3.2).  
Conditioned media was collected at various time points, after the addition of reovirus to 
PBMC, in order to determine an optimum time point for NK cell activation. Purified NK 
cells upregulated surface CD69 when cultured in conditioned media collected at 24 or 
48 hours, but not that collected 4 hours post reovirus treatment (Figure 3.3a, top panel). 
Expression of surface tetherin (CD317), an IFN inducible protein (Neil et al., 2008), was 
also measured. Expression of tetherin by NK cells was similarly upregulated by reovirus 
conditioned media, more so by that collected 24 and 48 hours post reovirus treatment 
than that collected at 4 hours (Figure 3.3a, bottom panel). 
 
Conditioned media that was collected at 24 hours post reovirus treatment was selected 
to take forward for further experiments, as it induced the highest levels of CD69 and 
tetherin on the surface of purified NK cells. Virus free, conditioned media from this time 
point reproducibly upregulated CD69 and tetherin expression on purified NK cells from 
multiple donors and the differences were statistically significant (Figure 3.3b). Together, 
these data suggest that molecules released by reovirus treated PBMC, most likely 
cytokines (with IFN-I being a favoured candidate), are directly responsible for the 
activation of NK cells in this setting. 
   











Figure 3.2 Schematic diagram of experimental pipelines  
Conditioned media (CM) was collected from PBMC, cultured with or without reovirus at an MOI of 1, by centrifugation, then virus particles were 
removed using a Viresolve filter.  a)  Purified NK cells (from a separate donor) were cultured in the filtered CM. b) IFN-I concentration in CM 
was analysed by ELISA. c) Purified NK were cultured in filtered CM, plus IFN-I blocking cocktail.      




Figure 3.3 Effect of conditioned media on NK cell surface CD69 and tetherin 
a) PBMC were cultured for 4, 24 or 48 hours either without virus (resting) or with reovirus 
at an MOI of 1 (reo). Conditioned media (CM) was collected as in Figure 3.2 and purified 
NK cells were cultured in the collected media, for 48 hours. CD69 and Tetherin 
expression on the surface of purified NK was measured by flow cytometry. Whole PBMC 
from the same donor were cultured with or without reovirus at an MOI of 1 for 48 hours, 
and NK cells within PBMC were analysed  alongside. This experiment was performed 
once.  b) CM collected at 24 hours was tested further for potential to activate purified NK 
cells. On the left are purified NK cells cultured in CM, and on the right  are NK cells within 
PBMC (PBNK). Plotted are the percentage of NK cells positive for CD69, and Tetherin 
median fluorescence intensities. Graphs show mean and standard deviation for 4 
separate donor PBMC. The effect of treatment on MFI was tested by one way repeated 
measures ANOVA, followed by Tukey’s multiple comparisons test to determine 
significant differences between treatments. * p<0.05 ** p<0.01.  
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The induction of IFN-α and IFN-β by reovirus was analysed, by measuring the 
concentrations of these cytokines in conditioned media using ELISA (as in figure 3.2). 
Conditioned media from reovirus treated PBMC and untreated PBMC was compared. 
The concentration of IFN-α in conditioned media was much higher at 24 hours of reovirus 
treatment than at 8 hours, and was still detectable at high levels at 72 hours. (Figure 
3.4a). The 48 hour time-point was chosen for further analysis. In reovirus conditioned 
media from 48 hours, both IFN-α and IFNβ were detected (Figure 3.4b and c), with higher 
concentrations of IFN-α. PBMC transfected with the dsRNA analogue poly(I:C), also 
released detectable levels of IFN-α and IFN-β, as expected. However, PBMC secreted 
higher concentrations of IFN-I when exposed to reovirus, than when transfected with 
poly(I:C), at the doses used in this study. 
Conditioned media collected from reovirus treated PBMC contained both IFN-α and IFN-
β, but was likely to contain many other cytokines. This could include  IL-12 or IL-15, also 
known to activate NK cells. The importance of IFN-I in the reovirus induced cytokine 
milieu was investigated, using an optimised antibody cocktail to specifically block IFN-α 
and β. The cocktail contains antibodies against the IFN-I receptor, IFN-α and IFN-β. 
Culture of purified NK cells in  conditioned media from untreated or reovirus treated 
PBMC was repeated, with or without inclusion of the IFN-I antibody cocktail (as in Figure 
3.2), and expression of CD69 and tetherin was analysed by flow cytometry. 
I analysed whether IFN-I had a direct role in NK cell activation by reovirus. Blocking IFN-
I within the conditioned media  inhibited the upregulation of surface CD69 and tetherin 
on purified NK cells (Figure 3.5a), while a control blocking cocktail, consisting of isotype 
matched antibody and sheep serum, did not block upregulation of these molecules. 
These data confirmed that IFN-I, induced by reovirus-stimulated PBMC, acts directly on 
NK cells to upregulate activation markers in the absence of any other cell type. 
Furthermore, purified IFN-α was able to upregulate CD69 and tetherin on isolated NK 
cells, in a dose-dependent manner (Figure 3.5b). These results confirm that reovirus-
induced activation of NK cells is IFN-I dependent and that IFN-I is sufficient to induce NK 
cell activation, as characterised by CD69 and tetherin expression.  




Figure 3.4 IFN-I concentrations in conditioned media from reovirus treated PBMC 
a) PBMC were cultured with or without reovirus at an MOI of 1. At the time points shown 
above, media was collected and IFN-α concentration was measured by ELISA.  b) PBMC 
were cultured alone, or with reovirus at an MOI of 1, poly(I:C) effectene transfection or 
mock transfection, for 48 hours. Media was collected and IFN-α and c) IFNβ 
concentrations were measured by ELISA. N = minimum of 3, BLD = below limit of 
detection.  




Figure 3.5 Inhibition of NK cell activation by IFN blocking antibodies 
NK cell CD69 and tetherin expression after culturing in conditioned media with IFN-I 
block, or purified IFN.  a) Purified NK cells were cultured in CM collected at 24 hours, as 
in Figure 3.3. Additionally, CM was either left untreated or treated with an IFN-blocking 
antibody cocktail or a control blocking cocktail. NK cells were cultured in CM and blocking 
antibodies for 48 hours, then NK cell surface expression of CD69 and tetherin was 
measured by flow cytometry. N=3 donors. b)  A titration of purified IFN-α induces a dose-
dependent upregulation of CD69 and tetherin on the surface of NK cells. Purified NK 
cells were cultured with IFN-α for 48 hours. N=2. Graphs in a) and b) show the mean 
and standard deviation for each condition.  
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3.2.3 Cytokines activate different JAK/STAT signalling pathways in 
NK Cells 
The results described in Section 3.2.2 suggest that reovirus induces IFN-I production, 
which acts directly on NK cells to induce activation. Type I interferons typically induce 
the phosphorylation of STAT1 and STAT2 (Platanias, 2005), while other cytokines 
activate different JAK/STAT signalling pathways (Thierfelder et al., 1996; Tagaya et al., 
1996). Flow cytometric analysis of phosphorylated proteins is a convenient method that 
enables the analysis of JAK/STAT signalling within a mixed population of cells. The 
phosphorylation of three different signalling proteins, namely STAT1, STAT4 and 
STAT5, was analysed after treatment of PBMC with several different cytokines, including 
IFN-α. The aim was to validate the assay, by comparing results with that reported in the 
literature, and to establish NK cell STAT phosphorylation profiles for relevant cytokines. 
Comparing the STAT phosphorylation profile of reovirus activated NK cells to the profiles 
generated for each cytokine might then indicate which cytokines are responsible for 
reovirus-induced NK cell activation. 
PBMC were treated individually with three different cytokines for 1 hour and STAT 
phosphorylation in the NK cell population was analysed by permeabilisation, antibody 
staining and flow cytometry. The cytokines IFN-α, IL-12 and IL-15 were chosen as each 
have been implicated in viral activation of NK cells (section 1.1.7). Different patterns of 
STAT phosphorylation were induced in NK cells by IFN-α, IL-12 and IL-15 (Figure 3.6). 
Flow cytometry allowed the further subdivision of NK cells into CD56dim and CD56bright 
subsets, based on CD56 staining intensity. The phosphorylation of STAT molecules was 
quantified in both NK cell subsets (Figure 3.7). Only IFN-α significantly increased the 
levels of STAT1 phosphorylation, and both NK cell subsets responded similarly. In 
contrast, STAT4 phosphorylation differed across subsets. In CD56dim NK cells, STAT4 
phosphorylation was significantly increased by all treatments, including IL-15. Although 
STAT4 is thought to be primarily activated downstream of IL-12, in the CD56dim subset 
the highest upregulation was observed with IFN-α stimulation. In CD56bright NK cells, IL-
12 treatment induced the highest levels of STAT4 phosphorylation. Finally, IL-15 
treatment increased STAT5 phosphorylation, which was statistically significant only in 
the CD56bright subset.. These results match the typical JAK/STAT pathways reported for 
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each cytokine (Section 1.2.6 and 1.2.8), and show that STAT phosphorylation profiles 
vary across NK cell subsets.  
Next, I analysed the duration of NK cell STAT activation following stimulation with the 
three cytokines. IFN-α treatment induced a transient increase in STAT1 and STAT4 
phosphorylation, which decreased to baseline levels at 8 hours post treatment (Figure 
3.8). In contrast, IL-12-induced STAT4 phosphorylation gradually increased and was 
detectable both 8 and 24 hours post cytokine treatment. Thus, whilst IFN-α and IL-12 
activate overlapping pathways, the duration of STAT phosphorylation differs depending 
on the cytokine. The duration of STAT5 phosphorylation was variable across donors, but 
the mean staining intensity was similar at all three time-points.  




Figure 3.6 Intracellular phosphoprotein staining to detect activation of JAK STAT 
pathways  
PBMC were treated with 100 IU/ml IFNα, 10 ng/ml IL-12 or 50 IU/ml IL-15 for 1 hour. NK 
cells within PBMC were evaluated for levels of phosphorylated STAT1, STAT4 and 
STAT5 by intracellular flow cytometry. Histograms show isotype control or 
phosphorylated protein staining in total NK cells, representative of 3 donors. 




Figure 3.7 Cytokine induced STAT phosphorylation in CD56dim and CD56bright NK 
cells 
PBMC were treated with 100 IU/ml IFNα, 10 ng/ml IL-12 or 50 IU/ml IL-15 for 1 hour. 
CD56dim and CD56bright NK cells within PBMC were evaluated for levels of phosphorylated 
STAT1, STAT4 and STAT5 by intracellular flow cytometry. Graphs show median 
fluorescence intensities, with mean MFI and standard deviation from three separate 
donors. The effect of treatment on MFI was tested by one way repeated measures 
ANOVA, followed by Dunnet’s multiple comparison test to determine which cytokine 
treatments were significantly different from untreated. * p < 0.05  ** p < 0.01 




Figure 3.8 STAT phosphorylation kinetics in cytokine treated CD56dim and 
CD56bright NK cells 
PBMC were treated with 100 IU/ml IFNα, 10 ng/ml IL-12 or 50 IU/ml IL-15 for 1 hour, 8 
hours or 24 hours. CD56dim and CD56bright NK cells within PBMC were evaluated for 
levels of phosphorylated STAT1, STAT4 and STAT5 by intracellular flow cytometry. 
Graphs show median fluorescence intensities, with mean MFI and standard deviation 
from two separate donors.  
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3.2.4 Reovirus-induced JAK/STAT signalling in NK Cells resembles 
IFN-I signalling.  
Reovirus treatment is likely to trigger the production of multiple cytokines over time, 
which may lead to the activation of several different JAK/STAT pathways.  NK cell STAT 
phosphorylation was measured at several time points during culture of PBMC with or 
without reovirus (Figure 3.9). In order to ensure enough time for virus-induced cytokines 
to be produced in the culture medium, the earliest time point at which the cells were 
assessed was 8 hours post cytokine treatment.  
Reovirus treatment induced a statistically significant increase in phosphorylated STAT1 
and phosphorylated STAT4, at 8 hours post treatment, when compared to untreated cells 
(Figure 3.9). Levels of phosphorylated STAT1 remained significantly higher in reovirus 
treated cells at 24 hours and 48 hours, when compared to untreated cells, and the mean 
staining intensity remained similar at all three time points. In contrast, levels of 
phosphorylated STAT4 decreased after 8 hours. STAT1 and STAT4 activation profiles 
were similar in both CD56dim and CD56bright NK cells. Phosphorylated STAT5 levels 
appeared similar between resting and reovirus treated cells; there was a very small but 
significant increase in phosphorylated STAT5 staining after 8 hours, but only in CD56bright 
NK cells. The upregulation of STAT1 and STAT4 phosphorylation following reovirus 
treatment is similar to the profile of STAT activation induced  by IFN-I (shown in Figure 
3.7 and 3.8), except reovirus treatment led to more sustained levels of STAT1 
phosphorylation.   
  




Figure 3.9 Reovirus induced STAT phosphorylation in CD56dim and CD56bright NK 
cells 
PBMC were cultured without virus (untreated) or with reovirus at an MOI of 1, for 8, 24 
and 48 hours. At these time points, CD56dim and CD56bright NK cells within PBMC were 
evaluated for levels of phosphorylated STAT1, STAT4 and STAT5 by intracellular flow 
cytometry. Graphs show median fluorescence intensities (MFI), with mean MFI and 
standard deviation from three separate donors;. The effect of time and treatment on MFI 
was tested by two way repeated measures ANOVA, followed by Sidak multiple 
comparisons test to determine at which time-points there were significant differences 
between untreated and reovirus treated cells. * p < 0.05  ** p < 0.01 
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Next, a more extensive set of time points were tested, with the aim to define when the 
peak of STAT1 and STAT4 phosphorylation occurred. PBMC were treated with either 
reovirus or a high concentration of IFN-α (Figure 3.10a). The results show that reovirus 
induced a peak of STAT4 phosphorylation approximately 6 hours post-treatment, before 
returning to baseline levels. Following IFN-α stimulation, peak phosphorylation of STAT4 
was detected very rapidly and decayed with similar kinetics to the reovirus induced 
STAT4 phosphorylation. The delay between IFN-α induced and reovirus induced STAT4 
phosphorylation was probably due to the time taken for reovirus exposed PBMC to 
produce sufficient levels of IFN, in agreement with the kinetics of IFN-α production shown 
in Figure 3.3.  Similarly, STAT1 phosphorylation in NK cells from reovirus treated PBMC 
also resembled a delayed IFN response, except that there was a striking upregulation of 
phosphorylated STAT1 between 12 and 24 hours (Figure 3.8a top left). Phosphorylated 
STAT5 staining was similar between untreated and reovirus treated cells at all time 
points, with no evidence of induction. Furthermore, IFN treatment did not upregulate 
STAT5 phosphorylation (Figure 3.8a bottom graph). These results suggest that reovirus 
induced NK cell activation in PBMC stems from the virus-induced production of IFN-I 
which acts directly on the NK cells and triggers STAT1 and STAT4 signalling cascades. 
The production of IFN-I in response to viral infection occurs as a result of the interaction 
between host cell pattern recognition receptors (PRRs) and pathogen associated 
molecular patterns (PAMPs) present in viruses. An important PAMP in reovirus infection 
is dsRNA (Goubau et al., 2014) and this PAMP can be mimicked using the synthetic 
dsRNA analogue, poly(I:C). A comparison of reovirus treatment and poly(I:C) 
transfection of PBMC showed that poly(I:C) induced a similar pattern of STAT 
phosphorylation to that observed with the virus (Figure 3.10b), suggesting that similar 
cytokines are produced following poly(I:C) treatment.  Interestingly, the simple addition 
of poly(I:C) to the culture medium (as opposed to transfection) did not induce these 
responses, suggesting that intracellular detection of poly(I:C) via PRRs such as RIG-I 
and MDA5 was more important than engagement of TLR3 in endosomes (data not 
shown).  




Figure 3.10 STAT phosphorylation during reovirus, IFN-α or poly(I:C) treatment 
PBMC were cultured without virus (untreated), with reovirus at an MOI of 1 or with 
1000U/ml IFNα in (a), or with 1 µg/ml poly(I:C) via effectene transfection or mock 
transfection in (b). At the time points above, NK cells within PBMC were evaluated for 
levels of phosphorylated STAT1, STAT4 and STAT5 by intracellular flow cytometry. 
Results shown in a) are from one experiment. Results in b) are representative of two 
experiments from 2 separate donor PBMC.  




The experiments presented in this chapter had two key aims. First, to establish and 
characterise a simple in vitro model which mimics the responses of human NK cells to 
intravenous reovirus therapy, and second, to use this system to explore the pathway of 
NK cell activation. The results suggest a model in which reovirus detection by PBMC  
(probably by recognition of dsRNA via RIG-I) leads to the production of IFN-I. This IFN-I 
acts directly on NK cells, via STAT1 and STAT4 signalling pathways, to induce NK cell 
activation.  The possibility that IFN-I induces IL-15 and that IL-15 then acts on the NK 
cells has not been formally disproven (e.g. using an anti-IL-15 blocking antibody), but 
the absence of STAT5 activation (a major signal downstream of IL-15) suggests that its 
role is, at most, secondary to IFN-I. 
 
A link between IFN-I and NK cell activation has been in the literature for four decades, 
after Gidlund et. al showed that interferon injection into mice enhanced NK cell 
cytotoxicity (Gidlund et al., 1978). However, the mechanistic link between IFN-I and NK 
cell activation is not well defined. A clinical trial of oncolytic reovirus demonstrated that 
NK cells were activated 24-48hrs post-treatment and this overlapped with a IFN-I 
response (El-Sherbiny et al., 2015), implicating reovirus induced IFN-I in NK cell 
activation in vivo. In vitro studies have shown that blocking IFN-I reduces NK cell 
activation in response to reovirus (El-Sherbiny et al., 2015; Parrish et al., 2015) and the 
results shown here confirm these findings. Expanding on these studies, I demonstrated 
that IFN-I released by PBMC acts directly on NK cells to induce an activated phenotype 
(figure 3.5). Work by Parrish et al., showed that treatment of PBMC with reovirus 
activates NK cells in a monocyte dependent manner and that these monocytes produced 
IFN-I (Parrish et al., 2015). Host cells produce IFN-I following detection of RNA viruses, 
usually via TLR or RLR activation.  Although most mammalian cells probably produce 
some level of IFN in response to viral infection, there are cell types particularly 
specialised for this role. Plasmacytoid DC are rare cells capable of producing high levels 
of IFN-I, and are believed to play a key role in initiating many antiviral responses 
(Izaguirre et al., 2003). However, monocytes are highly abundant, presumably 
compensating for the reduced IFN-I production per cell, indeed one study demonstrated 
that monocytes produce most of the PBMC derived IFN-α in response to transfected 
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poly(I:C) (Hansmann et al., 2008). In my experiments, reovirus treatment of purified NK 
cells did not upregulate CD69 to the same extent as treatment of whole PBMC (Figure 
3.1b), probably due to the removal of monocytes by the NK cell isolation column. There 
was however, a small percentage of CD69+ cells in the purified NK cell population 
exposed to reovirus. This suggests that a proportion of NK cells are able to respond 
directly to reovirus. This might occur by NK cell detection of reovirus (e.g. via RIG-I) and 
autocrine IFN-I production. Alternatively, a recent paper showed that the NK cell receptor 
NKp46 recognises the reovirus σ1 protein (Bar-On et al., 2017), allowing direct activation 
of NK cells by reovirus. However, optimal responses were obtained using PBMC, 
presumably reflecting the role of monocytes in IFN-I production. Use of PBMC in these 
experiments is convenient. However, PBMC do not contain the full complement of blood 
cells, lacking neutrophils, red blood cells and platelets (which do not survive in culture). 
Whilst these cell types are not typically described as IFN producing cells, their absence 
does reflect a limitation of the in vitro model.  
 
Experiments performed here indicate that IFN-I is necessary and sufficient for NK cell 
activation. However, this does not exclude a role for other cytokines. It is possible that 
IFN-I acts on NK cells to induce autocrine production of activating cytokines, such as NK 
cell cis-presentation of IL-15 in response to IFN-β (Zanoni et al., 2013). Furthermore, I 
have only tested how type I IFN blocking affects the expression of CD69 and tetherin. 
Others have shown that IFN-I blockade reduces NK cell degranulation and tumour cell 
killing in response to reovirus (El-Sherbiny et al., 2015; Parrish et al., 2015). However, 
other functions such as IFN-γ production may be under the control of other cytokines, 
and this has not been explored in the context of oncolytic reovirus. In an MCMV model, 
NK cytotoxicity was dependent on type I IFN while NK IFN-γ production was dependent 
on IL-12 (Nguyen, K.B. et al., 2002a). On the other hand, overlapping pathways can 
trigger the same function in NK cells; both IL-12 and type I IFN are able to trigger IFN-γ 
production through activation of STAT4 (Nguyen, K.B. et al., 2002b; Mack et al., 2011).  
 
Activation of transcription factors such as STAT4 can tell us a lot about how NK cells 
respond in certain conditions. Therefore, as part of this study, the activation of different 
STAT factors was investigated. Initial experiments tested the action of purified cytokines 
on PBMC and confirmed the findings of previous studies, showing that IFN-α, IL-12 and 
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IL-15 induced different patterns of STAT phosphorylation in NK cells (Figures 3.6 and 
3.7).  After 1 hour of stimulation, IFN-α induced STAT1 and STAT4 phosphorylation, but 
no STAT5 phosphorylation.  STAT1 and STAT2, together with IRF9, form the ISGF3 
complex, the canonical transcription factor of the IFN-I signalling pathway (Platanias, 
2005).  More recently, STAT4 has been implicated in the response to IFN-I (Nguyen, 
K.B. et al., 2002b), particularly in NK cells (Mack et al., 2011).  The cytokine IL-12 is 
reported to signal predominantly through STAT4 (Thierfelder et al., 1996), which I 
observed in CD56bright, but not CD56dim NK cells (Figure 3.7). It appears that CD56bright 
NK cells may be more sensitive to IL-12 than CD56dim cells, possibly due to a higher 
density of IL-12 receptor on the surface of the CD56bright sub type. The CD56bright NK cell 
subset produces higher levels of IFN-γ than CD56dim NK cells, in response to IL-12 
(Trotta et al., 2005), however not much is known on a molecular level about what makes 
CD56bright NK cells better cytokine producers. It has been reported that a higher level of 
constitutive SHP-1 expression in CD56dim cells inhibits IFN-γ production, possibly 
through inhibition of NF-κB, and that this explains the lower level of IFN-γ produced by 
CD56dim cells in response to IL-12 and IL-18 (Trotta et al., 2005). However, there may 
be a number of mechanisms by which CD56bright NK cells respond with higher levels of 
IFN-γ than CD56dim cells. Here I have shown that greater phosphorylation of STAT4 in 
response to IL-12 might be one such mechanism. 
 
IL-15 signals through a number of different pathways, including JAK/STAT signalling. 
The JAK molecules involved are JAK1 and JAK3, activation of which leads to the 
downstream phosphorylation of STAT3 and STAT5 (Tagaya et al., 1996). In agreement 
with this, IL-15 induced the phosphorylation of STAT5 in this study (figures 3.6 and 3.7). 
These experiments also revealed the activation of both STAT1 and STAT4 during IL-15 
stimulation. Although this isn’t the canonical JAK/STAT pathway downstream of IL-15, 
activation of STAT1 and STAT4 has been reported in NK-92 cells (Strengell et al., 2003). 
Much of the published research on STAT mediated signalling pathways is based on 
western blotting data, but the results in this study show that intracellular phosphoprotein 
staining and flow cytometry is a reliable alternative technique to analyse signalling 
pathways within primary human NK cells. Furthermore, this technique allows the analysis 
of multiple different cell subsets within a mixed population, which is an important 
advantage over western blotting (which would require laborious and costly cell isolation).  




Interestingly, the duration of STAT phosphorylation, observed during time course 
experiments, differed with each cytokine. IFN-α induced transient phosphorylation of 
STAT1 and STAT4, which was evident at 1 hour post-treatment, but decreased at 8 
hours (Figure 3.8). In contrast, IL-12 induced a sustained phosphorylation of STAT4, 
which actually increased between 1 and 8 hours post-treatment. The differential duration 
of STAT4 phosphorylation induced by IFN-α and IL-12 has been demonstrated before, 
in an NK cell line (Matikainen et al., 2001) and in T helper cells (Athie-Morales et al., 
2004). I have shown that the same events occur in primary NK cells within PBMC.  
 
There are a number of possible explanations for the differential timing of STAT4 
activation by these cytokines. Firstly, STAT activation may depend on the concentration 
of cytokine remaining in the culture medium at the time point measured. After 8 hours of 
treatment, the concentration of IFN-α may have dropped below the threshold needed to 
activate STAT signalling, whilst the concentration of IL-12 might remain stable in culture. 
This could be due to quicker degradation of IFN-α, possibly because more cell types in 
the PBMC population are taking up IFN-α than IL-12. Alternatively, the concentration of 
IL-12 may remain higher than IFN-α due to a positive feedback loop which replenishes 
IL-12 in the medium. Positive feedback loops are common in innate immunity, when it is 
important to amplify a response as quickly as possible, in order to respond to infection. 
However, both IFN-I and IL-12 are reported to induce positive feedback loops, enhancing 
their own production (Ma et al., 1996) (Sato, M. et al., 1998).  
 
A refractory period following IFN-I stimulation of cells in culture has been reported 
previously (Larner et al., 1986; Sarasin-Filipowicz et al., 2009). During IFN-α treatment 
in vitro and in vivo, downregulation of IFNα/β receptor (IFNAR) at the surface of 
peripheral blood lymphocytes has been reported (Lau et al., 1986). It has been 
suggested that inhibition of signalling may occur through internalisation of the IFNAR 
(Athie-Morales et al., 2004). Alternatively, differential expression of the inhibitory 
suppressor of cytokine signalling (SOCS) proteins may explain the transient STAT 
phosphorylation following IFN-α treatment, compared with the sustained response 
following IL-12 treatment. This could be confirmed by comparing the levels of different 
SOCS proteins following these two treatments, by western blotting or flow cytometry.  It 
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is possible that SOCS proteins are recruited preferentially to the IFNAR over other 
cytokine receptors, as it has now been shown that SOCS1 is able to interact directly with 
the IFNAR, independently of JAK1 (Fenner et al., 2006).  
 
Treatment of PBMC with reovirus induced a similar pattern of STAT phosphorylation to 
IFN-I treatment (Figures 3.9 and 3.10). However reovirus induced a sustained level of 
STAT1 phosphorylation. In fact, in the longer time course, there was an increase in 
STAT1 activation observed at 24 hours.  This is in contrast with the transient activation 
of STAT1 observed after stimulation with purified IFN-α (Figure 3.8 and 3.10). Firstly, it 
is possible that viral treatment triggers a much higher concentration of IFN-α or IFN-β in 
the culture medium, which is sufficient to sustain STAT1 mediated signalling. 
Alternatively, virus present in the media could lead to constant production of type I IFN, 
leading to sustained STAT1 activation.  To the best of our knowledge, reovirus does not 
replicate within blood cells which may allow for it to persist and continually stimulate IFN-
I. However, recovery of replication competent reovirus from the PBMC of patients 
receiving intravenous viral therapy suggests that PBMC can act as ‘cellular carriers’ for 
reovirus (Adair et al., 2012). Replicating reovirus was recovered from blood samples 
taken on the day of reovirus infusion, but not at later time-points some weeks after 
treatment. Considering the evidence for cellular carriage of reovirus, it would be 
interesting to compare the STAT phosphorylation time course during treatment with live 
virus and treatment with virus free conditioned media. Secondly, perhaps other cytokines 
produced during reovirus exposure may enhance the IFN-I signalling pathway, or 
multiple subtypes of type I interferons were present, either of which could induce a 
different effect to that induced by purified IFN-α. Reovirus also induced phosphorylation 
of STAT4, which peaked at approximately 6 to 8 hours and decreased at 24 and 48 
hours. The kinetics of STAT4 phosphorylation during reovirus treatment appeared to 
closer represent the transient phosphorylation induced by IFN-α rather than the 
sustained phosphorylation induced by IL-12 .  
 
Interestingly, reovirus did not increase levels of STAT5 phosphorylation above the levels 
observed for untreated cells at the time points analysed, apart from a small shift seen in 
the CD56bright subset (Figure 3.9). This shift was very small relative to the change induced 
by purified IL-15, suggesting that IL-15 is probably not involved in the response to 
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reovirus. This is surprising as recent research has shown that IL-15 is required for the 
activation of NK cells by dsRNA (Mortier et al., 2008) and that IL-15 signalling through 
STAT5 and mTOR was essential for the homeostasis and the activation of NK cells 
during viral infection (Marais et al., 2014). There are several possible explanations for 
the lack of STAT5 phosphorylation seen during reovirus treatment. Firstly, the assay 
used in my study may not be sensitive enough. The soluble IL-15 shown to induce STAT5 
activation in Figure 3.7 is likely much higher than physiological IL-15 levels. It is difficult 
to know how sensitive the assay should be, because soluble IL-15 is not often present 
in infection models at detectable levels. Instead, it is now thought that trans presentation 
of IL-15 on the cell surface membrane of monocytes or macrophages is more important 
than soluble IL-15 release (Dubois et al., 2002) (Burkett et al., 2004). Another possible 
technical issue is that STAT5 phosphorylation may be transient and, as a result, the peak 
of phosphorylation may have been missed. 
 
Alternatively, IL-15 may not actually play an important role in the periphery during 
infection with reovirus. Analysis of NK cells from patients taking part in a reovirus clinical 
trial showed high levels of type I interferon induced genes, but did not bear the hallmarks 
of IL-15 stimulation. Specifically, NK activation receptors, such as DNAM-1 and NKG2D, 
were not upregulated in the peripheral blood of patients, whereas in vitro stimulation with 
IL-15 increased the expression of all the NK cell activatory receptors tested (El-Sherbiny 
et al., 2015). Perhaps reovirus therapy stimulates NK cells similarly to vaccinia virus, 
which requires intrinsic STAT1 signalling in NK cells (Fortin et al., 2013). Most of the 
studies demonstrating virus induced IL-15 signalling in NK cells are based on samples 
taken from mouse spleens, rather than peripheral blood. IL-15 may be more important in 
primed activated cells reaching lymph nodes during reovirus therapy. At these sites, 
there are dendritic cells (DCs) present, known to trans present IL-15 (Lucas et al., 2007). 
Future work could include studying STAT phosphorylation in DC/NK and tumour/NK co-
cultures.  
 
The evidence presented in this chapter supports a mechanism of optimal NK activation 
that a) requires other cell types present in PBMC and b) requires type I interferons acting 
directly on NK cells, inducing the activation of STAT1 and STAT4. Activation of type I 
interferon signalling, as well as additional undefined pathways, will induce important 
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transcriptional changes in peripheral blood NK cells. In the next chapter, gene expression 
analysis was performed in order to further define activation mechanisms, and to predict 
the functional changes induced by reovirus in NK cells. 
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Chapter 4. Gene expression profiling of reovirus treated NK 
cells 
4.1 Introduction 
In chapter 3, I showed that the direct actions of type I interferons are required to activate 
NK cells in response to reovirus. This NK cell activation was marked by CD69 
upregulation; CD69 is widely used as a marker of human peripheral NK cell activation 
(Clausen et al., 2003), and was induced by reovirus in vivo in the clinical trial (El-Sherbiny 
et al., 2015). An activated NK cell phenotype suggests that reovirus treated NK cells 
might respond to target cells more efficiently. This is supported by a number of in vitro 
studies, demonstrating increased killing of cancer cells by reovirus treated NK cells within 
PBMC. However, NK cell responses to viruses likely involve much more than just 
increased degranulation and release of cytotoxic molecules. Additional NK cell functions 
such as cytokine production, NK cell migration and proliferation are also affected by 
viruses, but have not been studied in the context of oncolytic virus therapy. To determine 
the spectrum of NK cell activity regulated by reovirus, I performed gene expression 
profiling (using microarray analysis) on NK cells treated with reovirus within PBMC. In 
this chapter, the main findings from this microarray analysis are discussed.  
4.2 Results 
4.2.1 Gene expression profiling strategy 
For transcriptome profiling, healthy donor PBMC were treated with reovirus in vitro, using 
the model described in chapter 3; Figure 4.1 illustrates the sample collection process. 
Briefly, PBMC (isolated from 5 healthy donors) were cultured with or without reovirus. 
After 48 hours treatment, NK cells were isolated from the PBMC using magnetic 
immunoselection (Section 2.1.2) and a small fraction (approximately 1 x 105 cells) were 
stained with antibodies for surface markers and analysed by flow cytometry. This was to 
check that the NK cells were pure, and that reovirus treated samples had acquired an 
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activated phenotype (as determined by upregulation of CD69); all 5 donor PBMC 
upregulated NK cell CD69 in response to reovirus (figure 4.2). Surface staining with 
antibodies against CD56, CD3 and CD19 confirmed that there was no detectable 
contamination from T cells (CD3+) or B cells (CD19+).  
 
 
Figure 4.1 Sample collection for transcriptome array 
Schematic showing NK cell collection for the gene expression study. PBMC from healthy 
donors were cultured for 48 hours, either untreated or with reovirus at an MOI of 1, then 
NK cells were isolated by magnetic labelling.   
 
 




Figure 4.2 Phenotype and purity of NK cell samples 
a) CD69 expression on the surface of NK cells, measured by flow cytometry. Shown are 
NK cells from 5 separate donors, collected for the gene expression study, after 48 hours 
culture of PBMC with or without reovirus at an MOI of 1. b) Purity of the NK cell isolation 
process was tested by flow cytometry analysis of NK cell, T cell and B cell markers: 
CD56, CD3 and CD19. PBMC were cultured for 48 hours with or without reovirus at an 
MOI of 1, and PBMC (before NK cell isolation) and NK cell samples (after isolation) were 
surface stained and analysed by flow cytometry. 
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The bulk of the isolated NK cell samples were sent to an external service provider who 
performed the necessary processing steps, from isolation of mRNA to measurement of 
probe intensities on an Affymetrix Human Transcriptome Array (HTA) 2.0 microarray 
chip. (Section 2.6). The raw intensity files were received and primary analysis was 
carried out using Affymetrix software. Each microarray chip was quality checked by 
testing the internal controls, and intensities were processed into normalised signal 
values. Finally, signal values for each probe were analysed with the Affymetrix 
transcriptome analysis console, comparing the 5 untreated samples to the 5 reovirus 
treated samples using a paired statistical test (Section 2.6). This generated a list of fold 
change expression values (reovirus treated/ untreated for each donor) with false 
discovery rate p values.  
In order to predict which NK cell pathways or functions might be regulated by reovirus 
treatment, pathway enrichment analysis was carried out using the online software, 
Metacore. Metacore contains a database of gene and protein names, with manually 
curated links between names, based on protein interactions. The database also 
classifies networks of gene names according to function or disease, called functional 
ontologies.  Enrichment analysis consists of mapping gene names from an experiment 
(for example a list of significantly upregulated genes) onto gene name IDs in Metacore’s 
built-in functional ontologies, and calculating the statistical relevance of the matches. 
Firstly, data from the microarray was filtered, to produce a list of differentially expressed 
transcripts that were upregulated more than 1.5 fold, false discovery rate (FDR) p value 
< 0.05. This list of gene names, with fold change values, was submitted for enrichment 
analysis, mapping to Metacore’s database of process networks. The top 20 enriched 
process networks are shown in figure 4.3, with associated p values for the match, given 
by the Metacore enrichment calculation. The top process identified was Interferon 
signalling, supporting the conclusions from chapter 3, that direct interferon signalling is 
necessary for NK activation during reovirus treatment. Another top process was Antigen 
presentation, which is explained by an upregulation of MHC transcripts. The pathway NK 
cell cytotoxicity was also identified as an important process, flagging up several 
associated transcripts which may play a role in enhancing tumour cell killing. Considering 
the results from the previous chapter, it was not surprising that both interferon and NK 
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cytotoxicity pathways were identified from the gene expression profiling analysis. 
However, what was unexpected was that cell cycle processes were also amongst the 








Figure 4.3 Functional enrichment analysis of transcripts upregulated by reovirus 
Microarray results were filtered to give a list of gene names upregulated more than 1.5 
fold in reovirus treated PBMC-NK cells, compared to untreated cells, FDR p value <0.05.  
The filtered list of gene names, with fold change values, was submitted to Metacore, 
which identified the most enriched process networks within the data. Shown are the top 
20 ranked process networks and associated p values. 
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Metacore also contains a database of openly available microarray data from previous 
studies, called the microarray repository. It consists of only Affymetrix microarray data 
that has passed all quality control checks. It is a useful tool to compare a new dataset 
against, to check for similarities in gene expression signatures. I used this online tool to 
compare the reovirus NK cell dataset against the microarray repository. The similarity 
search was based on gene names, comparing all gene IDs in the reovirus dataset with 
gene IDs in the repository, provided that expression of those genes exceeded a specified 
threshold. In this case, the threshold was set at > 1.5 fold upregulated, p value < 0.05. 
For my reovirus dataset, this meant transcripts had to be 1.5 fold upregulated in the 
reovirus treated samples compared to untreated samples. For microarray repository 
datasets, this meant expression was 1.5 fold upregulated in any given case group 
compared to a given control group sample. Metacore calculated a gene overlap between 
the reovirus dataset and each microarray repository dataset. The top 10 most similar 
datasets from the repository are shown in Figure 4.4.  The top result was Normal blood, 
interferon alpha stimulated. This came from a study where healthy donor blood was 
stimulated in vitro with IFN-α (Lauwerys et al., 2013). In addition, 6 out of 10 of the top 
most similar results are from interferon stimulated cells or tissue, suggesting that reovirus 
must induce a strong interferon response signature in NK cells. Several of the most 
similar datasets were from in vitro stimulated immune cells, but there were also matches 
from in vivo experiments. For example, Mononuclear Leukocytes from Symptomatic 
Influenza A Virus Challenge, a dataset from a clinical study in which healthy volunteers 
were given influenza virus and PBMC gene expression was tested (Zaas et al., 2013). 
Thus, the gene expression signatures observed in this model of oncolytic virus therapy 
show similarities to both interferon and virus induced gene signatures seen previously in 
peripheral blood in vivo. This further highlights the importance of interferon in the 
stimulation of NK cells by reovirus and shows that the in vitro stimulation of PBMC with 
reovirus used here is a useful model of intravenous reovirus delivery, as used in oncolytic 
virus therapy. 
 




Figure 4.4 Comparison of reovirus upregulated transcripts with Metacore 
microarray repository. 
Transcripts upregulated by reovirus in PBMC-NK cells were compared against the 
Metacore microarray repository, using similarity search by genes. Reovirus microarray 
results were filtered to give a list of gene names upregulated more than 1.5 fold in 
reovirus treated PBMC-NK cells, compared to untreated cells, FDR p value <0.05. The 
same filter was applied to microarray repository data, so only transcripts upregulated 
more than 1.5 fold in the case group compared to the control group were included, p 
value < 0.05. Above is the result of the similarity search by genes, with the most similar 
dataset at the top. 
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4.2.2 Comparative analysis of reovirus induced and IL-15 induced 
gene expression 
Comparisons with the microarray repository revealed a strong interferon response 
signature in peripheral blood NK cells treated with reovirus. However, it is not known 
whether other cytokines play a role in this setting. Gene expression data comparing 
purified untreated NK cells with purified IL-15 stimulated NK cells was available in our 
group (Helen Close, unpublished data). This data was generated using an identical 
microarray (Affymetrix Human Transcriptome Array 2.0), providing a good opportunity to 
compare transcripts upregulated by reovirus with transcripts upregulated by IL-15. Both 
lists were filtered to give a list of gene names upregulated more than 2 fold relative to 
each untreated control, FDR p value <0.05, before taking further for analysis. IL-15 
treatment triggered the differential expression of thousands of genes, so a stricter filter 
was applied this time. The lists were compared using a Venn diagram generator, 
http://bioinformatics.psb.ugent.be/webtools/Venn/. The resulting Venn diagram is shown 
in figure 4.5a; 182 transcripts were upregulated (2 fold, FDR p value <0.05) by both 
reovirus and IL-15. However, the majority of transcripts regulated were unique to either 
reovirus or IL-15 treatment, demonstrating that these two methods of activating NK cells 
likely occur by distinct mechanisms, with potentially different functional outcomes. The 
comparison generated three lists of transcripts: 1) Upregulated by reovirus only 2) 
Upregulated by both and 3) Upregulated by IL-15 only. Figure 4.5b shows the results of 
functional enrichment analysis (using Metacore, as described earlier) of the three lists. 
The list of genes upregulated by reovirus only was enriched for Interferon signalling and 
Innate immune response to RNA viral infection, while the IL-15 only list was enriched for 
multiple cell cycle processes. In the list of genes upregulated by both IL-15 and reovirus, 
there was also enrichment for cell cycle processes. Therefore, reovirus treatment 
upregulates a small proportion of genes upregulated by IL-15, involved in cell cycle 








Figure 4.5 Comparison of reovirus upregulated transcripts with IL-15 upregulated 
transcripts 
a) Transcripts upregulated by reovirus in PBMC-NK cells were compared with transcripts 
upregulated by IL-15 in pure NK cells (microarray data generated by Helen Close). Both 
lists were filtered to give a list of gene names upregulated more than 2 fold relative to 
each untreated control, FDR p value <0.05, before Venn diagram analysis. b) Metacore 
enrichment analysis was performed on gene name lists taken from the Venn diagram 
analysis. Top 20 ranked process networks are shown. Yellow = Reovirus only. Blue = 
Both. Red = IL-15 only. 
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4.2.3 Reovirus treatment upregulates NK cell cytotoxicity pathways 
Functional enrichment revealed NK cytotoxicity as a potentially important process 
upregulated by reovirus (figure 4.3). NK cells can kill target cells through a granule 
dependent mechanism, or through alternative mechanisms such as death receptor 
pathways. Transcripts of GZMB and PRF1 (encoding the cytotoxic granule components 
granzyme B and perforin respectively) were upregulated by reovirus treatment (figure 
4.6a). However, transcripts encoding the death receptor ligands TRAIL and FASL were 
upregulated to a greater extent, especially TRAIL which was increased 19 fold in reovirus 
treated cells. In IL-15 treated NK cells, the pattern of cytotoxicity gene expression was 
different, with GZMB the most upregulated transcript and the death receptor ligands less 
highly expressed. It is likely that NK cell TRAIL and FASL expression is sensitive to 
interferon signalling, which would explain the differences observed. 
To validate the findings from transcriptome profiling, protein expression of NK cytotoxicity 
components was measured by flow cytometry. Granzyme B expression was measured 
by intracellular flow cytometry while TRAIL expression was measured on the cell surface. 
The results confirmed that granzyme B is more highly upregulated by IL-15 treatment, 













Figure 4.6 NK cell cytotoxicity associated gene expression and validation 
a) NK cytotoxicity associated transcripts and fold change expression in reovirus treated 
PBMC-NK cells relative to untreated PBMC-NK cells (Reo), and in IL-15 treated NK cells 
relative to untreated NK cells (IL-15) (data from Helen Close). Data from microarray. b) 
Protein level expression of  intracellular granzyme B and surface level TRAIL on NK cells 
within PBMC, analysed by flow cytometry. Representative histograms (top) and median 
fluorescence intensities from 3 separate donors (bottom). Differences in mean MFI, 
between untreated, reovirus treated and Il-15 treated samples, were tested by a repeated 
measures one way ANOVA, with Tukey’s multiple comparison test. * p < 0.05. ** p < 
0.01. 
a) 
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4.2.4 Reovirus treatment regulates lymph node homing pathways 
Migration of human NK cells, especially during oncolytic virus treatment, is not well 
studied. Unpublished data from our group (Yasser El-Sherbiny) showed that peripheral 
blood NK cell population frequencies changed over time in patients receiving intravenous 
reovirus treatment in a clinical trial (EUDRACT number 2007/000258-29). This data is 
summarised in figure 4.7. 10 colorectal patients received multiple intravenous infusions 
of reovirus, and blood was collected at 1 time-point before virus treatment, and 6 time-
points after the first infusion.  The proportion of CD56bright NK cells within total peripheral 
blood NK cells decreased at the 48 hour time-point and increased again at later time-
points. The loss of CD56bright NK cells coincided with a peak in NK cell CD69 expression 
at 48 hours, which itself in coincident with a peak in the interferon response (El-Sherbiny 
et al., 2015). Migration out of the blood, into lymph nodes, is one possible explanation 
for the disappearance of the CD56bright NK cells observed at this time-point. Therefore, I 
interrogated the transcriptome profiling results from the in vitro treated NK cells, to 
investigate and test this hypothesis. Several receptors are involved in lymphocyte 
homing to lymph nodes. The adhesion molecule, L selectin (also known as CD62L), is 
encoded by the SELL gene and is essential for the attachment of lymphocytes to high 
endothelial venules (HEV) of lymph nodes (Arbones et al., 1994). Migration to lymph 
nodes is mediated by chemokines and the chemokine receptors CCR7 and CXCR4 
recognise the lymph node chemokines, CCL19/21 and CXCL12, and have been 
implicated in lymph node homing of T and B cells (Baekkevold et al., 2001; Okada et al., 
2002). In addition, entry into lymph nodes is antagonised by the sphingosine-1-
phosphate receptor (S1PR1) which promotes egress of lymphocytes from lymph nodes 
(Matloubian et al., 2004). Relative transcript expression for genes encoding these 
receptors in reovirus treated NK cells are shown in Figure 4.8a; CXCR4 and SELL 
transcript levels were not significantly changed by reovirus treatment, but S1PR1 mRNA 
was significantly downregulated. CCR7 mRNA was upregulated by 5.62 fold on average, 
although FDR p value was > 0.05 due to donor variability.  
Upregulation of CCR7 and downregulation of S1PR1 mRNA was confirmed by 
quantitative reverse transcription PCR (qRT-PCR) and additional time-points were also 
assessed (Figure 4.8b). The ΔΔCt (ddCt) method was used to quantify mRNA transcripts 
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by real time PCR. For this analysis method, the cycle threshold (Ct) values are 
normalised to a housekeeping gene and expressed relative to the untreated control 
(section 2.7.4). In this study, ABL1 was selected as the housekeeping gene, as previous 
experiments in our group have demonstrated stable expression in NK cells. A change of 
one Ct indicates a doubling in transcripts, so ddCt is equal to log2 fold change. CCR7 
mRNA was upregulated in reovirus treated cells at 24, 48 and 72 hours. S1PR mRNA 
levels was downregulated at all time-points in reovirus treated cells, with the lowest 
expression at the earliest time-point tested, and appearing to increase towards untreated 
levels at later time-points. Upregulation of CCR7 could enhance lymph node homing of 
NK cells, while downregulation of S1PR1 might prevent egress, keeping NK cells in 










Figure 4.7 CD56bright NK cell dynamics in human blood following reovirus treatment 
Data generated by Yasser El-Sherbiny, showing in vivo peripheral blood NK cell 
dynamics during a clinical trial of intravenous reovirus (EUDRACT number 2007/000258-
29). 10 patients received multiple doses of reovirus, as detailed in (El-Sherbiny et al., 
2015). Top graph: CD69 expression on NK cells, from blood taken at the specified time 
points (also published in (El-Sherbiny et al., 2015)). Healthy control CD69 expression is 
in light red, patient CD69 expression in dark red. Bottom graph: Mean percentage of 
CD56bright cells within total NK cells, from the same samples (unpublished). CD56bright 
population was determined by flow cytometric staining of CD56 and CD16.  Healthy 
control CD56bright is in grey, patient CD56bright in black. 




Figure 4.8 Expression of transcripts involved in lymphocyte homing to lymph 
nodes 
a) Lymph node homing associated transcripts and fold change expression in reovirus 
treated PBMC-NK cells relative to untreated PBMC-NK (data from microarray). b) 
Expression of CCR7 and S1PR1 transcripts in untreated and reovirus treated PBMC-NK 
cells, at three separate time points, measured by qRT-PCR. Relative differences were 
calculated by the ddCt method, normalising to ABL1 expression. Shown above are the 
ddCt values, relative to the 24 hour untreated sample, in three separate donors.  
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Next, the expression of these transcripts was measured separately in the CD56dim and 
CD56bright populations of NK cells. In Figure 4.7, CD56bright NK cells were selectively lost 
from the blood in vivo during a clinical trial . This subset of NK cells was therefore 
expected to selectively regulate the lymph node homing receptors. PBMC were treated 
with reovirus as before for 48 hours, but this time NK cell isolation by magnetic labelling 
was followed by fluorescence activated cell sorting (FACS), to further separate NK cells 
into CD56dim and CD56bright populations (figure 4.9a). For FACS, NK cells were separated 
according to CD16 and CD56 expression, reproducing the staining strategy used in the 
in vivo study in Figure 4.7. In both donors analysed, the expression of CCR7 mRNA in 
untreated cells was higher in the CD56bright than in CD56dim NK cells (Figure 4.9b), which 
matched findings from previous studies (Campbell et al., 2001; Berahovich et al., 2006). 
However, unexpectedly reovirus treatment did not increase expression of CCR7 mRNA 
in the CD56bright population, only in the CD56dim population. S1PR1 mRNA expression 
was slightly lower in untreated CD56bright than CD56dim NK (reflecting the preference of 
CD56bright NK cells for the lymph nodes over the blood), but there was no consistent 














Figure 4.9 Expression of lymph node homing transcripts in CD56dim and CD56bright 
NK cells 
a) Flow cytometry cell sorting to isolate CD56dim CD16+ and CD56bright CD16- NK cells 
for real time PCR analysis of transcript expression. b) Expression of CCR7 and S1PR1 
transcripts in untreated and reovirus treated PBMC-NK cells, sorted into separate 
CD56dim CD16+ and CD56bright CD16- NK cell populations. PBMC were cultured for 48 
hours before NK isolation, and transcript expression was measured by real time PCR. 
Relative differences were calculated by the ddCt method, normalising to ABL1 
expression. Shown above are the ddCt values, relative to the untreated CD56dim CD16+ 
sample, in two separate donors.  
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In order to validate these observations at protein level, CCR7 expression was analysed 
by flow cytometry. PBMC cultured with or without reovirus were stained using a two-step 
method, using a primary antibody against CCR7 followed by a secondary fluorochrome 
conjugated antibody, and finally with antibodies against surface markers. CD56dim and 
CD56bright NK cells were gated as above, separated by CD56 dim/bright expression and 
CD16 expression (Figure 4.10a). CCR7 expression was observed on a proportion of T 
cells, typically 70 % of CD3+ lymphocytes. However, NK cells were negative for CCR7 
expression, even the CD56bright population. This was surprising as sorted CD56bright NK 
cells had strikingly higher expression of CCR7 mRNA than CD56dim NK cells (Figure 4.9). 
To rule out problems with reagents, the same experiment was repeated with a new 
antibody against CCR7 (antibody 2), which was a different clone and directly conjugated 
with a fluorochrome. Again, a proportion of T cells were positive for CCR7 but both 
populations of NK cells were negative. The median fluorescence values obtained from 
antibody 1 and antibody 2 are shown in Figure 4.10b. The lack of CCR7 surface 
expression on CD56bright NK cells does not reflect the results of previous studies, 
suggesting that the approach used here to detect cell surface CCR7 is not optimal. 
Despite this, mRNA expression data suggests that CCR7 is probably not the trigger for 
the selective loss of CD56bright NK from the blood of patients, as reovirus treatment does 
not upregulate expression in this subset. However S1PR1 mRNA expression did 
decrease in both subsets when treated with reovirus, so may contribute to lymph node 












Figure 4.10 CCR7 protein levels on the surface of T cells, CD56dim and CD56bright 
NK cells 
a) Histograms showing flow cytometry indirect surface staining with an antibody against 
CCR7, comparing T cells, CD56dim CD16+ NK cells and CD56bright CD16- NK cells within 
PBMC (gating shown for CD56dim and CD56bright populations). CCR7 positive gate was 
set on 2 % of the secondary only control. b) CCR7 median fluorescence staining 
intensities with two separate antibodies, antibody 1 and antibody 2. PBMC from 4 
separate donors were cultured either with or without reovirus at an MOI of 1, then CCR7 
expression on the surface of lymphocyte subsets was quantified by flow cytometry.  
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4.2.5 Reovirus treatment upregulates cell cycle pathways 
The microarray data showed that reovirus upregulated transcripts were enriched for cell 
cycle associated processes (Figure 4.3), suggesting that reovirus treatment might 
regulate NK cell proliferation. The top cell cycle process in the enrichment contained S 
phase associated proteins, involved in checkpoint control or triggering DNA replication. 
Reovirus treatment enhanced expression of many pro-proliferation S phase transcripts; 
the full list is shown in Appendix 1. Two transcripts from this list, MCM4 and CDK2, and 
an additional cell cycle associated gene, CCNB1 (cyclin B1), were tested by qRT-PCR, 
which confirmed significant upregulation of MCM4 and CDK2 following reovirus 
treatment (Figure 4.11a). Cyclin B mRNA expression was higher on average in reovirus 
treated NK cells, but this difference was not significant when tested by paired T test. 
MCM4 is a subunit of the minichromosome maintenance (MCM) complex, involved in 
DNA replication licensing, while CDK2 and Cyclin B are involved in checkpoint control of 
the cell cycle. These transcripts are all upregulated in NK cells in response to IL-15, 
which is mitogenic for NK cells (Helen Close microarray data), indicating that their 
expression is indeed associated with NK cell proliferation. I investigated whether 
expression of cell cycle associated transcripts differed between subsets of NK cells. 
Using RNA from sorted CD56dim and CD56bright NK cells (Figure 4.9), MCM4 expression 
levels were measured by qRT-PCR. The 2 donors tested showed the same pattern of 
expression; in reovirus treated cells, MCM4 was upregulated more in CD56bright NK cells 
than in CD56dim NK cells (Figure 4.11b). Therefore, for cell cycle associated genes, it is 
likely that the fold changes reported by the microarray are primarily due to increased 










Figure 4.11 Expression of transcripts involved in cell cycle progression 
a) Expression of MCM4, CDK2 and CCNB1 transcripts in PBMC-NK cells cultured with 
or without reovirus at an MOI of 1 for 48 hours, measured by qRT-PCR. Relative 
differences were calculated by the ddCt method, normalising to ABL1 expression. Shown 
above are the ddCt values, relative to the untreated sample, in three separate donors. 
Differences between mean ddCt values from untreated and reovirus treated samples 
were tested by paired T test. * p < 0.05.  b) MCM4 transcript expression in untreated and 
reovirus treated PBMC-NK cells, sorted into separate CD56dim CD16+ and CD56bright 
CD16- NK cell populations (as in figure 4.8). PBMC were cultured for 48 hours before 
NK isolation, and transcript expression was measured by qRT-PCR. ddCt values are 
calculated relative to the untreated CD56dim CD16+ sample, in two separate donors. 
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To test whether these changes in mRNA were reflected at the protein level, expression 
of MCM4, CDK2 and Cyclin B was analysed by Western Blot (Figure 4.12). MCM4 
protein was detected in untreated NK cells and was highly upregulated by IL-15 
treatment, as expected. Furthermore, quantification of band densities confirmed that 
MCM4 was reproducibly upregulated by reovirus at 48 hours (Figure 4.12a); this 
timepoint matches that used in the microarray analysis, demonstrating that the reovirus-
mediated induction of MCM4 gene expression was accompanied by increased 
expression of the protein. However, at 72 hours the differences were not as clear and 
expression of MCM4 in both untreated and reovirus treated NK cells was variable at this 
time-point. Untreated NK cells were not expected to proliferate in culture, however in one 
donor, untreated NK cells upregulated MCM4 expression between 48 and 72 hours. It is 
possible that primary cells from some donors may be more sensitive than others to 
factors in the growth medium, or NK cells might be proliferating in response to 
endogenous growth factors (e.g. as the result of a sub-clinical infection in the donor). 
Cyclin B and CDK2 protein levels were also tested, shown on the same blot (Figure 
4.12b). The positive control, IL-15 treatment, upregulated both of these proteins. 
However, levels of CDK2 and Cyclin B protein appeared similar between untreated and 
reovirus treated NK cells. This suggests that these molecules may not be upregulated at 
the protein level despite reovirus-induced expression of their respective genes. 
Alternatively, some cell cycle proteins might only be upregulated in the minority CD56bright 
population, making detection difficult within total NK cells. Therefore, I next tested the 
expression of proteins which are detectable by flow cytometry. This enabled the 
separation of CD56dim and CD56bright NK cells during analysis, without needing an 
expensive isolation step beforehand. The proteins PCNA and Ki67 are markers 
associated with proliferation, and were both significantly upregulated by reovirus 
treatment according to the transcriptome profile: PCNA 3.35 fold and Ki67 8.7 fold. 
PBMC cultured with or without reovirus were stained intracellularly for total PCNA (Figure 
4.13) or Ki67 (Figure 4.14). IL-15 was again tested as a positive control and, as expected, 
IL-15 highly upregulated both markers in NK cells, more so in the CD56bright population. 
A gate was set during analysis, to separate PCNA/Ki67 low cells from PCNA/Ki67 high 
cells. Reovirus treatment increased the mean percentage of PCNA high NK cells in both 
subsets, although this did not reach statistical significance according to paired T tests. 
In contrast, the mean percentage of Ki67 high NK cells did not increase in response to 
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reovirus. This was surprising as Ki67 mRNA was more highly upregulated than PCNA. 
This suggests that Ki67 mRNA expression may not reflect the level of its protein in NK 
cells. Overall, reovirus treatment appears to upregulate some proliferation associated 










Figure 4.12 Expression of proteins involved in cell cycle progression: Western 
Blot 
NK cells were magnetically isolated after culturing PBMC with or without reovirus at an 
MOI of 1, or with 10 ng/ml IL-15, for either 24, 48 or 72 hours (numbered 1 to 7). Protein 
expression of MCM4, cyclin B and CDK2 were analysed by Western Blot.  a)  Top: MCM4  
blot  example. Bottom: MCM4 expression was analysed in 3 separate donors, and 
normalised to β actin expression, using ImageJ.  The graph shows protein expression 
relative to the 48 hour untreated sample. b)  Cyclin B and CDK2 expression was 
analysed together. Representative of 3 donors.  




Figure 4.13 Expression of PCNA protein in CD56dim and CD56bright NK cells 
PBMC were cultured with or without reovirus at an MOI of 1, or with 10 ng/ml IL-15, for 
48 hours. Protein expression of PCNA was analysed in CD56dim and CD56bright NK cell 
populations by intracellular flow cytometry. a) Representative histograms from 1 of 3 
separate donors, with gating separating PCNA low from PCNA high cells. Grey 
histograms are isotype controls. b)  % PCNA high cells in each subset are plotted for 3 
separate donors. Differences between mean % values were tested by paired T test.  




Figure 4.14 Expression of Ki67 protein in CD56dim and CD56bright NK cells 
PBMC were cultured with or without reovirus at an MOI of 1, or with 10 ng/ml IL-15, for 
48 hours. Protein expression of Ki67 was analysed in CD56dim and CD56bright NK cell 
populations by intracellular flow cytometry. a) Representative histograms from 1 of 3 
separate donors, with gating separating Ki67 low from Ki67 high cells. Grey histograms 
are isotype controls. b)  % Ki67 high cells in each subset are plotted for 3 separate 
donors. Differences between mean % values were tested by paired T test.  




In the previous chapter, I showed that reovirus treated NK cells acquired an activated 
phenotype, with increased CD69 expression. Whilst CD69 is a useful, broad marker 
of NK cell activation, NK cells can be activated by many different stimuli, resulting in 
different responses. As observed in this study, both reovirus and IL-15 upregulate 
CD69, but their effects on the NK cell transcriptome are distinct. In this chapter, whole 
transcriptome profiling revealed a wide range of reovirus induced changes in NK 
cells. 
Functional enrichment analysis was a useful method for analysing such a large 
dataset (Figure 4.3) and can help discover unexpected upregulated pathways. In this 
case, interferon signalling was the top enriched function, which was unsurprising 
given the importance of interferon in regulating anti-viral responses. Comparison with 
previous studies revealed similarities between the reovirus-induced gene expression 
analysed here and interferon induced transcriptomes (Figure 4.4, microarray data 
from Metacore repository). Together, these results support the model proposed in 
chapter 3, in which interferon acts directly on NK cells. Most of the most highly 
upregulated genes are interferon stimulated genes such as IFI44L and RSAD2. 
Sustained high levels of STAT1 activation (chapter 3) probably leads to accumulation 
of these transcripts, such that NK cells acquire an anti-viral state. Comparison with 
previous microarray studies was useful, but does have limitations. Ideally, 
comparison should be between datasets produced with identical microarrays. 
Otherwise, it is not clear whether transcriptome differences are due to biological 
differences, or differences in probe lists (including the coverage of newly annotated 
genes) or probe location within the gene. If costs were unlimited, it would be 
interesting to run the experiment again, and compare reovirus treatment with 
interferon treatment, or reovirus treated NK cells with reovirus treated T cells or other 
cell types. This could identify pathways unique to reovirus treatment, or unique to NK 
cells.  
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Since IL-15 transcriptome data from an identical array was available, I used this to 
compare reovirus upregulated genes with IL-15 regulated genes specific to NK cells 
(Figure 4.5). Out of 1431 IL-15 upregulated genes, only 182 were shared with the list 
of reovirus upregulated genes. IL-15 generally upregulated cell cycle associated 
transcripts while reovirus treatment upregulated interferon signalling and innate anti-
viral immune responses. Clearly, IL-15 and reovirus have distinct effects on NK cells. 
The 182 overlapping transcripts were enriched for cell cycle processes. Similar sets 
of cell cycle processes were highlighted in the first enrichment analysis, in the list of 
reovirus upregulated transcripts. Reovirus treatment might trigger NK cell 
proliferation, as similar sets of cell cycle transcripts are upregulated by virus 
treatment and by IL-15, a cytokine known to promote NK cell division. However, IL-
15 upregulated cell cycle associated transcripts to a much higher degree than 
reovirus. It is possible that both type I IFNs and IL-15 are acting on NK cells during 
reovirus treatment, leading to downstream effects of both cytokines. However the 
lack of detectable STAT5 activation seen in chapter 3 does not support this 
hypothesis. Possibly, another stimulus is triggering the upregulation of cell cycle 
associated transcripts during reovirus treatment. 
Transcriptome profiling identified a number of expected as well as unexpected 
changes in mRNA expression, which were then followed up with validation 
experiments. Reovirus treatment of PBMC enhances NK cell degranulation against 
cancer cell targets (chapter 3), which could be explained by altered expression of 
activating or inhibitory receptors, enhanced expression of degranulation machinery, 
or some other signalling pathway enhancement. Reovirus induced changes in NK 
activating receptor expression has previously been assessed in patient PBMC 
samples and in vitro treated PBMC, but no significant changes were observed (El-
Sherbiny et al., 2015). The expression of GZMB mRNA increased with reovirus 
treatment, but intracellular granzyme B protein did not significantly increase when 
assessed by flow cytometry (Figure 4.6). NK cell granzyme B protein levels at rest 
were already high, relative to isotype control binding and to non-NK cell levels (not 
shown). Indeed, one reason that NK cells are able to respond very rapidly to infection 
and cancer is because they are “pre-armed” with cytotoxic proteins, unlike T cells 
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which induce granzyme B expression upon activation. Rather than increasing 
granzyme B concentration in the cell, reovirus exposed NK cells may enhance some 
other process, to enhance granule dependent killing of target cells; this could include 
regulation of the granule exocytosis pathway or the activation of granzyme molecules 
which are synthesised as inactive zymogens requiring proteolytic processing (Meade 
et al., 2006). Transcripts encoding components of the granule independent killing 
machinery were also upregulated by reovirus treatment. The death receptor ligand 
TRAIL was upregulated at the mRNA level, and TRAIL protein was upregulated on 
the surface of NK cells (Figure 4.6). IL-15 stimulation did not upregulate TRAIL 
expression to the same extent, suggesting this is a response unique to viral activation 
of NK cells. Indeed, the TRAIL gene promoter contains an ISRE, a type I interferon 
responsive element, and TRAIL upregulation on NK cells has been implicated in the 
control of viral infections (Sato, K. et al., 2001). The upregulation of NK cell TRAIL 
by oncolytic viruses could be an advantage during therapy, as high expression of 
TRAIL receptors has been reported on some cancer types including melanoma and 
colon cancer tissue (Daniels et al., 2005), as well as colon cancer and lung cancer 
cell lines (Kim, K.H. et al., 2000). Furthermore, TRAIL protein has been proposed as 
a anti-cancer therapy, though clinical trials have proved negative to date (Lemke et 
al., 2014). 
The transcriptome profile data also provided an opportunity to investigate a poorly 
studied function of NK cells; migration. Although there have been numerous studies 
of mouse NK cell migration, there are few regarding human NK cells. The CD56bright 
and CD56dim NK cell subsets preferentially locate to different tissues. In the blood, 
CD56dim outnumber CD56bright NK cells, whereas in the lymph nodes the opposite is 
observed (Cooper et al., 2001; Fehniger et al., 2003). However, these subsets do not 
exist in mice (although equivalent populations have been suggested, as discussed 
in section 1.2.4). Furthermore, oncolytic virus studies have mainly focused on the 
cytotoxic capabilities of NK cells and have not considered the effects of viral 
treatment on NK cell distribution. Unpublished data from this lab (performed by 
Yasser El-Sherbiny) showed that CD56bright NK cells transiently disappear from the 
blood of patients receiving reovirus infusions (data summarised in Figure 4.7). It was 
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hypothesised that this subset was migrating out of the blood into secondary lymphoid 
tissue. CD56bright NK cells are present in higher proportions in the lymph nodes than 
in the blood, where they are thought to regulate T cell responses through IFN-γ 
release (Fehniger et al., 2003). Therefore, increased numbers of CD56bright NK cells 
in the lymph nodes might enhance adaptive immune responses during oncolytic virus 
therapy.  In the model used here, reovirus treatment of PBMC led to increased levels 
of CCR7 and decreased levels of S1PR1 mRNA in a mixed population of NK cells. 
However when NK cells were sorted to separate the CD56bright and CD56dim subsets, 
enhanced CCR7 expression was only observed in the CD56dim population. CCR7 
expression remained higher in the CD56bright subset, both at rest and during reovirus 
treatment. Thus, even though CD56dim CCR7 mRNA increased, it never reached the 
levels found in the CD56bright population. Perhaps CD56bright NK cells have reached a 
maximum expression level and increases are only seen in the CD56dim subset. 
However this observation does not help to explain why the CD56bright subset was 
selectively lost from the blood in the clinical trial. Neither CCR7 nor S1PR1 mRNA 
expression was selectively altered in the CD56bright subset.  
As CCR7 mRNA levels were already elevated in CD56bright compared to CD56dim NK 
cells, there may be an mRNA pool ready to be rapidly translated following stimulation. 
Surface protein levels were tested by flow cytometry, but CCR7 could not be detected 
on either subset of NK cells after 48 hours culture, either with or without reovirus. 
This was surprising, as several studies have determined CCR7 expression on the 
surface of CD56bright NK cells (Campbell et al., 2001; Berahovich et al., 2006).  CCR7 
was clearly detectable on a proportion of T cells, and two separate antibodies gave 
the same result, suggesting that the methodology and reagents were robust.  
However, PBMC were cultured for two days before staining, whereas previously 
published studies analysed freshly isolated PBMC (Campbell et al., 2001; 
Berahovich et al., 2006). It is possible that culture of primary NK cells leads to loss 
of surface CCR7; when Berahovich et al. analysed CCR7 expression on NK cell lines, 
only 1 out of 3 was positive by flow cytometry (Berahovich et al., 2006). Chemokine 
receptor internalisation is a widely reported phenomenon, and might be responsible 
for the lack of cell surface expression. It would be interesting to study NK cell 
   
125 
 
chemotaxis towards lymph node cytokines following in vitro reovirus treatment, 
however the experimental model would need to be further validated due to these 
inconsistencies with previous studies. It is unclear whether in vitro culture of PBMC 
is an appropriate method for the study of chemokine receptors and chemotaxis.   
S1PR1 mRNA was downregulated in both CD56dim and CD56bright NK subsets during 
reovirus treatment. The ligand for this receptor, Sphingosine-1-Phosphate (S1P), is 
present in higher concentrations in the blood than other tissue compartments. This 
concentration gradient promotes egress of lymphocytes from the lymph nodes into 
the blood (Matloubian et al., 2004). Therefore, downregulation of S1P receptors 
might slow the egress of lymphocytes from lymph nodes (allowing NK cells to act in 
the lymph node, for example by providing IFN-γ to skew Th1 responses). CD69 has 
also been implicated in the control of lymphocyte egress from lymph nodes, by 
inhibiting the action of S1PR1 (Shiow et al., 2006). NK cell CD69 is clearly 
upregulated by reovirus treatment (chapter 3) and transient CD69 upregulation 
overlaps with the loss of CD56bright NK cells from the blood of patients (Figure 4.7). 
The downregulation of S1PR1 combined with upregulation of CD69 may therefore 
enhance retention of NK cells in the lymph nodes. Since the S1P gradient does not 
exist solely in lymph nodes, NK cells might be transiently retained in other tissues as 
well, depending on additional homing signals. In the clinical trial, the patients 
receiving reovirus were being treated for colorectal cancer, so NK cells might have 
homed to the cancerous tissue (where signs of reovirus replication were observed 
(Adair et al., 2012)). Although CD69 upregulation and S1PR1 mRNA downregulation 
were not specific to CD56bright NK cells, this subset does express higher levels of 
many chemokine receptors, including CCR7 transcripts as I confirmed here. 
Therefore, the reason why only CD56bright NK cells are lost from the blood could be 
because of an innate migratory ability, causing this subset to leave the periphery, 
followed by an enhanced retention in lymph node (or tissue) triggered by changes in 
CD69 and/or S1PR1. To test these hypotheses, in vivo study would be required. A 
mouse study would be ideal for tracking changes in a controlled way, however 
information about the human CD56bright and CD56dim subsets would be lost.  
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Finally, cell cycle associated transcript expression was investigated further, after 
functional enrichment identified cell cycle processes were upregulated by reovirus. 
Compared with some of the interferon stimulated genes (e.g. IFI44L, up 128.98 fold), 
cell cycle transcripts were relatively weakly upregulated (e.g. MCM4,  up 2.08 fold). 
Real time PCR on a small selection of genes confirmed modest upregulation of 
transcripts associated with DNA replication or cell cycle progression. However, when 
NK cells were sorted into CD56dim and CD56bright subsets, expression of MCM4 was 
much more highly upregulated in the CD56bright population. Therefore, transcriptome 
profiling on whole NK cells probably underestimates the enhancement of these 
pathways in the CD56bright subset.  CD56bright NK cells are known to proliferate more 
than the CD56dim subset in response to IL-2, which has been explained by their 
expression of the high affinity IL-2 receptor (Caligiuri et al., 1990), now known as the 
IL-2Rαβγ. CD56bright NK cells are also the more proliferative subset under other 
conditions, such as pDC induced proliferation (Romagnani et al., 2005) or IL-4 and 
IL-7 induced proliferation (Robertson et al., 1993). A recent paper showed that 
CD56bright NK cells are more metabolically active than the CD56dim subset (Keating 
et al., 2016), which might explain their enhanced ability to proliferate in response to 
a range of stimuli. Protein expression validation confirmed upregulation of some 
proliferation associated markers in response to reovirus, but not others. Of those that 
were upregulated (MCM4, PCNA), the changes induced by reovirus were small 
compared to the effects of IL-15, but this was expected considering the comparative 
analysis of the reovirus and IL-15 transcriptome profiles. Flow cytometry allowed the 
separate analysis of PCNA and Ki67 levels in CD56dim and CD56bright NK cells. As 
expected, there was higher proportion of PCNA high cells in the CD56bright subset. 
Flow cytometry also allowed single cell level of analysis of protein levels, which 
revealed that the majority of NK cells at rest have uniform levels of PCNA or Ki67, 
with a small percentage of cells staining more strongly. PCNA is a component of DNA 
replication machinery, is  used as an S phase marker (Landberg and Roos, 1991) 
and PCNA high cells are probably cells in (or about to enter) S phase. Ki67 is thought 
to function during mitosis (Cuylen et al., 2016), and accumulates later in the cell cycle 
(Sobecki et al., 2017). This could explain why I observed higher proportions of PCNA 
high cells compared to Ki67 high cells at the same time-point. Surprisingly, 
intracellular protein levels of Ki67 did not increase with reovirus treatment. The 
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proportion of Ki67 high cells in reovirus treated samples was typically less than 
untreated samples, although this was not significantly significant. This was despite 
an 8 fold upregulation of Ki67 mRNA in reovirus samples, when measured by 
transcriptome profiling. These apparently conflicting results suggest that reovirus 
mediated effects on NK cell proliferation may be more complex than originally 
predicted.  
In conclusion, transcriptome profiling both confirmed the expected – that interferon 
signalling is the dominant pathway activated by reovirus – and revealed new 
pathways to explore further. Reovirus treatment influenced the expression of 
transcripts involved in granule independent cytotoxicity, lymph node homing, and 
proliferation; functions which could be important for optimal therapeutic effect of NK 
cells during oncolytic virus therapy. In the final chapter, I have investigated the effects 
of reovirus on NK cell proliferation.  
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Chapter 5. Regulation of NK cell proliferation by reovirus  
5.1 Introduction 
In the previous chapter, I analysed the transcriptional responses of NK cells in PBMC 
treated with reovirus. Gene expression profiling revealed an upregulation of cell cycle 
associated transcripts in reovirus treated NK cells, suggesting that reovirus may affect 
NK cell proliferation. NK cell expansion has been reported in some viral infection models, 
the most widely studied example being the MCMV mouse model, and in a few human 
viral infections, but not in others. The mechanisms underlying NK cell proliferation differ 
across types of viruses; MCMV induces clonal proliferation through the Ly49 receptor 
(Dokun et al., 2001), while hantavirus induces IL-15 on endothelial cells to trigger human 
NK cell proliferation (Bjorkstrom et al., 2011; Braun et al., 2014). Clearly, not all viruses 
affect NK cell proliferation equally. Furthermore, it is difficult to predict how intravenous 
virus therapy will impact on NK cell turnover or expansion, as little is known about NK 
proliferation in the blood. Therefore, it was important to study how NK cells within PBMC 
might proliferate in response to reovirus treatment. In this chapter, I have used 
proliferation assays to study how reovirus affects human NK cell division, and 











5.2.1 Reovirus treatment does not induce NK cell proliferation in 
vitro 
To study proliferation in vitro, PBMC isolated from healthy donors were labelled with 
carboxyfluorescein succinimidyl ester (CFSE) (Section 2.3.8). CFSE binds covalently to 
free amines on the cell surface and inside of cells, and emits a bright signal when 
analysed by flow cytometry. Upon cell division, the CFSE inside the cell is diluted by half 
– allowing the tracking of cell division events in a population. Tracking of lymphocyte 
proliferation usually requires longer term culture of cells, in order to visualise multiple 
divisions. I cultured CFSE labelled PBMC for 5 days, as in (Romagnani et al., 2005). As 
the CFSE dilution assay is a flow cytometry based method, it allows the simultaneous 
analysis of separate subsets of cells. This was ideal for the analysis of NK cell within 
PBMC. In the previous chapter, mRNA expression analysis of sorted CD56dim and 
CD56bright NK cells revealed much higher cell cycle transcript upregulation in the 
CD56bright population. In order to assess proliferation in both of these NK cell subsets, 
PBMC were stained with CD3, CD56 and CD16 antibodies. The gating for this 
experiment is shown in Figure 5.1a. Untreated cells are not expected to proliferate; the 
majority of untreated NK cells are found in a peak of undivided cells. A gate was drawn 
to separate this peak of undivided cells from the less brightly staining, divided cells. The 
gate was positioned at the edge of the undivided peak, in untreated cells. Within IL-15 
treated PBMC, proliferation of NK cells was observed, with clear peaks of dividing cells. 
CD56bright NK cells proliferated more than the CD56dim population in response to IL-15, 
which is consistent with the pattern of Ki67 expression shown in Figure 4.14. In contrast, 
reovirus treated cells did not proliferate at this time-point. Across 3 separate donors, 
there were no statistically significant differences between untreated and reovirus treated 
cells, although in CD56bright NK cells the mean level of proliferation was actually lower in 
reovirus treated cells than untreated cells (Figure 5.1b).  
 
It was possible that reovirus treatment did induce NK cell proliferation, but at a later time-
point. However, when PBMC were kept in culture for longer, the viability of reovirus 
   
130 
 
treated lymphocytes dropped dramatically (Figure 5.2). This meant that longer term 
culture experiments were not possible, and also suggested that reovirus treatment might 
actually activate anti-survival signals in lymphocytes, rather than pro-survival, pro-










Figure 5.1 NK cell proliferation during in vitro reovirus treatment  
a) PBMC were labelled with 0.2 µM CFSE, then cultured for 5 days either with or without 
reovirus at an MOI of 1, or 10 ng/ml IL-15. After 5 days, PBMC were stained with viability 
dye to exclude dead cells, and surface markers and dilution of CFSE were analysed by 
flow cytometry.  Left hand dot plots show gating of NK cells within PBMC, and gating of 
CD56dim and CD56bright cells within total NK cells. Right hand histograms are CFSE 
dilution plots. Cells falling to the left of the gate are classed as dividing. b) Percentage of 
CD56bright (left) and CD56dim (right) NK cells classed as dividing by the CFSE dilution 
assay above, from 3 separate donor PBMC. Paired T test results are shown. Differences 
between treatment means were tested by paired T test. NS = not significant. 




Figure 5.2 Long term culture of CFSE labelled PBMC 
PBMC were labelled with 0.2 µM CFSE, then cultured alone, with reovirus at an MOI of 
1, or with 10 ng/ml IL-15, for 6, 8 or 10 days. Viability of lymphocytes within PBMC was 
analysed by viability dye staining.  Cells within the gate (staining dimly for the viability 
dye) were classed as live lymphocytes, whereas cells falling outside of the gate (staining 
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5.2.2 Reovirus pre-treatment inhibits IL-15 induced proliferation 
Although reovirus treatment induces the expression of several cell cycle genes (Chapter 
4), reovirus treatment alone did not trigger NK cell proliferation (Figure 5.1). Reovirus 
alone might not be a strong enough stimulus to initiate cell division. In some cases, 
certain cytokines are able to augment proliferation, but only in combination with other 
stimuli (Robertson et al., 1993). Potentially, reovirus might prime NK cells for enhanced 
proliferation in response to a second stimulus, such as IL-15. The cytokine IL-15 has 
been used throughout this study as a positive control for proliferation, and it plays an 
important role in NK cell homeostasis (Ranson et al., 2003). Therefore, I tested whether 
reovirus pre-treatment affected NK cell proliferation in response to IL-15. CFSE labelled 
PBMC were primed with reovirus for 4 hours before stimulation with IL-15 for 5 days. 
Surprisingly, reovirus priming did not enhance NK cell proliferation, but instead inhibited 
proliferation in response to IL-15 (Figure 5.3). In the CD56bright subset, reovirus pre-
treatment significantly reduced the mean proportion of dividing cells; this difference was 
also observed in the CD56dim subset but the differences were not statistically significant. 
Thus, although reovirus treatment upregulated markers of proliferation in NK cells 
(chapter 4), the functional consequence of treatment was actually to inhibit in vitro 
proliferation. 
While CFSE is a good indicator of cell division, it does not reveal anything about cell 
cycle phase. Therefore, propidium iodide (PI) staining of DNA was performed, to test 
how reovirus treatment affected cell cycle progression. Previous work in our group 
determined 72 hours as an optimal time-point to detect S phase in IL-15 treated NK cells 
using PI staining. The dye PI intercalates between DNA or RNA bases in a quantitative 
manner (similar to ethidium bromide); after RNase treatment, PI staining indicates the 
total DNA content of each cell when analysed by flow cytometry. However, this method 
of DNA staining requires ethanol fixation which is incompatible with cell surface antigen 
staining. Hence, for these experiments, NK cells were treated with reovirus and/or IL-15 
within the context of PBMC and then purified by magnetic labelling before the staining 
process. After doublet exclusion (Figure 5.4a), PI staining was analysed in histogram 
format using Modfit software, which fits G0/G1 and G2 peaks to the data and defines S 
phase cells. After 72 hours culture with IL-15 alone, S phase and G2 cells were clearly 
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observed. However when PBMC were pre-treated with reovirus before IL-15 stimulation, 
the proportion of NK cells in S phase was dramatically reduced. The duration of reovirus 
treatment did not change the result; cell cycle progression was inhibited with 4 hour, 24 
hour or 48 hour pre-treatments with reovirus (Figure 5.4). The proportion of cells in each 
cell cycle compartment was quantified by Modfit, shown in figure 5.4b. Reovirus pre-
treatment led to an accumulation of cells in G0/G1 phase, relative to treatment with IL-
15 alone (Figure 5.4b). Therefore, reovirus treatment inhibited NK cell proliferation by 










Figure 5.3 Effect of reovirus priming on IL-15 induced NK cell proliferation 
a) PBMC were labelled with 0.2 µM CFSE, then primed for 4 hours with reovirus at an 
MOI of 1 or  cultured without virus. 10 ng/ml IL-15 was then added directly to all samples 
and cells were cultured for a further 5 days. After 5 days, PBMC were stained as in figure 
5.1.  Histograms show CFSE dilution of CD56dim and CD56bright NK cells. b) Percentage 
of CD56bright (left) and CD56dim (right) NK cells classed as dividing by the CFSE dilution 
assay above, from 4 separate donor PBMC. Differences between treatment means were 
tested by paired T test. ** p < 0.01. NS = not significant 





Figure 5.4 Effect of reovirus priming on cell cycle progression 
a) PBMC were either treated with 10 ng/ml IL-15 for 3 days, or primed with reovirus at 
an MOI of 1 for 4, 24 or 48 hours, followed by IL-15 treatment for 3 days. NK cells were 
then isolated by magnetic labelling, fixed and  DNA stained with propidium iodide (PI). 
Staining was analysed by flow cytometry, which required doublet exclusion by height Vs 
area of signal (top left). PI cell cycle profiles were analysed using Modfit software. b) The 
bar graph shows percentage of NK cells in each cell cycle compartment, after 3 days 
culture with 10 ng/ml Il-15 (no virus), or  3 days culture with IL-15 after 4 hours priming 
with reovirus at an MOI of 1 (Reovirus). Values were calculated by Modfit software. Bar 
graph shows mean values plus standard deviation for 3 separate donor PBMC. 
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As shown in chapter 3, PBMC treated with reovirus secreted high concentrations of IFN-
α, a cytokine long known to inhibit the proliferation of virus infected cells, as part of its 
broad antiviral activity (Sangfelt et al., 2000). The effect of IFN-α on lymphocyte 
proliferation is more controversial, but some studies have shown that IFN-α inhibits the 
IL-2 induced proliferation of T cells and NK cells (Erickson et al., 1999; Jewett and 
Bonavida, 1995). Therefore, high levels of IFN-α in reovirus treated PBMC might inhibit 
NK cell proliferation, and block any pro-proliferation signals that may be present. To test 
this, I cultured PBMC in reovirus conditioned media, filtered to remove virus particles. 
Reovirus conditioned media had a similar effect to live reovirus treatment, inhibiting NK 
cell proliferation in response to IL-15 (Figure 5.5). When cultured in reovirus conditioned 
media, there were fewer cell division events – which was most striking in the CD56bright 
NK subset. This suggested that soluble factors released into the media in response to 
reovirus treatment were responsible for blocking proliferation. To test whether IFN-α was 
the factor responsible, a cocktail of antibodies blocking the action of IFN-α was utilised. 
Inclusion of type I IFN blocking antibodies prevented the inhibition of proliferation by 
reovirus conditioned media, with the CFSE histograms for both untreated CM and 
reovirus CM conditions appearing very similar. In contrast, inclusion of isotype control 
antibodies did not prevent inhibition of proliferation. Therefore, type I IFN released by 
reovirus stimulated PBMC was responsible for inhibiting NK cell proliferation in response 













Figure 5.5 Effect of type I interferon neutralisation on IL-15 induced NK cell 
proliferation 
PBMC were labelled with 0.2 µM CFSE and resuspended in conditioned media from 
either untreated PBMC (untreated CM) or Viresolve filtered conditioned media from 
reovirus treated PBMC (Reo CM). The samples were split and some were treated with 
IFN-blocking antibody cocktail and some with isotype control blocking cocktail. 10 ng/ml 
IL-15 was then added directly to all samples and cells were cultured for 5 days. After 5 
days, PBMC were stained as in figure 5.1.  Histograms show CFSE dilution of 
CD56bright and CD56dim NK cells, representative of 3 separate donors. 
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5.2.3 Type I interferon inhibitory effects on NK cell proliferation 
The results above show that type I IFN, released from reovirus treated PBMC, inhibited 
proliferation of IL-15 stimulated NK cells, but it was unclear whether this inhibitory effect 
was specific to IL-15. The cytokine IL-12 is also reported to contribute to NK cell 
proliferation, although it is not as strong a stimulus as IL-15 (Vitale et al., 2002). To 
compare the effects of distinct proliferative cytokines, purified NK cells from healthy 
donors were cultured in combinations of IFN-α with IL-15 or IL-12, then subjected to cell 
cycle analysis by PI staining (Figure 5.6). IL-12 treatment increased the proportion of S 
phase cells, although the increase was small relative to IL-15 treated cells (33% in S 
phase for IL-15, but only 6% for IL-12). Addition of IFN-α to both IL-12 treated NK cells 
and IL-15 treated cells decreased the S phase fraction. 
NK cells from the same experiment were also analysed for mRNA expression of cell 
cycle associated transcripts, using quantitative real time PCR. Both IL-12 and IL-15 
increased the expression of MCM4, CDK2 and Cyclin A and B transcripts (Figure 5.7). 
However, IFN-α inhibited expression of these transcripts, both in IL-12 treated and IL-15 
treated NK cells, and even reduced expression in otherwise untreated cells. These 
results, together with the proliferation assays above, demonstrate that IFN-α mediated 
inhibition of proliferation is not specific to IL-15 based proliferation and that IFN-α inhibits 
expression of cell cycle genes. On the other hand, reovirus treatment – which clearly 
induces IFN-α release – triggered the upregulation of cell cycle gene expression. The 
possible reasons for this inconsistency were explored further in section 5.2.6. 
Lastly, a similar experiment was conducted to analyse the dose response to IFN-α. Since 
IFN-α has been reported to promote lymphocyte proliferation in some cases (Curtsinger 
et al., 2005), I next tested the possibility that low concentrations might promote NK cell 
proliferation, while high concentrations (such as those resulting from reovirus treatment 
of PBMC) might activate different pathways to inhibit proliferation. However, all of the 
tested concentrations of IFN-α inhibited proliferation of IL-15 treated NK cells, as 
determined by the proportion of cells in S phase (Figure 5.8). Similarly, all dilutions of 
the reovirus conditioned media inhibited proliferation.  
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In certain cell lines, treatment with IFN-I has been shown to upregulate expression of cell 
cycle inhibitory proteins, including INK4 proteins and CIP/KIP proteins such as p19 and 
p21 (Sangfelt et al., 2000) These families of proteins inhibit the action of cyclin dependent 
kinases (CDKs), therefore inhibiting progression through the cell cycle. Expression of 
these factors was examined in the transcriptome profiles from untreated and reovirus 
treated NK cells (chapter 4). However, no significant changes were observed in a range 








Figure 5.6 NK proliferation during treatment with different cytokine combinations 
Purified NK cells were cultured with the combinations of cytokines above, all at 100 
ng/ml, for 3 days. Samples were then fixed and DNA stained with propidium iodide (PI). 
Staining was analysed by flow cytometry and cell cycle profiles were analysed using 
Modfit software, to calculate percentages of NK cell in S phase for each sample. The 
results above are representative of three donors.   
 




Figure 5.7 Expression of cell cycle associated transcripts after treatment of NK 
cells with different cytokine combinations 
Purified NK cells were cultured with the combinations of cytokines above, all at 100 
ng/ml, for 3 days. Expression of MCM4, CDK2, CCNA2 (Cyclin A) and CCNB1 (Cyclin 
B) transcripts was measured by real time PCR. Relative differences were calculated by 
the ddCt method, normalising to ABL1 expression. Shown above are the ddCt values, 
relative to the untreated sample, in 2 separate donors. 
 




Figure 5.8 Effect of IFN-α concentration on NK cell proliferation 
Purified NK cells were cultured with 10 ng/ml IL-15 plus increasing concentrations of 
IFNα, or decreasing dilutions of reovirus conditioned media (Viresolve filtered) for 3 days. 
Samples were then fixed and  DNA stained with propidium iodide (PI). Staining was 
analysed by flow cytometry and cell cycle profiles were analysed using Modfit software, 
to calculate percentages of NK cell in S phase for each sample. The experiment was 
performed in one donor.   












1.05 0.540408 CDKN2D 
cyclin-dependent kinase inhibitor 2D (p19, 
inhibits CDK4) 
1.03 0.986728 CDKN2A 
cyclin-dependent kinase inhibitor 2A; 
cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
1.03 0.319032 CDKN2B 
cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 
-1.13 0.243265 CDKN2C 
cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
CIP/KIP proteins 
Fold Change (linear) 
(Reo vs. Resting ) 
FDR p-value (Reo 
vs. Resting ) 
Gene 
Symbol Description 
1.16 0.275991 CDKN1A 
cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
1 0.757898 CDKN1C 
cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) 
-1.01 0.391143 CDKN1C 
cyclin-dependent kinase 
inhibitor 1C (p57, Kip2) 
-1.02 0.91586 CDKN1B 
cyclin-dependent kinase 
inhibitor 1B (p27, Kip1) 
-1.09 0.510175 CDKN1B 
cyclin-dependent kinase 
inhibitor 1B (p27, Kip1) 
Table 5.1 Expression of potential anti proliferative transcripts during reovirus 
treatment 
Fold change expression of INK4 family and CIP/KIP family transcripts in reovirus treated 
PBMC-NK cells relative to untreated PBMC-NK . Data from microarray. 
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5.2.4 Effects of reovirus treatment on IL-15 signalling 
During the proliferation analysis, I observed that reovirus pre-treatment had additional 
effects on NK cells treated with IL-15. IL-15 stimulated NK cells upregulate expression 
of cell surface CD56, which can be observed by flow cytometry (Figure 5.9). However, 
in PBMC pre-treated with reovirus conditioned media, this upregulation of CD56 was 
inhibited. Addition of IFN-I blocking antibodies into the conditioned media rescued CD56 
upregulation, while isotype control blocking antibodies did not (Figure 5.9). This 
suggested that reovirus induced IFN-I has wider inhibitory effects on NK cells, other than 
the inhibition of proliferation. One possibility was that reovirus treatment interferes with 












Figure 5.9 Effect of reovirus conditioned media on IL-15 induced NK surface 
phenotype 
CFSE labelled PBMC were cultured in conditioned media plus 10 ng/ml IL-15 for 5 days, 
with the addition of type I interferon blocking cocktail (IFN block) or isotype control 
blocking cocktail (Isotype control block). A sample left untreated for 5 days was also 
included for comparison. After 5 days, surface staining for CD56, CD3 and CD16 was 
analysed by flow cytometry. Shown above are lymphocyte CD3/CD56 dot plots for each 
sample, with back gating of the CD56dim CD16+ NK population (dark blue) and the 
CD56bright CD16- NK population (orange).  
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To test whether reovirus pre-treatment affects IL-15 signalling, intracellular staining of 
phosphorylated proteins was utilised. PBMC were pre-treated with reovirus for 48 hours, 
enough time for IFN-I to accumulate in the media and IFN-I mediated changes to take 
place. After 48 hours, PBMC were then stimulated with IL-15 for 30 minutes, to enable 
optimum detection of rapid phosphorylation events. IL-15 is known to activate several 
different signalling pathways, including JAK/STAT pathways as well as mTOR and PI3K-
Akt signalling (section 1.1.7). Therefore, a range of molecules were tested for 
phosphorylation: STAT1 and STAT5 tyrosine phosphorylation (as in chapter 3), serine 
phosphorylation of mTOR (as a marker of mTOR activity), and serine phosphorylation of 
Akt, which is downstream of PI3K activation. Levels of phosphorylation were quantified 
by reporting the median fluorescence intensity (MFI) of NK cells within PBMC, both in 
unstimulated and IL-15 stimulated cells (Figure 5.10). STAT1 phosphorylation was 
induced by reovirus pre-treatment, as reported in chapter 3. STAT1 phosphorylation in 
reovirus treated cells was enhanced following IL-15 stimulation, whereas STAT1 
activation in non-virus treated cells did not change. This was clearest at 10 ng/ml of IL-
15, where there was a statistically significant difference between non-primed and 
reovirus primed pSTAT1 levels. STAT1 is not typically phosphorylated downstream of 
IL-15 (as demonstrated in chapter 3, Figure 3.7), but high levels of STAT1 present in 
reovirus treated cells (the transcriptome profile showed a 17.36 fold upregulation of 
STAT1 transcripts in reovirus Vs untreated NK cells), could increase the probability of 
STAT1 phosphorylation. STAT5 phosphorylation was induced by IL-15, consistent with 
previous experiments (Figure 3.7), but STAT5 phosphorylation levels did not significantly 
differ between non-primed and reovirus primed NK cells. mTOR phosphorylation was 
also induced by IL-15, but similarly did not change between non-primed and reovirus 
primed cells. In contrast, reovirus pre-treatment had a statistically significant effect on 
Akt phosphorylation. In PBMC stimulated with IL-15, reovirus primed NK cells contained 
lower levels of phosphorylated Akt than non-virus primed cells. Without addition of IL-15, 
levels of phosphorylated Akt were similar between non-primed and virus primed NK cells. 
These results suggest that reovirus treatment promotes changes in NK cells that 
selectively interfere with Akt signalling but not STAT5 signalling, downstream of IL-15. 
This could contribute to the inhibition of proliferation observed in reovirus treated cells.  
 




Figure 5.10 Phosphorylation of signalling proteins in response to IL-15, following 
priming with reovirus 
PBMC were cultured for 48 hours alone (no virus) or primed with reovirus at an MOI of 
1 (+ reovirus). After 48 hours, 10 ng/ml IL-15 was added directly to all samples for 30 
minutes. NK cells within PBMC were evaluated for levels of phosphorylated STAT1, 
STAT3, STAT5, mTOR and Akt by intracellular flow cytometry. Graphs show median 
fluorescence intensities for  2 or 3 separate donors.  The effect of IL-15 concentration 
and  effect of virus on MFI were tested by 2 way repeated measures ANOVA. When the 
effect of virus was statistically significant, post hoc Sidak multiple comparison test was 
applied, to identify statistically significant differences between “no virus” and “reovirus” 
MFI values.  
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To further investigate the mechanisms of proliferation inhibition, the expression of cell 
cycle associated proteins was tested in PBMC cultured with or without virus, followed by 
IL-15 stimulation. The aim was to test whether reovirus pre-treatment inhibited the 
upregulation of any of these proteins by IL-15. PCNA and Ki67 expression was measured 
by intracellular flow cytometry, gating on CD56dim and CD56bright NK cells within PBMC 
(Figure 5.11). Reovirus pre-treatment inhibited the expression of both PCNA and Ki67 in 
response to IL-15. Inhibition of PCNA expression was evident in both NK cell subsets, 
but Ki67 inhibition was clearest in the CD56bright subset. Protein expression of MCM4, 
Cyclin B and CDK2 was measured by Western Blot, using lysates from total NK cells 
isolated from PBMC. A similar result was observed; reovirus primed cells contained lower 
levels of all three proteins than non virus primed cells. Therefore, reovirus treatment 
prevented the accumulation of cell cycle associated proteins triggered by IL-15 
stimulation. This finding appears to contradict the results of transcriptome profiling, which 
showed that reovirus treatment increased the transcript expression of Ki67, PCNA, 
MCM4, CDK2 and Cyclin B (appendix 1 and chapter 4, Figure 4.11). A possible 
explanation could be that reovirus triggers the activation of two pathways: one that 
promotes proliferation, and the other inhibiting proliferation through the release of IFN-I. 
The first pathway may trigger the upregulation of cell cycle transcripts, while IFN-I 
released into the media would act to repress transcription of these genes. In this 
hypothetical situation, it is unlikely that all cell cycle gene expression would be repressed 












Figure 5.11 Expression of cell cycle associated proteins in IL-15 treated NK cells, 
following priming with reovirus 
PBMC were cultured for 4 hours alone (no virus) or primed with reovirus at an MOI of 1 
(Reo). 10 ng/ml IL-15 was then added directly to all samples for 48 hours (a) or 3 days 
(b). a) NK cells within PBMC were assessed for levels of PCNA and Ki67 by intracellular 
flow cytometry. Green=CD56dim NK cells. Purple=CD56bright NK cells. b) Expression of 
MCM4, Cyclin B and CDK2 was assessed by Western Blot, after isolation of total NK 
cells from PBMC by magnetic labelling.  
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5.2.5 Proliferation of NK cells from patients with an IFN-I driven 
disease 
The evidence shown above suggests that IFN-I, released by PBMC exposed to reovirus, 
is a potent inhibitor of NK cell proliferation in culture. However, the in vivo effects of IFN-
I on peripheral NK cell proliferation are not clear. It was hoped that blood samples from 
cancer patients receiving reovirus as part of a clinical trial might be used to address the 
effects of reovirus on human NK cell proliferation in vivo. However, suitable samples 
were not forthcoming during this work and an alternative approach was attempted. 
Systemic lupus erythematosus (SLE) is an autoimmune disease associated with high 
IFN-I activity (Kaul et al., 2016). Upregulation of an IFN-I signature in the blood during 
SLE has been widely reported (Baechler et al., 2003; Bennett et al., 2003; Crow et al., 
2003). I hypothesised that NK cell proliferation in response to IL-15 would be repressed 
in peripheral blood NK cells from patients with SLE, relative to healthy control NK cells, 
due to the activation of IFN-I signalling. To test this, PBMC isolated from patients with 
SLE (from blood donated at a local clinic) or healthy donors were stimulated ex vivo with 
IL-15. On the day of donation, phenotyping of PBMC populations was performed, to 
determine the  proportions of NK cells and T cells, and to quantify expression of CD69 
and the IFN-I inducible molecule Tetherin. Due to time constraints at the end of the 
project, I was only able to analyse 4 healthy donors and 4 patients with SLE. Gating of 
NK cells within PBMC on the day of donation is shown in Figure 5.12. Dead cell 
discrimination was included, but only for the last 5 of 8 donors. However, the viability of 
cells in the lymphocyte gate was consistently over 99%, so dead cells probably did not 
impact greatly on staining results. The proportion of NK cells and T cells within PBMC 
was not significantly different between healthy donors and patients with SLE (Figure 
5.13). NK cell CD69 and Tetherin expression was also not significantly changed in 
patient blood, relative to healthy donors. However, there was a greater spread of Tetherin 
expression in NK cells from patients, consistent with SLE being a heterogeneous 
disease, with high IFN-I scores seen only in a subset of patients (Kirou et al., 2005).  
Ex vivo proliferation of NK cells from patients and healthy donors was assessed by the 
CFSE dilution assay. PBMC isolated from blood donors was labelled with CFSE and split 
into two samples: one to be cultured alone, and the other to be cultured with IL-15. After 
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5 days, NK cells within PBMC were analysed by flow cytometry. Unlike previous 
experiments in the chapter, where the control (untreated) and treatment (reovirus) 
samples were matched, i.e. from the same pool of labelled PBMC, this time the control 
(healthy donors) and treatment (patients with SLE) were from separate samples. Each 
sample takes up slightly different concentrations of CFSE, so to avoid bias when setting 
the non dividing/dividing gate, Modfit software was used for analysis. Modfit fits peaks to 
the CFSE histograms and identifies generations of dividing cells, given the co-ordinates 
of the parent generation. Examples of Modfit analysis are shown in Figure 5.14 (top). A 
proliferation index value was calculated by the software, which measures how much the 
parent population has grown, taking into account the proportions of cells in each 
generation. Using this approach, a comparison of IL-15 stimulated PBMC from patients 
with SLE and healthy donors revealed no significant difference in proliferation index. It is 
possible that the high variability of responses might be linked to differences in disease 
severity or IFN score, however stratification of patients was not possible with such low 















Figure 5.12 Flow cytometry analysis of PBMC from patients with SLE 
PBMC were isolated from blood of healthy donors and patients with SLE, then surface 
stained with antibodies and analysed on the day of donation. a) Examples of lymphocyte 
subset staining. CD56 CD3 staining plots are shown for one healthy donor and 
onepatient, b) Examples of CD69 and Tetherin staining within NK cell gate. 




Figure 5.13 Phenotype of PBMC from patients with SLE 
PBMC isolated from 4 healthy donors and 4 patients with SLE were surface stained and 
analysed by flow cytometry, on the day of donation. Samples were donated on 3 
separate days. Top: proportions of NK cells (CD56+ CD3-) and T cells (CD3+ CD56-) 
within total lymphocytes. Bottom: CD69 and Tetherin expression on NK cells. Statistical 
differences between healthy controls and patients were tested by unpaired T test (NS = 
not significant). 
 




Figure 5.14 Proliferation of NK cells from patients with SLE 
PBMC from healthy donors and patients with SLE were labelled with 0.2 µM CFSE, then 
cultured with or without 20 ng/ml IL-15. After 5 days, PBMC were stained with viability 
dye to exclude dead cells, and surface markers and dilution of CFSE were analysed by 
flow cytometry. a) CFSE plots for NK cells within PBMC were analysed using Modfit 
software, which estimated the proportion of events in each generation and calculated a 
proliferation index (PI). The parent generation peak was reset for each donor, using 
CFSE plots from untreated cells. b) Proliferation index values for NK cells within IL-15 
stimulated PBMC. Statistical differences between healthy controls and patients were 
tested by unpaired T test (NS = not significant). 
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5.2.6 Why does reovirus treatment upregulate cell cycle machinery? 
Pathway enrichment analysis and validation experiments suggested that reovirus 
treatment upregulated groups of cell cycle associated transcripts (chapter 4, section 
4.2.5), however the results in this chapter show that reovirus treatment is actually 
inhibitory to NK cell proliferation. It was hypothesised that reovirus treatment activates a 
separate pro-proliferation pathway in NK cells (and that this pathway drives induction of 
the cell cycle genes), which is then opposed by the high levels of IFN-I in culture. The 
potential source of a pro-proliferation signal was unknown, but one possibility was that a 
soluble cytokine was responsible. Soluble cytokines released during reovirus treatment 
should be present in reovirus PBMC conditioned media. Therefore, the potential of 
reovirus induced cytokines to induce a pro-proliferation response was tested by culturing 
purified NK cells in conditioned media (filtered to remove virus), followed by analysis of 
MCM4 transcript expression. I tested conditioned media collected from PBMC at 24 
hours and 48 hours of reovirus exposure, but neither appeared to upregulate MCM4 
expression (Figure 5.15). This is in contrast to the effect of live reovirus on PBMC, which 
does upregulate NK cell MCM4 expression (Figure 4.11) 
Alternatively, a cell to cell contact mechanism might be required for activation of the pro-
proliferation signal. Trans-presentation of IL-15 is known to induce survival and 
proliferation of NK cells, and requires cell to cell contact (Dubois et al., 2002). Therefore 
I tested whether blocking IL-15 during reovirus treatment had any effect on the 
expression of cell cycle associated transcripts in NK cells. PBMC were cultured with or 
without reovirus, plus either anti-IL-15 blocking antibody, isotype control antibody, or 
nothing added. The IL-15 blocking antibody was separately validated by demonstrating 
inhibition of IL-15 stimulated CD69 expression in NK cells (data not shown). Reovirus 
treatment upregulated the expression of two cell cycle associated transcripts, CDK2 and 
CCNB1, consistent with what was shown previously in Figure 4.11. However, the 
addition of IL-15 blocking antibody did not inhibit these changes, in the one donor tested. 
These two experiments suggest that the pro-proliferation signal is probably not 
downstream of IL-15, or soluble factors present in reovirus conditioned media. This is 
consistent with the lack of STAT5 phosphorylation detected in chapter 3.  




Figure 5.15 Potential mechanisms for cell cycle transcript upregulation induced 
by reovirus 
mRNA transcript expression was measured by real time PCR and relative differences 
were calculated by the ddCt method, normalising to ABL1 expression. Shown above are 
the ddCt values, relative to the untreated sample in each case. a) MCM4 transcript 
expression in purified NK cells, cultured in either conditioned media from untreated 
PBMC (untreated CM) or Viresolve filtered conditioned media from reovirus treated 
PBMC (Reovirus CM). NK cells were cultured for 48 hours. b) Effect of IL-15 
neutralisation on the upregulation of CDK2 and CCNB1 (Cyclin B) transcript expression. 
PBMC were cultured with or without reovirus, plus the addition of IL-15 blocking antibody 
or a matched isotype control. PBMC were cultured for 48 hours, then NK cells were 
isolated by magnetic labelling, for transcript analysis.  




Understanding the role of the innate immune system in the host response to oncolytic 
viruses (OVs) is important for the development of improved therapeutic regimes using 
these agents. However, the majority of studies on NK cell responses to OVs have 
focused on their cytotoxic capability, and have not explored other aspects of NK cell 
biology. Expansion of NK cell numbers during therapy could be a great advantage. In 
the previous chapter, I showed that reovirus upregulated transcripts associated with cell 
cycle progression in NK cells, which prompted an investigation into NK cell proliferation 
during virus treatment.  
Despite the upregulation of these transcripts, reovirus treatment did not trigger in vitro 
proliferation of NK cells, measured by dilution of CFSE. When combined with a second 
stimulus, IL-15, reovirus clearly inhibited NK cell proliferation, rather than enhancing it. 
Further experiments confirmed that IFN-I was responsible for the inhibition of 
proliferation. In the literature, IFN is known to exert anti-proliferative responses in many 
cell types, particularly transformed cells (Sangfelt et al., 2000). In most of these cases, 
IFN has been found to induce G1 phase arrest (Sangfelt et al., 1999; Erickson et al., 
1999). Consistent with this, I showed in this chapter that reovirus treatment, through IFN-
I, blocked NK cell progression into S phase when stimulated with IL-15. Suggested 
mechanisms for G1 arrest in cell lines stimulated with IFN include the upregulation of 
CDK inhibitor molecules including the CIP/KIP proteins and the INK4 proteins (Sangfelt 
et al., 2000). In particular, p21 is thought to be transcriptionally upregulated by IFN, 
shown in multiple cell lines (Sangfelt et al., 1997; Xaus et al., 1999). However, when I 
searched the reovirus NK transcriptome dataset, I did not find any significant changes in 
expression of a range of CIP/KIP and INK4 transcripts. A more detailed examination of 
transcript levels, at different time-points after reovirus addition, would be required to rule 
out transcriptional regulation of CDK inhibitors as a potential mechanism. Additionally, 
some more widely recognised interferon stimulated genes such as IFIT1 have been 
implicated in cell cycle arrest (Niu et al., 2016). IFIT1 was highly upregulated by reovirus 
treatment in NK cells, according to transcriptome profiling (93 fold upregulated, FDR p 
value = 0.005). 
   
159 
 
Interestingly, reovirus induced IFN-I had wider effects on NK cells, other than inhibition 
of proliferation. IL-15 stimulated NK cells upregulate CD56 on their surface (Van Acker 
et al., 2017) (Figure 5.9), but pre-treatment with reovirus attenuated this effect in an IFN-
I dependent manner. This suggested that IFN-I could inhibit additional NK cell activatory 
pathways, separate to proliferation.  A possible explanation could be that reovirus treated 
cells have attenuated responses to IL-15, due to altered signalling pathway activation. 
Two studies, one based on NK cells and one on T cells, were the first to show that IFN-
α inhibited the proliferative effect of IL-2 (Jewett and Bonavida, 1995; Erickson et al., 
1999), a cytokine with similar downstream signalling to IL-15. The T cell study also 
demonstrated that IFN-I blocked the accumulation of proteins required for cell cycle 
progression, similar to my results following reovirus treatment. These findings are 
consistent with an early inhibition of proliferation, potentially an inhibition of IL-2 
signalling. To test whether reovirus treatment affected signalling downstream of IL-15, a 
panel of signalling molecules were examined for phosphorylation events associated with 
their activation. STAT5 phosphorylation was not significantly changed by reovirus pre-
treatment, but interestingly, STAT1 phosphorylation downstream of IL-15 was 
significantly enhanced. In non-virus primed cells, IL-15 primarily activates STAT5 with 
very little STAT1 activation (chapter 3 and 5). However in virus primed cells, IL-15 
appeared to enhance STAT1 activation as well as STAT5. This may be due to highly 
upregulated expression of total STAT1 protein during reovirus treatment (transcriptome 
profiling revealed 17.36 upregulation of STAT1 transcripts, FDR p value = 0.004). The 
balance of different STAT proteins inside the cell influences which signalling pathways 
become activated. For example, murine NK cells are basally high in STAT4, so initially 
during LCMV infection there is a strong STAT4 signal, leading to production of IFN-γ. 
However as more IFN-I is produced in response to virus, STAT1 levels rise leading to 
higher activation of STAT1 through IFN and lower activation of STAT4 (Miyagi et al., 
2007). Importantly, this mechanism confines the production of IFN-γ to early in the 
infection. Similarly, rising levels of STAT1 protein during virus treatment may increase 
the probability of IL-15 signalling through STAT1.  
My results on STAT5 phosphorylation are in agreement with previous studies on the 
effects of IFN-I: one showed that IFN-I treatment does not affect  IL-7 induced STAT5 
phosphorylation in T cells (Nguyen, T.P. et al., 2015) (IL-7 being another common γ chain 
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receptor cytokine like IL-15) and another reported that IFN-α priming triggers a modest 
increase in IL-15 induced STAT5 phosphorylation in NK and T cells (Hansen et al., 
2011). Therefore the inhibitory effect of reovirus treatment on IL-15 induced proliferation 
(and the CD56 phenotype) cannot be explained by reduced STAT5 phosphorylation.  
 
In contrast, I showed that reovirus exposure did affect NK cell Akt signalling downstream 
of IL-15. Expression of the IL-15 receptor was not measured, but since STAT5 
phosphorylation was unaffected, it was unlikely that receptor expression would have 
been downregulated. In fact, analysis of the transcriptome data revealed that IL15RA – 
the transcript encoding the α subunit – was upregulated 4.97 fold (FDR p value = 0.014). 
Therefore, viral treatment selectively interfered with the Akt pathway, which has not been 
previously reported in NK cells. In human T cells, Nguyen et al. recently showed that 
IFN-α selectively inhibited Akt phosphorylation, but not STAT5 phosphorylation, in 
response to IL-7 or IL-2 (Nguyen, T.P. et al., 2015). They also found that IFN-α inhibited 
the proliferative response to both cytokines. Recently, there has been much focus on the 
importance of PI3K-Akt-mTOR signalling in NK cells. Experiments using inhibitors to 
either STAT5 or PI3K showed that IL-15 could not induce proliferation in NK cells if either 
of these pathways was blocked (Nandagopal et al., 2014). Therefore, the selective 
inhibition of Akt signalling in reovirus primed NK cells is probably at least partly 
responsible for the inhibition of proliferation, and potentially the inhibition of other 
activatory pathways. Akt signalling is also induced by other pro-proliferative cytokines, 
such as IL-12 (Yoo et al., 2002), which could explain why IL-12 induced proliferation was 
also inhibited by IFN-α (figure 5.6 and 5.7). Furthermore, these results show that reovirus 
priming changes the balance of signalling pathways activated by IL-15. The enhanced 
activation of STAT1 in response to IL-15 may contribute to enhanced cytotoxicity of 
reovirus primed NK cells, as NK cell intrinsic STAT1 can promote cytotoxic function 
during viral infection (Nguyen, K.B. et al., 2002a; Fortin et al., 2013). A previous study 
investigated the effect of IFN-I priming on NK cell responses to IL-15 (Hansen et al., 
2011); they showed that IFN-I primed NK cells had enhanced cytotoxicity towards target 
cells following stimulation with IL-15. However they did not measure IL-15 induced 
proliferation, which would probably have been inhibited by IFN-α priming.   
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Although IFN-I inhibits growth in many cell lines, and NK cells in the model described 
here, in certain cases IFN-I can actually promote immune cell proliferation. In some 
cases, this can be explained by indirect effects of IFN, such as the enhancement of IL-
15 trans-presentation by DCs, induced by IFN-I (Lucas et al., 2007). On the other hand, 
IFN-I can also act directly, and has an important role in the activation of T cells. Using 
IFN-I receptor knockout T cells, Curtsinger et al. showed that IFN acts directly on naive 
CD8 T cells to enhance clonal expansion (Curtsinger et al., 2005). IFN provided a third 
signal, after TCR stimulation and CD28 co-stimulation, to enhance expansion. Why does 
IFN act so differently in this situation? Importantly, the enhancing effect on expansion 
was mediated by STAT4 (Curtsinger et al., 2005), and STAT4 signalling promotes 
survival and effector differentiation pathways in T cells (Crouse et al., 2015). STAT1 
signalling, on the other hand, is inhibitory to lymphocyte proliferation (Lee et al., 2000). 
It has since been proposed that TCR activation leads to a modulation of STAT signalling, 
so the IFN-I signal is directed through STAT4 rather than STAT1. Evidence for this 
includes the specific downregulation of STAT1 in antigen specific proliferating CD8 T 
cells during LCMV infection (Gil et al., 2006), and a loss of STAT1 phosphorylation in 
superantigen (bacterial derived antigen capable of activating up to 20% of T-cells through 
the TCR) activated T cells (Van de Wiele et al., 2004). This seems to be a mechanism 
specific to TCR activation, to allow rapid clonal expansion. Consistent with this, a recent 
study showed that IFN-α treatment enhanced the proliferation of superantigen activated 
T cells, but inhibited the proliferation of cytokine induced proliferation (Cha et al., 2014). 
The results in this chapter and chapter 3 showed that STAT1 signalling in NK cells was 
highly activated and sustained, while STAT4 phosphorylation was only transient. High 
levels of STAT1 phosphorylation in reovirus treated NK cells may stimulate cytotoxicity 
pathways, but also act to inhibit proliferation. Further experiments to inhibit STAT1 in this 
model could be performed, to confirm the anti-proliferative mechanism.    
Ideally, the next step in the investigation would have been to measure NK cell 
proliferation in patients receiving reovirus therapy. Unfortunately, there were no suitable 
trials with patients recruited at the time. I attempted to measure NK cell proliferation from 
the peripheral blood of systemic lupus erythematosus (SLE) patients instead, to test the 
effects of high IFN-I in vivo. In patients with SLE, it is thought that IFN-I levels (or 
responsiveness to IFN-I) is chronically high, whereas during a reovirus therapy trial, IFN 
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response peaked and fell (El-Sherbiny et al., 2015). Although there was a slight trend 
towards lower proliferation in of NK cells from patients with SLE, there were no 
statistically significant differences. SLE is a heterogeneous disease, with some patients 
experiencing flares or more severe symptoms than others (Kaul et al., 2016), so many 
more samples would be required to make any real conclusions.  
It was hypothesised that NK cells receive opposing signals during reovirus treatment: 
one signal to promote proliferation and a separate signal to inhibit proliferation, through 
IFN-I/STAT1. This could explain why reovirus treatment upregulated so many cell cycle 
associated transcripts, but also inhibited proliferation. When PBMC were treated with 
reovirus, a wide range of changes were induced in NK cells, including CD69 
upregulation, IFN induced genes - including Tetherin expression - and cell cycle 
associated transcripts were upregulated (chapters 3 and 4). Conditioned media 
treatment of purified NK cells induced similar changes in CD69 and tetherin (chapter 3). 
However, conditioned media did not upregulate MCM4, used as a marker for cell cycle 
associated transcripts. This could be because CD69 and tetherin upregulation is 
activated by soluble factors including IFN-I, whereas cell cycle transcripts are 
upregulated by a separate pathway.  This would make sense, as IFN present in 
conditioned media actually inhibited proliferation (Figure 5.5). It is unclear what the 
mechanism responsible for proliferative transcript upregulation is. Good candidates 
would be IL-2 and IL-15, which are potent inducers of NK cell proliferation. However 
neutralisation of IL-15 during reovirus treatment had no effect, and conditioned media – 
which should contain IL-2 if it were secreted by PBMC – also failed to upregulate 
proliferative transcripts. Additionally, STAT5 phosphorylation was not detected in this 
model (chapter 3), which would be expected downstream of either IL-2 or IL-15. A recent 
paper identified a cell contact mechanism inducing NK cell proliferation in HCV, which 
required OX40L expression on monocytes (Pollmann et al., 2017). Another possibility 
could be the direct activation of NK cell receptors by reovirus proteins, leading to 
proliferation. Conditioned media was filtered to remove virus particles, so direct effects 
of reovirus would not have been detected.  
Interestingly, expansion of NK cells was detected during a clinical trial of reovirus therapy 
(El-Sherbiny et al., 2015), but it was unclear whether this was the result of proliferation. 
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The expansion happened later on in the trial, between 6 and 28 days after the first virus 
infusion, and some time after the peak of IFN responsiveness. It is possible that NK cell 
proliferation was delayed due to high levels of IFN early during treatment. Further study 
would be required to test this hypothesis, ideally tracking NK cell proliferation during 
another reovirus trial. 
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Chapter 6. Conclusions 
In this study, I investigated the effects of the oncolytic virus (OV) reovirus on human NK 
cells, using an in vitro model. In chapter 3, I showed that, within PBMC, NK cells were 
activated by reovirus in a directly type I interferon (IFN-I) dependent manner. Activation 
of NK cells was assessed by analysing the activation marker CD69 on the cell surface; 
upregulated CD69 is predictive of increased NK cell cytotoxicity (Clausen et al., 2003). 
A directly IFN-I dependent mechanism was supported by blocking experiments, 
demonstrating that NK cells were activated by IFN-I present in reovirus conditioned 
media. Secondly, activation of both STAT1 and STAT4 was consistent with pathway 
activation downstream of the IFN-I receptor. Finally, gene expression profiling revealed 
dramatic upregulation of IFN induced genes (ISGs). 
Gene expression profiling (described in chapter 4) revealed that, as well as ISGs and 
NK cytotoxicity associated genes, there were changes in additional NK cell functions and 
pathways. Non granule dependent killing strategies are likely important, especially 
involving the death ligand TRAIL, which was highly upregulated. Genes associated with 
lymph node homing and chemotaxis were significantly upregulated. However I was 
unable to detect the chemokine receptor CCR7 on cultured NK cells, so this could not 
be confirmed at the protein level. Further work to improve the detection of CCR7, and to 
assess NK cell chemotaxis, should be carried out to confirm the effects of reovirus 
treatment on NK cell migration. Increased NK cell migration to the lymph nodes during 
therapy, where NK cell derived IFN-γ can induce T helper cell polarisation, would likely 
enhance the adaptive immune response. Finally, gene expression profiling revealed the 
upregulation of many cell cycle associated genes, suggesting that reovirus treatment 
may also regulate NK cell proliferation.  
Despite the upregulation of cell cycle associated transcripts, the total effect of reovirus 
on NK cell proliferation was actually inhibitory. The results presented in chapter 5 showed 
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that reovirus treatment inhibited NK cell proliferation, due to high levels of IFN-I released 
by virus treated PBMC. IFN-I acting through STAT1 is known to inhibit lymphocyte 
proliferation (Lee et al., 2000; Gil et al., 2006), but exactly how this is achieved is not well 
understood. I showed that pre-treatment of PBMC with reovirus selectively inhibited Akt 
phosphorylation downstream of IL-15, but not STAT5 phosphorylation. The inhibition of 
this pathway likely contributes to the inhibition of IL-15 induced proliferation in reovirus 
primed cells.  
Together, these results show that reovirus treatment has the potential to enhance some 
NK cell functions while inhibiting others. High levels of IFN-I are released by reovirus 
treated PBMC, leading to the activation of IFN sensitive pathways, but may temporarily 
inhibit NK cell proliferation pathways. In Figure 6.1, the proposed model for reovirus 
induced NK cell activation is shown.  
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Figure 6.1 Proposed model of NK cell activation by reovirus 
Detection of reovirus particles by PBMC triggers the release of cytokines, including IFN-I, which act on NK cells to induce functional changes. 
The diagram summarises the pathways activated within NK cells, supported by the results described in this thesis. Many functions were 
dependent on IFN-I in this study; for functions in italics IFN-I dependency has been shown by others. Other functions may be activated 
downstream of cytokines or other factors, marked as (?).  
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In vitro treatment of PBMC replicates many features of in vivo therapy. In patients treated 
with intravenous reovirus, a strong IFN-I response was observed within 24-48 hours, as 
well as CD69 and Tetherin upregulation on NK cells (El-Sherbiny et al., 2015). The same 
was observed within in vitro treated PBMC in this study. On the other hand, there are 
limitations of the in vitro model. In chapter 5, I showed that PBMC could not be cultured 
long term with reovirus, as it caused increased level of cell death relative to untreated 
cells. It is possible that, without the in vivo context of circulation and additional immune 
cell types, reovirus is capable of damaging PBMC, perhaps through overstimulation. 
Because a large proportion of the population has been already exposed to reovirus, 
neutralising antibodies present in the blood may also trigger the removal of virus 
particles.  
In conclusion, in vitro culture of PBMC is a convenient model that accurately represents 
many aspects of in vivo therapy. Using this model, I was able to explore NK cell 
responses to reovirus in great detail. While previous studies have demonstrated that OVs 
activate NK cell granule dependent cytotoxicity, my results show that oncolytic reovirus 
acts on the spectrum of NK cell activity, with the potential to modulate TRAIL-mediated 
cytotoxicity, NK cell migration (potentially important in providing IFN-γ in lymph nodes for 
cytotoxic T cells), and to have effects on NK proliferation. Therefore, the results 
presented in this thesis add previously unknown detail to current models of reovirus 
therapy. Future directions could include studying samples from current clinical trials of 
reovirus, to confirm the findings discussed here. An important next step could be to 
compare the mechanisms of NK cell activation and functional effects of reovirus with 
other OVs, and to determine how these pathways might be enhanced or inhibited by 
combination therapies.  
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Appendix 1 
Metacore pathway enrichment 
Reovirus differentially expressed genes (>1.5 fold or <-1.5 fold, FDR p value<0.05) in 




Network Object Name 
Gene 
Symbol 





AHR  AHR  AHR_HUMAN  2.02 0.032744 
BRIP1  BRIP1  FANCJ_HUMAN  2.42 0.021595 
BUB1  BUB1  BUB1_HUMAN  3.71 0.017424 
Brca2  BRCA2  BRCA2_HUMAN  6.19 0.005472 
CAF-1  CHAF1A  CAF1A_HUMAN  1.51 0.046469 
CAF-1  CHAF1B  CAF1B_HUMAN  -1.56 0.01233 
CDC45L  CDC45  CDC45_HUMAN  1.51 0.044396 
CDC7  CDC7  CDC7_HUMAN  1.94 0.009222 
CDK1 (p34)  CDK1  CDK1_HUMAN  1.99 0.048162 
CDK2  CDK2  CDK2_HUMAN  2.68 0.00482 
CRM1  XPO1 XPO1_HUMAN  1.59 0.009648 
Cyclin A  CCNA2  CCNA2_HUMAN  3.04 0.048542 
DNA polymerase sigma PAPD7  PAPD7_HUMAN  2.36 0.02835 
DRF1  DBF4B  DBF4B_HUMAN  1.72 0.018988 
Emi1 FBXO5 FBX5_HUMAN  1.63 0.007568 
FEN1  FEN1  FEN1_HUMAN  1.58 0.033812 
Geminin GMNN  GEMI_HUMAN  1.72 0.046444 
HSP90  HSP90AA1  HS90A_HUMAN  1.51 0.030584 
Histone H1  HIST1H1C  H12_HUMAN  1.8 0.012946 
MCM10  MCM10  MCM10_HUMAN  1.94 0.02193 
MCM4  MCM4  MCM4_HUMAN  2.08 0.026898 
MCM4/6/7 complex  MCM6  MCM6_HUMAN  2.06 0.02371 
Nek2A NEK2  NEK2_HUMAN  1.53 0.036101 
Nibrin  NBN  NBN_HUMAN  1.56 0.01028 
PCNA  PCNA  PCNA_HUMAN  3.35 0.020906 
POLD reg (p68)  POLD3  DPOD3_HUMAN  2.3 0.010331 
Sgo1  SGO1  SGO1_HUMAN  1.89 0.010876 
TEP1 TEP1 TEP1_HUMAN  1.54 0.00344 
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TOP1 TOP1 TOP1_HUMAN  2.53 0.002621 
 
 
 
 
